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Chemokines are a highly conserved family of chemoattractant cytokines that are 
key to the movement of cells around the body under both inflammatory and 
homeostatic conditions. Chemokines bind to seven transmembrane G protein 
coupled receptors that signal and induce cell movement upon ligand binding. As 
well as the ‘classical’ chemokine receptors, there also exists a family of atypical 
chemokine receptors that do not induce a canonical signalling response upon 
ligand binding.  
These atypical chemokine receptors (ACKR) have been shown to modify the 
chemokine response through processes such as the scavenging of inflammatory 
chemokines. One such receptor with this scavenging function is ACKR2 which has 
been shown to bind and internalise all of the inflammatory CC chemokines. The 
functional repertoire of ACKR2 continues to be expanded and it is now thought 
to have a role in inflammation, lymphatic drainage and lymphatic vessel 
development. It has been shown that the absence of this receptor results in 
impaired resolution of inflammation and, as a result, increased inflammatory 
pathologies in vivo. In models of skin inflammation a lack of ACKR2 has been 
shown to result in increased pathology and impaired inflammatory resolution. 
Multiple models of cutaneous inflammation, including excisional wound healing 
and chemically induced damage, were used to further investigate the role of 
ACKR2 in this context. Work on wound healing suggested that although ACKR2 
appears to play no role in wound closure it does have a role in the formation of 
scar tissue in an excisional wound. Our data suggest that ACKR2 has a role in 
collagen deposition in developing and maturing scars. We also found that ACKR2 
had a protective role in chemically-induced models of skin inflammation. 
We then looked at the role of ACKR2 in ocular inflammation. The main work 
performed in this section involved the use of the experimental autoimmune 
uveitis (EAU) model. Here we found that ACKR2 had a protective effective 
resulting in reduced pathology and infiltration of inflammatory leukocytes. This 
work also suggested, using in vitro analysis, that a human retinal pigmented 
epithelial cell line expresses functional ACKR2 protein and that our findings may 
be relevant to human disease. 
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Finally we looked at the role of ACKR2 in the inflammatory autoimmune disease 
rheumatoid arthritis (RA). By taking samples of peripheral blood from RA 
patients we assessed the transcript levels of Ackr2 and correlated them with 
clinical measurements. Our findings suggested that, in patients with ‘well-
controlled’ RA, there was an increase in the transcription of Ackr2 in peripheral 
blood leukocytes. Additional work using in vitro methods suggest that the 
hypoxic nature of the rheumatoid joint, and some of the drugs used to treat the 
disease, may increase the transcription of Ackr2. 
Overall the findings in this work suggest novel roles for ACKR2 in the skin and the 
eye. They also shed light on further environmental factors that may alter the 
local expression of ACKR2 in the rheumatoid joint. Taken together this work 
suggests that ACKR2 may have great therapeutic potential and, furthermore, this 
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Chapter 1 Introduction 
Given the nature of the work in this thesis, this section will provide an overview 
of inflammation and chemokine biology. Introduction sections in individual 
results chapters will provide greater detail on the background relevant to that 
work. 
 
1.1  Inflammation 
Inflammation is the body’s response process to tissue damage and/or infection. 
It involves the accumulation of fluid and cells at the site of trauma. This process 
is driven by the immune system, a network of cells that serves to protect the 
body by attacking anything that is considered to be ‘non-self’. It is important, 
during this process, to effectively and efficiently resolve the issue at hand whilst 
keeping ‘collateral damage’ to a minimum. When this system fails chronic 
inflammation can ensue and result in many years of continual damage. There are 
four classical signs of inflammation each of which are described in Latin. These 
are calor (heat), tumor (swelling), dolor (pain) and rubor (redness) as described 
by Celsus (circa 30 B.C.) in De Medicina (Donaldson, 2014). Loss of function was 
added as a fifth sign later on.  
 
1.1.1 The Innate Immune Response 
The immune response is the activation of the immune system following an insult 
such as physical damage, bacterial, viral or fungal infection. The first lines of 
defence are the barriers formed by epithelial tissues such as the skin and the 
mucosa of the gut. These tissues provide physical barriers that keep pathogens 
out of the body. The importance of these tissues can be seen when there is a 
breach in them during wounding. It is often following a wound that an infection 
can occur as pathogens may enter opportunistically. If these barriers are 
breached then the immune system responds to kill the pathogen. 
The innate immune system develops prenatally and so is functional from birth 
(Pagenkemper and Diemert, 2014). One of the main functions of the innate 
immune system is to be a rapid responder to trauma/infection. Upon recognition 
of damage, or an invading pathogen, the innate immune system mounts an 
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immediate response that works to neutralise the infectious agent. The rapid 
recognition of ‘non-self’ is of utmost importance for the cells of the innate 
immune system. One of the ways in which the cells of the innate immune system 
are able to determine self from non-self is through pattern recognition receptors 
(PRR) (Sellge and Kufer, 2015). One of the main groups of PRRs are the Toll-like 
receptor (TLR) family which were originally discovered in Drosophila 
melanogaster (Hashimoto, Hudson and Anderson, 1988). These receptors are 
able to sense pathogen-associated molecular patterns (PAMPs) that tend to be 
molecules that are absolutely essential for the survival of pathogens and cannot 
be evolved away. In bacteria, and fungi, constituent parts of the cell wall make 
up these PAMPs whereas in viruses it tends to be viral DNA/RNA that is 
recognised (Sellge and Kufer, 2015). Activation of TLRs result in the downstream 
activation of the inflammatory transcription factor nuclear factor- kappa B (NF-
κB) (Sellge and Kufer, 2015). 
 
There are 11 members of the TLR family in mammals and the targets of these 
molecules have been well characterised. TLR1 forms heterodimers with TLR2 to 
sense triacylated lipopeptides (Takeuchi et al., 2002), whilst TLR2 on its own 
can recognise peptidoglycans and lipoteichoic acid from Gram positive bacteria 
(Schwandner et al., 1999). TLR2 can also combine with TLR6, and the 
heterodimer recognises diacylated bacterial lipoproteins (Takeuchi et al., 2001). 
TLR3 is the cognate receptor for double stranded viral RNA that is common in 
retroviruses (Alexopoulou et al., 2001). TLR4 recognises lipopolysaccharide (LPS) 
from Gram-negative bacteria (Termeer et al., 2002). LPS is a key constituent of 
the cell wall of these bacteria. TLR5 is the receptor for flagellin which is a key 
protein expressed on bacterial flagella and is involved in the motility of these 
pathogens (Hayashi et al., 2001). TLRs 7 and 8 recognise single stranded viral 
RNA (Heil et al., 2004, Lund et al., 2004). Both viral and bacterial genomes 
express a higher percentage of CpG regions than mammalian DNA and TLR9 is 
responsible for recognising these motifs (Hemmi et al., 2000). The exact 
function/ligand of TLR10 is, as yet, unknown. TLR9 is highly expressed in 
lymphoid tissues such as the spleen, lymph node and tonsil (Chuang and 
Ulevitch, 2001). Mouse TLR11 has been shown to be able to recognise 
Toxoplasma gondii and uropathic Escherichia coli (Mathur et al., 2012). Although 
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humans have the TLR11 gene they do not seem to express the protein due to 
premature stop codons in the RNA sequence (Ishii et al., 2008).  
 
TLRs are able to recognise pathogenic signals that are present both within and 
outwith the cell but there are also further mechanisms to detect foreign 
invaders once they have infected host cells. One of the main contributors to the 
recognition of intracellular PAMPs are the Nucleotide Oligomerisation Domain 
(NOD)-like receptors (NLRs) (Fritz et al., 2006). There are two members of the 
NOD family, NOD-1 and NOD-2, and each has been shown to activate the NF-κB 
pathway. NOD-1 recognises D-glutamyl-meso- diaminopimelic acid (iE-DAP) and 
NOD-2 is activated by muramyl dipeptide (MDP). Activation of NODs has also 
been shown to induce apoptosis in host cells in a caspase-1 dependent manner 
(Warren et al., 2008). 
As well as PAMPs, additional activators of the innate immune system are 
endogenous damage-associated molecular patterns (DAMPs). These are 
molecules such as heat-shock proteins that are released by damaged or stressed 
cells and induce an immune response similar to that triggered by pathogens 
(Gallucci and Matzinger, 2001). 
 
1.1.1.1 Cells of the Immune Response 
All of the cells that make up blood, including red blood cells and the leukocytes 
of the immune system are derived from pluripotent haematopoietic stem cells 
(HSCs) and originate in the bone marrow (Janeway, 2001). Many of these cells 
also mature at this site.  
 
HSCs give rise to progenitor cells that are more restricted in the type of cells 
that they can produce. HSCs can give rise to either lymphoid or myeloid 
progenitor cells. Lymphoid progenitors are the precursor cells of lymphocytes 
and natural killer (NK) cells. The myeloid precursor cells give rise to 
granulocytes (neutrophils, eosinophils, basophils and monocytes), macrophages, 
mast cells and myeloid-dendritic cells (DC). This lineage is also responsible for 
the generation of red blood cells and platelets. Figure 1.1 provides an overview 
of this system. 
 





As previously mentioned, infiltration of leukocytes into tissue is one of the 
classical features of inflammation. Macrophages are key ‘sentinel’ cells that 
patrol tissues under physiological conditions in order to check for any invaders 
(Davies and Taylor, 2015). They are often the first immune cells to recognise a 
pathogen and react to it. The activation and accumulation of immune cells is 
initiated via the release of inflammatory mediators from ‘stressed’ cells. The 
aforementioned macrophages, local epithelial and endothelial cells, release 
molecules including histamine, leukotriennes, prostaglandins, cytokines and 
chemokines (Metz and Maurer, 2009). These molecules activate and induce the 
infiltration of more cells to aid in the response. 
 
Cells such as, in order of activation, tissue-resident macrophages, mast cells, 
neutrophils, monocytes/recruited macrophages, then adaptive immune cells like 
T-helper cells, cytotoxic T cells, and B cells all have roles to play in the immune 
response (Metz and Maurer, 2009). The activation and arrival of these cells tends 
to accelerate and amplify the recruitment of more cells by further secretion of 
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cytokines and chemokines. More details will be given on these cell types and 
molecules in subsequent sections. 
 
1.1.1.2 Mast Cells (MC) 
These are large, long-lived cells that tend to be found in connective tissue and 
at perivascular sites (Mekori and Metcalfe, 2000) and can enter cell cycle and 
proliferate in situ (Galli, Nakae and Tsai, 2005). Upon activation they release 
the pre-formed contents of granules, that are stored in the cell cytoplasm, 
containing histamine, lipid mediators and cytokines (Voehringer, 2013). The 
granules also contain tumour necrosis factor (TNF)-α which is a classic 
inflammatory cytokine that aids in the recruitment of more innate immune cells 
to potentiate the inflammatory response (Suto et al., 2006). 
 
MCs are key cells in the initiation of the inflammatory response mainly due to 
their anatomical proximity to the vasculature (Mekori and Metcalfe, 2000). This 
means that MC-derived vasoactive mediators are able to work quickly and 
effectively (van Nieuw Amerongen et al., 1998). It has been shown that upon 
exposure of endothelial cells to leukotriene B4, histamine or TNF-α (all 
contained within MC granules) P-selectin is expressed on these cells (Walsh et 
al., 1991, Kubes and Kanwar, 1994). The functional significance of these 
molecules will be discussed in more detail in section 1.1.1.3. 
 
It is worth noting that MCs are able to limit, and quell, the immune response 
(Voehringer, 2013). These cells can produce, and release, the anti-inflammatory 
cytokine interleukin (IL)-10 (Grimbaldeston et al., 2007). It has been shown that 
MC are involved in immune suppression of the skin upon exposure to ultraviolet 
(UV) light via this IL-10 production (Chacón-Salinas et al., 2011). On the other 
hand it has been shown that MC can aid the adaptive immune response against 
parasitic infections such as nematodes by expressing both major 
histocompatibility complex (MHC) I and II to present antigen to T cells 
(Suurmond et al., 2013). They have also been shown to promote immunoglobulin 
(Ig) E production from B cells (Hong et al., 2014). As a result of these findings it 
has become apparent that these cells play an important role in promoting 
inflammation (Egozi et al., 2003). These cells also secrete chemokines such as  
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CC chemokine ligand (CCL) 2 and, as a result, contribute to inflammatory cell 
accumulation at sites of activation (Selander et al., 2009).  
 
1.1.1.3 Neutrophils 
Neutrophils are the first leukocytes to be recruited to sites of damage or 
infection during the inflammatory response (Nourshargh and Alon, 2014). Under 
the influence of CXC chemokine ligand (CXCL8) these cells leave the blood 
vessels and extravasate into tissue. Neutrophils are easily identifiable cells by 
histological staining and are described as having a ‘multi-lobed’ nucleus. 
 
These cells are multi-faceted in function and have a varied armoury to attack 
pathogens (Scapini and Cassatella, 2014). Neutrophils have the ability to 
phagocytose foreign bodies in a process that sees the cell literally envelope the 
pathogen. Once this has occurred the organism is degraded in lysosomes within 
the cell. Neutrophils also have the ability to degranulate at sites of danger in a 
process that involves the cell releasing cytoplasmic granules that are toxic to the 
invading pathogen. One of the main granule-types contained in neutrophils are 
the azurophilic granules. These granules contain microbicidal factors such as 
Cathepsin G, neutrophil elastase, defensins and myeloperoxidase (Faurschou and 
Borregaard, 2003). 
 
Finally, the most recently discovered addition to the offensive arsenal of the 
neutrophil is the release of neutrophilic extracellular traps (NETs). These NETs 
are extracellular fibres made predominantly of DNA that can bind and kill 
pathogens (Brinkmann et al., 2004). The formation of NETs is regulated by 
neutrophil elastase and myeloperoxidase, two key mediators of inflammation in 
these cells (Papayannopoulos et al., 2010). It has been shown that NETs are able 
to bind and kill both bacterial and fungal pathogens (Urban et al., 2006) but may 
have a role in the pathology of the autoimmune condition systemic lupus 
erythematosus (Hakkim et al., 2010). 
 
Neutrophils are the most abundant white cell in the human body making up 
around 40-75% of white blood cells in the adult and pus is comprised of dead 
neutrophils (Janeway, 2001). Aberrant activation of neutrophils can cause 
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extensive tissue damage in pathologies such as rheumatoid arthritis and chronic 
obstructive pulmonary disease (COPD) (Bazzoni et al., 2010). It has also been 
shown that they can exist in pro-inflammatory and anti-inflammatory forms 
(Tsuda et al., 2004). 
 
During infection/inflammation, changes in the endothelial cells in the locality of 
the trauma give neutrophils the ability to roll slowly along the vessel walls then 
extravasate. The local tissue releases the chemokine CXCL8 in high amounts 
rapidly upon trauma (Roupé et al., 2010). CXCL8 is stored within the Weibel-
Palade bodies of endothelial cells for rapid release (Wolff et al., 1998). Rolling is 
achieved via the interactions of adhesion molecules like P- and E-selectin, on 
the lumenal surface of the endothelial cell, that bind to the sialyl-Lewis x 
carbohydrate on the neutrophil surface- this protein is expressed by many other 
leukocytes (Zou et al., 2005). Neutrophils also recognise L-selectin (Andrian et 
al., 1992). To complement, and enhance, this binding, the integrin LFA 
(lymphocyte function-associated antigen)-1 (made up of β:α chains- CD18:CD11a 
respectively) expressed on the neutrophil binds the adhesion molecule ICAM 
(inter-cellular adhesion molecule)-1 (CD54) on the endothelial cells. At this 
point, the cell arrests and this is achieved via interactions between CXCL8 and 
CXC chemokine receptor (CXCR) 1 (Nourshargh and Alon, 2014). The cell can 















Although the monocytes of the mouse are different to those of man, many 
parallels can be drawn regarding the roles that they play in both species. 
Monocytes are blood-borne macrophage precursors and make up between 10-15% 
of white cells in healthy humans. Human blood contains at least three sub-types 
of monocytes and all of them express the LPS co-receptor, CD14. Classical 
monocytes are CD14HICD16- and are inflammatory cells that tend to give rise to 
inflammatory macrophages upon arrival in tissue (Yona et al., 2013). The ‘non-
classical’- CD14LOCD16HI monocyte subtype tend to be less inflammatory and are 
thought to be precursors to more pro-fibrotic and anti-inflammatory 
macrophages (Yona et al., 2013). Finally the CD14HICD16LO, so-called 
intermediate monocyte subtype, has been shown to give rise to monocyte-
derived dendritic cells (Ziegler-Heitbrock et al., 2010). 
 
One of the main functions of monocytes is to aid in the generation and 
replenishment of macrophages and dendritic cells under both physiological and 
inflammatory conditions. Many of the monocytes in the body are stored within 
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the red pulp of the spleen where they can easily access the peripheral blood 
vasculature when needed (Swirski et al., 2009). Monocytes are recruited to sites 
of inflammation through their expression of a variety of chemokine receptors 
including CCR1, CCR2, CCR5, CCR6 and CX3CR1 (Anon., 2011a).  
 
1.1.1.5 Macrophages 
The name ‘macrophage’ comes from the ancient Greek words makros (large) and 
phagein (to eat). Ilya Ilyich Metchnikov originally discovered these cells in 1882 
when he was studying starfish larvae. One of the main functions of resting 
macrophages is that of sentinels (Davies et al., 2013). These cells patrol tissues 
and constantly sample their surroundings in order to ensure a rapid detection of 
pathogens (Sellge and Kufer, 2015). Pathogen destruction is achieved using a 
receptor-independent mechanism known as macropinocytosis (Janeway, 2001). 
There is also emerging evidence that, like neutrophils, macrophages may be able 
to use extracellular traps to neutralise pathogens (Boe et al., 2015). 
 
Upon recognition of a pathogen, macrophages change state and become 
activated (Sellge and Kufer, 2015). Macrophages have a variety of molecules on 
their surface to detect any non-self proteins. Other than the previously 
mentioned TLRs, macrophages also express the mannose-receptor that 
recognises carbohydrates found on bacteria and another LPS receptor known as 
CD14 as well as many others. The classical inflammatory, or M1, type 
macrophage is key at early stages of the immune response in providing an anti-
microbial defence against any pathogens that may have entered the host (Murray 
and Wynn, 2011). These cells secrete proteins such as IL-6, and TNFα (Daley et 
al., 2010) when activated and therefore potentiate the inflammatory response. 
 
Alternatively activated (Stein et al., 1992), or M2, macrophages have a 
fundamental role in promoting tissue repair and fibrosis. These cells are an anti-
inflammatory subset of the classic macrophage. They express a very different 
cell surface receptor profile, including the mannose receptor CD206 that is 
absent on M1 cells. Key mediators released from these cells are IL-10 and 
transforming growth factor-beta (TGFβ)-1, both potent anti-inflammatory 
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agents. Over-expression of TGFβ is thought to be a major cause of hypertrophic 
scars (van der Veer et al., 2009).  
 
The idea of alternative activation was first proposed by Siamon Gordon’s group 
and the M1/M2 paradigm was then formulated by Mantovani and colleagues 
(Mantovani et al., 2004). In a review published in 2014, Gordon sought to 
reassess this paradigm and suggested that this concept has been over-
interpreted and needs further details added to it (Martinez and Gordon, 2014). 
Another recent development in macrophage biology was the identification of the 
origin of tissue-resident macrophages which showed that they are 
developmentally distinct from their recruited counterparts (Schulz et al., 2012). 
 
1.1.1.6 Dendritic Cells (DC) 
Dendritic cells (DC) were originally discovered by Steinman and Cohn in mouse 
spleen and were named due to their appearance that distinguished them from 
macrophages (Steinman and Cohn, 1973). DCs are antigen-presenting cells (APCs) 
and are therefore key cells involved in the development of adaptive immune 
responses. Macrophages (Yamashita and Shevach, 1978), neutrophils (Potter and 
Harding, 2001), mast cells (Stelekati et al., 2009) and basophils (Sokol et al., 
2009) have all been shown to have varying degrees of antigen presentation 
capability. However DCs represent the most professional of the APCs (Svensson, 
Stockinger and Wick, 1997). Following phagocytosis the pathogen is processed 
and molecular derivatives are presented on the surface of the cell on MHC II 
molecules. These cells change activation state and migrate through the draining 
lymphatics to the local draining lymph node under the CCR7/CCL19 axis (more 
details of this in section 1.3.2), where they interact with T cells via MHCII 
molecules (Sugamura, Ishii and Weinberg, 2004, Schumann et al., 2010). The 
interaction between T cells and DCs will be described in more detail in section 
1.2.1.1. 
 
Many different types of DCs exist including plasmacytoid DCs, myeloid DCs, 
Langerhans cells (skin-resident DCs) (Schulz et al., 2012) and interstitial DCs 
(Shortman and Liu, 2002). As previously mentioned these cells are known for 
their stellate morphology but also for their high expression of markers such as 
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MHCII (key to antigen presentation) and CD11c (Nussenzweig et al., 1981, 
Nussenzweig and Steinman, 1982).  
 
1.1.1.7 Other Granulocytes 
Eosinophils are a key innate immune cell in host defence against parasitic 
infections. Upon activation, eosinophils have been shown to release key 
inflammatory mediators such as leukotrienes and prostaglandins (Bandeira-Melo 
et al., 2002, Luna-Gomes et al., 2011). Eosinophils make up around 5% of white 
blood cells and have been shown to play a role in airway inflammatory processes 
such as asthma (Stokes et al., 2015). 
 
Basophils store immune modulators in granules that are released upon 
activation. The modulators include histamine, which increases vascular 
permeability and activates local endothelial cells (van Nieuw Amerongen et al., 
1998). Activation of basophils induces the release of IL-4 which again implicates 
these cells in allergy (Min et al., 2004). Finally, it has been suggested that these 
‘bi-lobed’ nuclear granulocytes have the ability to act as antigen presenting cells 
for haptens (Otsuka et al., 2013) and during parasitic infection (Perrigoue et al., 
2009). 
 
1.1.1.8 Natural Killer Cells 
Natural Killer (NK) cells come from lymphoid progenitors and function in a very 
similar fashion to cytotoxic T cells, which will be mentioned in more detail 
below (section 1.1.2.1.2). These cells have an essential role in host defence 
against tumours and virus-infected cells (Campbell and Hasegawa, 2013, Zhang, 
Basher and Wu, 2015). These cells contain granules that are ‘cytolytic’ as they 
can cause the rupture of cell membranes. One of the ways that the adaptive, 
and innate, immune systems interact is through a process known as antibody-
dependent cell-mediated cytotoxicity (ADCC). This antibody-mediated process 
results in the FC portion of IgG binding to the FCγRIII receptor on the NK cell. 
Following this binding the NK cell releases the granules mentioned above and 
induces the destruction of the target cell. 
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All of the cells, mentioned so far, combine to defend the host from many 
pathogens. One drawback of the innate immune system is that, although very 
effective, it does not have the ability to form immunological memory. The other 
arm of the immune system, the adaptive immune system, can augment the 
response of the innate immune system. This network of cells has a more antigen-
specific function. 
 
1.1.2 Cells of the Adaptive Immune System 
The cells of the innate immune system are not antigen specific and whilst the 
innate arm of the immune system probably does not have the ability to form 
‘memory’, the adaptive immune system does. It is worth noting, however, that 
some evidence has emerged of ‘innate memory’ formation (Saeed et al., 2014). 
The adaptive immune system is made up of cells from the lymphoid-arm of the 
haematopoietic system that gives rise to T and B cells. T cells develop in the 
bone marrow but then migrate to the thymus (hence T cell) to undergo further 
development, and stringent selection, to ensure that these cells are not 
‘autoreactive’ once they are released into circulation.  
 
1.1.2.1 T Cells 
1.1.2.1.1 CD4+		T	Cells	
 
A variety of T cells exist and each performs differing functions that are key to 
efficient immune responses. Naïve T lymphocytes, or T cells, circulate through 
the lymph nodes and tissues of the body and ‘look’ for antigens that are 
presented by APCs. Antigens, presented by APCs on the MHCII complex binds to 
the T cell receptor (TCR) on CD4+ T cells. If the antigen expressed on this 
complex is the cognate antigen for the TCR the first signal required for T cell 
activation is satisfied. This is called the recognition stage. It is now known that 
for complete activation of T cells multiple signals are required. Signal two, 
known as verification, comes from the so-called co-stimulatory molecules CD80 
and CD86 present on the APC binding to CD28 on the T cell (Caux et al., 1994). 
This binding event induces the release of IL-2 from the T cell itself to work in an 
   
 
29 
autocrine fashion to promote cell survival and clonal expansion (Ballesteros-Tato 
et al., 2012).  
 
CD4+ T cells, also known as T helper (TH) cells, have a major role in shaping the 
antibody-driven response brought about by B cells. Depending on the conditions 
in which antigen is presented TH cells can take different forms. Five main 
subsets exist known as TH1, TH2 (Tada et al., 1978), TH17 (Bettelli et al., 2006) 
and the more recently described TH9 (Dardalhon et al., 2008) and TH22 (Eyerich 
et al., 2009). The cell subsets are distinguished by the cytokines that they 
release upon activation. TH1 cells secrete some of the classical inflammatory 
cytokines such as interferon (IFN)-γ, TNF-α, IL-1, IL-6 and IL-12. TH2 cells are 
often associated with more allergic-type contexts and release many cytokines 
that are known to limit inflammation such as IL-4, IL-5 and IL-13. TH17 cells are, 
like TH1 cells, pro-inflammatory in nature. The defining cytokine released by this 
cell-type is IL-17A/F (hence the name) as well as IL-6, IL-22 and TNF-α. TH9 cells 
are named due to their production of IL-9 (Dardalhon et al., 2008). These cells 
play key roles in the defence against intestinal worms (Licona-Limón et al., 
2013) and allergy (Chang et al., 2010) and also play key roles in autoimmunity 
(Murugaiyan et al., 2012). TH22 cells are a newly described CD4+ T cell subset 
which were named, like TH17 and TH9 cells, in response to the main cytokine 
they produce, IL-22 (Eyerich et al., 2009). These cells have been shown to play a 
role in the skin in aiding the process of wound healing (Eyerich et al., 2009) and 
in psoriasis (Kagami et al., 2010, Luan et al., 2014). It has been suggested that 
skin-resident Langerhans cells play a major role in the induction of the TH22 cell 
type (Fujita et al., 2009). 
 
CD4+ T cells can take another form too. Unlike the helper T cells mentioned 
above which tend to be involved in driving immune responses, regulatory T cells 
(TREGS) are key immune suppressor cells. They play key roles in the maintenance 
of peripheral immunological tolerance and preventing autoimmunity (Sakaguchi 
et al., 2006). Immunological tolerance involves the cellular recognition of ‘self’ 
and the disabling of cells that may be autoreactive through anergy or apoptotic 
induction.  
 





The other main subset of T cells is the CD8+ T cell (cytotoxic T cell). These 
lymphocytes recognise their cognate antigen expressed on MHCI and undergo 
activation. MHCI is expressed by all nucleated cells and is the main way by which 
antigens from pathogens that have infected a cell are presented. Under normal 
conditions self-peptides are constantly expressed on MHCI molecules on the cell 
surface. If a cell becomes infected it then starts to express antigenic peptides on 
its surface and this in turn alerts cytotoxic T cells to a possible problem. Upon 
infection many pathogens and tumour cells also stop the process of MHCI 
expression by host cells in an attempt to evade the immune system. Effector 
cytotoxic T cells or NK cells usually kill any cell expressing no MHCI molecules. 
Upon activation these cells release cytolytic toxins that form holes in the 
membranes of target cells and result in its destruction. 
 
1.1.2.2 B Cells 
These cells are so called because in birds they are found in the Bursa of 
Fabricius. The main role of B cells is to produce antibodies. At around 150kDa, 
antibodies are fairly large proteins that carry out many important functions in 
immune defence. These include neutralising toxins, opsonising pathogens, 
preventing the entry of pathogens into host cells and activating the complement 
system. 
 
As mentioned in the previous section, T helper cells interact with B cells to help 
activate them. B cells can express MHCII molecules and present antigen to T 
cells in the lymph node. Given the interaction between the MHCII-presented 
peptide on the B cell, the correct TcR on the T cell and appropriate 
costimulation, the B cell can become activated and clonally expand. The result 
of this is a pool of specific antibody-producing B cells that can aid in the immune 
response. Upon the resolution of the immune response a pool of memory B cells 
and plasma cells (the name given to an antibody-producing B cell) are retained 
to quickly respond to reinfection with the same pathogen. 
 




There are two forms of chemically induced cell movement, chemokinesis and 
chemotaxis. Chemokinesis is random and undirected movement whereas 
chemotaxis is directed movement towards a chemical signal. Chemokines are 
small specialised cytokines that initiate chemotaxis in target cells. Their name 
derives from the amalgamation of the words chemotactic cytokines (Zlotnik and 
Yoshie, 2000). The chemokine family is made up of small (8-10 kDa) homologous 
proteins that are highly conserved throughout vertebrate evolution (Zlotnik and 
Yoshie, 2000). Chemokine nomenclature was historically confusing and poorly 
regulated. As a result of this, a standardised nomenclature was devised based on 




Four structural variants are clear within the family of chemokine ligands, these 
are depicted in Table 1.1. The determining factor is the presence, and relative 
position, of highly conserved cysteine (C) residues expressed at the amino 
terminus of the peptide (Zlotnik and Yoshie, 2000). These conserved cysteines 
form disulphide bonds and so influence the structure of chemokines (these 
interactions are depicted in figure 1.3). Chemokines are then numbered in order 
of when the sequence was added to the gene databases. There are two major, 
and two minor, chemokine subfamilies. 
 
CC C C CCL1-28 
CXC C C 
C C 
















1.2.1 CC Chemokines 
The first, and largest group is known as the beta (β), or CC, chemokine 
subfamily as two of the key cysteine residues sit adjacent to one another at the 
amino terminus of the sequence. There are twenty-eight ligands in this group 
(CCL1-CCL28) and these chemokines tend to be chemoattractive to monocytes, 
lymphocytes, and some granulocytes (Alam et al., 1994, Lee et al., 2000, Rot 
and Andrian, 2004).  
CCL3, previously known as macrophage inflammatory protein (MIP) 1-α, is a key 
recruiter of cells such as monocytes, macrophages, dendritic cells and both CD4+ 
   
 
33 
and CD8+ T cells during the acute immune response. It has been shown that 
neutrophils can release this chemokine in order to recruit these effector cells 
(Charmoy et al., 2010). CCL2, CCL7, CCL8 and CCL13 have roles in the 
recruitment of monocytes to inflammatory sites (Shi and Pamer, 2011). Whereas 
CCL20 has been shown to recruit TH17 cells.   
 
1.2.2 CXC Chemokines 
The second major group is the alpha (α), or CXC, chemokines that have the same 
cysteine groups at the N-terminal but with the addition of an intervening amino 
acid. There are seventeen ligands in this group (CXCL1-CXCL17). These 
chemokines are functionally divided into ELR positive, and ELR negative, groups 
depending on the presence, or absence, of a glutamic acid (E)- leucine (L)- 
arginine (R) motif that lies before the first cysteine of the CXC motif.  ELR 
positive chemokines in this group act on neutrophils specifically and are 
angiogenic (Strieter et al., 1995). CXC chemokines without the ELR motif have a 
more diverse target cell repertoire and tend to be more angiostatic (Zlotnik and 
Yoshie, 2000). Of the CXC chemokines, CXCL8 is the most potent attractor of 
neutrophils. Pre-formed molecules of this chemokine are stored within the 
Weibel-Palade bodies of endothelial cells and released upon their activation 
(Wolff et al., 1998). During the inflammatory response this chemokine is 
released in large quantities to rapidly recruit neutrophils to the site of trauma. 
Mice do not have this gene but do have CXCL1 and CXCL2 which both bind to the 
receptor CXCR2 for neutrophil recruitment (Hol, Wilhelmsen and Haraldsen, 
2010). 
 
1.2.3 XC Chemokines 
The penultimate group is the XC or gamma (γ) chemokines. This group is unique 
as its members only have two of the four conserved C residues. The 
lymphotactins (α and β) are the only two proteins that fit into this subdivision as 
XCL1 (lymphotactin α) and XCL2 (lymphotactin β). Originally these chemokines 
were associated with the TH1 response (Dorner et al., 2002). Activated CD8+ T 
cells in the thymus and peripheral blood have been shown to express XCL 
(Kennedy et al 1995). It has also recently been suggested that the XCL1 released 
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from these CD8+ cells may inhibit HIV-1 infection (Guzzo et al., 2013). One of the 
key roles of the lymphotactins is in DC biology (Dorner et al., 2009). In the 
thymus XCL1 mediates the accumulation of thymic DCs which, interact with and 
are key to, the development of natural regulatory T cells (Lei et al., 2011).  
 
1.2.4 CX3C Chemokine 
The fourth, and final, structural form that makes-up the family is the CXXXC 
(CX3C) chemokine. This is a single entity, rather than a group, and the most 
recently discovered (Bazan et al., 1997). CX3CL1, or fractalkine, is an interesting 
chemokine as it can exist as both a soluble ligand and as a membrane-anchored 
ligand (Bazan et al., 1997). The anchor is a mucin stalk and it is cleaved by TNF-
α converting enzyme (TACE) or a disintegrin and metalloproteinase (ADAM)17 in 
order to release the soluble chemokine ligand (Garton et al., 2001). Other than 
CX3CL1, only CXCL16 is thought to exist in this form (Matloubian et al., 2000). 
CX3CL1 is thought to play a role in the brain and has been shown to be expressed 
in the hippocampus and may play a role in glutamate signalling (Sheridan et al., 
2014).  
 
Chemokines can be characterised by functional as well as by the structural 
divisions mentioned above. These proteins can be either constitutive or 
inflammatory depending on the context with which they are most often 
expressed and function. There are also some ‘dual function’ chemokines that 
can play constitutive and inflammatory roles. 
 
1.2.4.1 Inflammatory Chemokines 
Inflammatory chemokines are expressed in such abundance after tissue damage 
that they were discovered and characterised early in the history of chemokines. 
These chemokines are inducible upon stimulation of cells by inflammatory 
signals. Interestingly, the genes for the inflammatory chemokines in the CC 
family are mainly clustered on chromosome 17 in the human (Naruse et al., 
1996, Nomiyama et al., 1999) whilst the counterpart CXC chemokine genes are 
clustered on chromosome 4 (O'Donovan, Galvin and Morgan, 1999). It is thought 
that this has been caused by gene duplication in response to specific pathogen 
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pressures on different organisms. Inflammatory chemokines can be expressed 
virtually anywhere in the body, in fact CCL2 can be expressed by all nucleated 
cells and acts as a warning signal to attract cells to sites of damage/trauma. 
Unlike their homeostatic relatives, inflammatory chemokines are said to be 
promiscuous and their receptors unfaithful (Bachelerie et al., 2014). This 
phenomenon seems to act as an immunological ‘skeleton key’ allowing 
inflammatory cells into almost any tissue in order to protect the host. That is to 
say that it would seem the inflammatory chemokine response promotes the 
recruitment of an array of effector cells in order to quickly resolve local trauma. 
This may seem like a very blunt and non-specific response but the field is now 
moving towards investigating if there is, in fact, more subtlety into how this 
system functions (Zweemer et al., 2014). 
 
1.2.4.2 Homeostatic Chemokines 
These proteins are involved in basal leukocyte trafficking and tend to have a 
much more specific ligand-receptor relationship than their inflammatory 
counterparts. This group of chemokines can be extremely tissue-specific. CCL25 
is expressed in the small intestine and so, under homeostatic conditions, CCR9 
expression is required for trafficking to this location. This relationship is also key 
to thymic migration. Other constitutive chemokines include CCL19, CCL21, 
CCL27, CXCL12 and CXCL13. The roles of some of these chemokines will be 
discussed in more detail below. 
 
1.3 Chemokine Receptors 
1.3.1 Receptor Structure 
Chemokine receptors are seven-transmembrane spanning proteins that are 
between 340 and 370 amino acids in length and are part of the Rhodopsin family 
of G-protein coupled receptors (GPCRs). Chemokine receptors have highly 
conserved structural and functional properties although they have moderately 
variable amino acid sequences (Clark-Lewis et al., 1995). One of the key 
examples of this is known as the DRYLAIV or DRY motif. All classical chemokine 
receptors contain the DRY motif in the second intracellular loop. DRYLAIV- D- 
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Aspartate, R- Arginine, Y- Tyrosine, L- Leucine, A- Alanine, I- Isoleucine, V- 
Valine. This motif seems to be indispensable for the ability to signal, as without 
this motif a calcium flux is not induced in the cell following ligand binding 
(Graham et al., 2012). The DRY motif is the main site for G-protein coupling in 
the chemokine receptors.  
 
These GPCRs are made up of a flexible N-terminus that is on the extracellular 
side of the cell membrane. This exposed section of the protein is responsible for 
initial ligand binding. It has been shown that chemokines bind their cognate 
receptor in a two-step mechanism (Monteclaro and Charo, 1996, Crump et al., 
1997). Firstly, the ligand binds the extracellular N-terminus of the receptor. This 
is a high-affinity bond that arrests the chemokine in position allowing the non-
bound portion of the chemokine to start making low-affinity bonds with the 
transmembrane spanning regions of the receptor. This results in receptor 
activation and down-stream signalling events. The C-terminus of chemokine 
receptors also contains many serine and threonine residues that can act as 
phosphorylation sites on the receptor. A two-dimensional cartoon depiction of a 
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Working out the three-dimensional structures of the chemokine receptors has 
proved technically difficult, however, in recent years the structure of CXCR4, 
CXCR1 and CCR5 have been elucidated. These studies helped confirm many of 
the hypothesised structural characteristics of chemokine receptors. The 
structures of CXCR4 and CCR5 were revealed using X-ray crystallography and, in 
the case of the former, confirmed the ability of the receptor to homodimerise 
(WU et al 2010). The structure of CCR5 was elucidated in association with the 
small molecule inhibitor of the receptor Maraviroc (Tan et al 2013). NMR 
spectroscopy was utilised to characterise the structure of CXCR1 (PARK et al 
2012). The studies mentioned here have been invaluable in shedding light on the 
nature of chemokine receptor interactions with ligands and other receptors. 
 
1.3.2 CC Chemokine Receptors 
As for the ligands, four receptor subgroups have been defined (Bachelerie et al., 
2014). The first of the chemokine receptor groups are the CC receptors. These 
receptors are responsible for binding CC chemokine ligands. There are ten 
identified receptors in this group (CCR1-10). Again chemokine receptors are 
numbered in chronological order of discovery and lower numbers tend to be 
inflammatory receptors. CCRs 1-3 and CCR5 are considered to be the classical 
inflammatory CC chemokine receptors. Like their CXC counterparts, these 
receptors each have many ligands. CCR2 is expressed on a subset of 
inflammatory monocytes and plays an important role in their recruitment into 
tissue. However, in the absence of CCR2 monocyte recruitment still takes place 
thanks to the receptors CCR1 and CCR5 which seem to act as substitutes in this 
case (Dagkalis et al., 2009). This is an example of the marked redundancy that 
appears to be present in the inflammatory chemokine system (Rot and Andrian, 
2004).  
 
CCR7 is a key homeostatic CC chemokine receptor. It has been shown that in 
mice lacking this receptor there is a catastrophic breakdown in organisation of 
cells in secondary lymphoid organs such as the lymph nodes and the spleen 
(Förster et al., 1999). CCR7 appears to play a key role in directed cellular 
movement during many key immunological processes. These include the exit of 
dendritic cells and T cells from the peripheral tissues to the lymph nodes, entry 
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of T cells to the lymph nodes via high endothelial venules (HEV) and subsequent 
organisation of these cells within these tissues. CCR7 has only two known 
ligands, CCL19 and CCL21 (Vander Lugt et al., 2013). A mouse strain with a 
mutation known as paucity of lymph node T cell (plt) has functional CCR7 but 
lacks expression of both of the receptors ligands in secondary lymphoid organs 
(Nakano et al., 1998). Naïve T cells and activated dendritic cells in these mice 
have an impaired ability to traffic to the lymph nodes. As a result of this 
mutation these mice show delayed but actually enhanced adaptive immune 
responses (Mori et al., 2001). In fact it was shown that plt mice express IL-2, a 
key cytokine for T cell proliferation, for around 8 weeks compared to around 20 
days in WT mice. The relationships between the CC chemokine receptors and 










1.3.3 CXC Chemokine Receptors  
Six classical CXC chemokine receptors exist (CXCR1-6). These receptors are 
mainly found on neutrophils and lymphocytes. Just like CC chemokine receptors, 
these receptors can be functionally characterised as either inflammatory 
(CXCR1-3) or homeostatic (CXCR4-6). CXCR1 and 2 have well defined roles in the 
migration of neutrophils during inflammation. The ligand CXCL8 is rapidly and 
abundantly released at sites of trauma in humans. Mice lack CXCL8 but appear to 
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use the CXCR2 receptor, along with CXCL1 and CXCL2, to coordinate movement 
of these key inflammatory cells during inflammation.  
 
CXCR3 interacts with the ligands CXCL9, 10 and 11 and is associated with TH1 
and NK cell recruitment. Two variants of this receptor exist, known as CXCR3-A 
and CXCR3-B. The latter binds all of the ligands previously mentioned with the 
addition of CXCL4 (Struyf et al., 2011). CXCR3 has been shown to be important 
for CD8 T cell responses and subsequent memory cell formation whilst CXCR3 is 
expressed along with CCR5 and is a key mediator of the TH1 cell response. CXCR3 
has been implicated in many inflammatory diseases such as type-1 diabetes 
mellitus (Frigerio et al., 2002) and rheumatoid arthritis (Laragione et al., 2011). 
 
CXCR4 is a chemokine receptor of utmost importance. This is illustrated best by 
the fact that mice lacking CXCR4 die perinatally (Zou et al., 1998). Along with 
its cognate ligand, CXCL12, this receptor is in involved in many key processes. In 
fact, by functionally deleting this receptor, abnormalities in the development of 
the immune system, the reproductive system, the kidneys, the lungs and the 
brain result. The interaction between CXCL12 and CXCR4 has been shown to be 
essential in the retention of haematopoietic stem cells in the bone marrow niche 
(Zou et al., 1998). Intravenous injection of AMD3100, a small-molecule inhibitor 
of CXCR4, results in the mobilisation of progenitors from the bone marrow and 
into the peripheral blood (Liles et al., 2003). This has brought about a significant 
advance in the field of stem cell transplantation. CXCR4 is also a co-receptor for 
the HIV-1 virus (Feng et al., 2011) and it has been shown that plerixafor (the 
trade name of AMD3100) can block viral entry of HIV-1 into host cells (Donzella 
et al., 1998).  
 
CXCR5, like CCR7, plays a key role in the organisation of secondary lymphoid 
tissues as well as migration of leukocytes within these structures (Breitfeld et 
al., 2000). CXCL13 is the only identified ligand for CXCR5 and is produced by 
follicular dendritic cells of the B cell zone to attract B cells (Yu et al., 2002). B 
cells that reside in the follicles of secondary lymphoid structures express CXCR5 
whilst T helper cells upregulate CXCR5 in order to interact with B cells to 
initiate the humoural immune response. CXCR6 also has only one known ligand, 
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CXCL16. Current literature suggests that this axis may have a minor role in both 
cancer development and HIV-entry (Paust et al., 2010). 
 
1.3.4 XC and CX3CR Chemokine Receptors 
Only one receptor has been discovered for the gamma chemokines, this is known 
as the lymphotactin receptor (XCR1) (Zlotnik and Yoshie, 2000). Like many 
chemokine receptors, XCR1 has been associated with rheumatoid arthritis. T 
cells within the synovium have been shown to express XCL1 and it is thought that 
this initiates the infiltration of XCR1+ mononuclear cells (Blaschke et al., 2003). 
It is also suggested that a population of dendritic cells express this receptor 
(Dorner et al., 2009). 
 
The final receptor to be mentioned is the fractalkine receptor or CX3CR1. As this 
is the cognate receptor for the membrane-anchored chemokine CX3CL1 it can 
function as an adhesion molecule (Haskell, Cleary and Charo, 2000). CX3CR1 has 
been found on NK cells, T cells, monocytes and microglial cells of the central 
nervous system. In the case of monocytes this molecule appears to play an 
important role in cell survival (Landsman et al., 2009). The CX3CL1/R1 axis is 
important for the engulfment of apoptotic cells by macrophages (Truman et al., 
2008). 
 
1.3.5 Chemokine Receptor Signalling 
Chemokine receptor signalling is a complex process that begins with the binding 
of a ligand to its cognate receptor. As already mentioned, chemokine receptors 
are heptahelical molecules that bind heterotrimeric G proteins that are 
associated with guanosine diphosphate (GDP) and are inactive as a result. Upon 
ligand binding there is a conformational change in the transmembrane domain of 
the receptor that allows binding of Gα proteins. This allows for the exchange of 
bound GDP for guanosine triphosphate (GTP) at the Gα subunit. This then allows 
the Gα/GTP complex to dissociate from the Gβγ subunits and leads to 
downstream signal transduction and a calcium ion flux (Wu, LaRosa and Simon, 
1993, Oldham and Hamm, 2008). The receptor is typically internalised and 
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desensitised before being recycled to the cell surface free of ligand. A simplified 




Ligand binding of conventional chemokine receptors can induce a multitude of 
downstream depending on the receptor, the ligand and the context in which the 
ligation occurs (Rot and Andrian, 2004). Upon ligand binding many downstream 
effector proteins are activated including members of the Janus kinase/signal 
tranducer and activation of transcription (JAK/STAT) family (Soriano et al., 
2003). The Gα subunit activates Rho family GTPases such as Rac1 to induce the 
formation of lamellipodia formation at the leading edge of the cell and 
subsequent movement (Gu et al., 2003). 
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1.3.5.1 Chemokines and Chemokine Receptors in Disease 
1.3.5.1.1 Cancer	
 
Along with malignant cells there are also many leukocytes at tumour sites. 
Cancers are known to move to secondary sites in a process known as metastasis 
and they also require a blood supply and so promote angiogenesis. The 
chemokine network is essential to all three of these aforementioned features of 
cancer biology (Balkwill, 2012). One of the main leukocytes found at cancer-sites 
are known as tumour associated macrophages (TAMs) and the levels of CCL2 and 
CCL5 correlate with the number of these cells present in the tumour (Mantovani 
et al., 2008). 
 
The GTPase Ras has been shown to be mutated in many cancers. Oncogenic Ras 
is a constitutively active form of the enzyme which can induce the production of 
CXCL8 and CXCL1 both of which have been shown to recruit neutrophils and 
increase tumour-associated angiogenesis (Sparmann and Bar-Sagi, 2004).  
 
The process of metastasis is a feature of malignant cancers and is key to disease 
progression (Joyce and Pollard, 2009). The chemokine receptor CCR7 and CXCR4 
have been shown to play a role in this process (Müller et al., 2001, Mashino et 
al., 2002, Günther et al., 2005). CCR7, as discussed in 1.3.2, is the key receptor 
involved in the trafficking of cells to lymph nodes (Gosling et al., 2000). This 
receptor is upregulated in many cancers, including colorectal and gastric 
carcinomas, which metastasise to the lymph node via the CCL19/CCL21/CCR7 
axis (Mashino et al., 2002, Günther et al., 2005). 
 
Tumours are sites of hypoxia and, in many cancers including breast cancer, this 
results in an increase in the expression of CXCR4. This results in metastatic 
migration towards CXCL12-expressing sites like the liver, the lung and the lymph 
nodes (Müller et al., 2001). 
1.3.5.1.2 Human	Immunodeficiency	Virus	(HIV)	
 
The retrovirus HIV was discovered in 1983 and is known to target and destroy the 
immune system of the host (Gallo and Montagnier, 2003). HIV infection leads to 
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the development of Acquired Immunodeficiency Syndrome (AIDS) (Gallo and 
Montagnier, 2003, Costin, 2007). The molecule glycoprotein (gp) 120 on the viral 
envelope of the virus binds to CD4 and so helps it infect CD4+ T cells (Dalgleish 
et al., 1984). This binding event leads to a conformational change in the viral 
envelope, which exposes chemokine receptor binding regions. It was also shown 
that the chemokine receptors CCR5 and CXCR4 facilitate the entry of the virus to 
the host cell (Deng et al., 1996, Dragic et al., 1996).  
 
M-tropic HIV, the initial stage of infection, uses CCR5 as a co-receptor for cell 
entry to target monocytes, macrophages and CCR5+ TH1 cells. This stage is 
followed by the T-tropic stage of the infection which uses CXCR4 as a co-
receptor to infect lymphocytes. This results in a vast reduction in the CD4+ T cell 
count of the host and leads to great susceptibility to opportunistic infections and 
the onset of AIDS. CCR5 ligands have been shown to reduce the ability of the 
virus to infect cells in vitro (Cocchi et al., 1995, Nibbs et al., 1999). To add to 
this, patients with high levels of CCL5 have been shown to be refractory to the 
progression of HIV infection to AIDS (Clerici et al., 1996).  
 
Around 1% of people of northern European descent have no functional CCR5 
receptor activity (Huang et al., 1996). People who are homozygous null for CCR5 
have what is known as the CCR5delta32 (CCR5Δ32) mutation. This results in a 32 
base pair deletion in the second extracellular loop of the receptor and renders 
the receptor non-functional. This deletion appears to be advantageous to the 
host in many pathologies. For example, patients who are CCR5Δ32 homozygous 
are highly resistant to infection by the human immunodeficiency virus (HIV)-1 
(Huang et al., 1996). In fact it was this property of the mutation that led to its 
discovery (Huang et al., 1996). It has also been shown that if a Δ32 heterozygous 
person does become HIV-positive they take longer to develop acquired 
immunodefiency syndrome (AIDS) (Huang et al., 1996). 
 
This mutation has also been shown to be protective for graft rejection and many 
inflammatory disorders (Zapico et al., 2000, Pokorny et al., 2005, Bettencourt et 
al., 2014). In many ways CCR5Δ32-positive individuals are less prone to 
inflammatory disease. There is, however, one case in which this 32 base pair 
deletion is non-protective. Specifically if a CCR5Δ32-positive host becomes 
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infected with West Nile virus they are at greater risk of developing lethal 
encepalopathy than a patient with wild-type CCR5 (Glass et al., 2006).  
 
1.4 Atypical Chemokine Receptors 
The receptors mentioned so far are conventional receptors as they convey 
intracellular messages downstream of ligand binding and induce cell movement. 
However another receptor type exists. Atypical chemokine receptors tend to be 
structurally homologous but fail to induce a typical signalling response 
downstream of chemokine binding (Graham et al., 2012). For this reason, they 
are sometimes known as ‘silent’ or scavenging receptors- both of these aliases 
giving a good description of some of the function of these molecules.  
 
They are known as silent as they fail to induce the canonical response from the 
target cell after receptor ligation. The chemokine ligand is internalised by the 
receptor and efficiently degraded, hence the scavenger synonym. Currently, 
there are four members of this receptor group. These are the Duffy antigen 
receptor for chemokines (DARC), CCX-CKR, CXCR7, and D6, which will be the 
focus of this work. In 2014 the atypical chemokine receptors were given a 
standardised nomenclature in much the same way as the classical chemokines 
and receptors. They are now named ACKR (atypical chemokine receptor) and 
numbered in order of their discovery. As a result DARC is ACKR1, D6 is ACKR2, 
CXCR7 is ACKR3 and CCX-CKR is now ACKR4 (Bachelerie et al., 2014). 
 
These chemokine receptors express variations of the DRY motif mentioned 
earlier. For example, ACKR2 has the amino acid sequence DKYLEIV in the second 
intracellular loop of its structure (Nibbs, Wylie, Pragnell, et al., 1997, Nibbs, 
Wylie, Yang, et al., 1997). Different atypical receptors express variations of the 
DRYLAIV motif but the variation of these amino acids is key to the inability of 
these receptors to mount classical signalling responses. These motif variations 
are shown in figure 1.7. Notably, studies have been carried out on ACKR2 in 
which the altered DKY motif was changed to DRYLAIV in an attempt to restore 
signals. This alteration imparted signalling activity (Smit, Lira and Leurs, 2010). 
 







The first atypical chemokine receptor to be discovered was the Duffy antigen 
receptor for chemokines, now known as ACKR1. Like all chemokine receptors 
this is a seven-transmembrane spanning receptor but unlike the canonical 
receptors it lacks the DRYLAIV motif and fails to induce a calcium flux upon 
ligand binding (Horuk et al., 1996). The primary amino acid sequence of ACKR1 
is unlike any other chemokine receptor and in fact is almost unrecognisable as a 
member of this family in this respect (Graham et al., 2012). Originally this 
molecule was found on red blood cells and is the most promiscuous of all 
chemokine receptors as it can bind both CC and CXC inflammatory chemokines 
(Novitzky-Basso and Rot, 2012). ACKR1 is the protein determinant in the Duffy 
antigen blood group system (Hadley and Peiper, 1997). 
 
It is also a receptor for the human malarial parasites Plasmodium vivax and 
Plasmodium knowlesi (Horuk et al., 1993). Individuals with an ACKR1 
polymorphism in the binding site for the erythroid transcription factor, GATA-1, 
have been shown to express no ACKR1 on their erythrocytes (Tournamille et al., 
1995). These same individuals with what is known as a Duffy-null polymorphism, 
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are highly resistant to malarial infection (Tournamille et al., 1995). It is worth 
noting that these individuals only lack erythrocyte expression but retain 
expression on blood endothelial cells (BECs). As a chemokine receptor, this 
molecule has been described as having two main roles. The first is in chemokine 
ligand transcytosis. In in vitro studies using polarized cells that had been 
transfected with ACKR1 it was shown that ligand could be internalised by the 
receptor on one face of the cell and presented, intact, on the opposite side 
(Middleton et al., 1997, 2002). This gives ACKR1 the ability to act as a ligand 
presentation receptor to leukocytes for example. It is important to note that 
although ACKR1 internalises chemokines it does not degrade them and so is not 
considered to be a scavenging receptor like some of the other atypical 
chemokine receptors (Middleton et al., 1997, 2002, Pruenster et al., 2009). 
ACKR1 has also been reported to be expressed by endothelial cells, especially 
blood endothelial cells, and in the cerebellum (Horuk et al., 1996). Due to the 
nature of the CXC chemokines that ACKR1 has specificity for it is suggested that 
it has an anti-angiogenic ability. An in vivo study using ACKR1 transgenic mice 
that over-expressed the receptor in a melanoma model showed a reduced 
angiogenic capability when compared to WT mice (Horton et al., 2007). 
 
The other function that ACKR1 on erythrocytes is thought to serve is that of a 
chemokine buffer in the blood. As inflammatory chemokines are released into 
the bloodstream they are thought to become associated with ACKR1 on the 
surface of erythrocytes. These bound chemokines can then be released as the 
inflammation subsides and so this help prevent large fluctuations in blood-
chemokine levels (Novitzky-Basso and Rot, 2012). ACKR1-null mice take longer to 
clear peripherally administered chemokines compared to WT mice. It was also 
shown that, in a model of LPS-driven peripheral inflammation, null mice had an 
increased leukocyte infiltrate into the liver and the lungs (Lee et al., 2006).   
 
One of the most striking human phenomena associated with ACKR1 is that of 
benign ethnic neutropenia. It has been shown that individuals of European 
descent tend to have a higher peripheral blood leukocyte (PBL) count than those 
of an African background (Kulkarni et al., 2009). It has been shown, by genome-
wide association studies, that these findings correlate very strongly with the 
Duffy-null polymorphism (Kulkarni et al., 2009).  




The atypical chemokine receptor ACKR3 was originally thought to be a member 
of the classical chemokine receptor group and was in fact designated as CXCR7 
until quite recently. The receptor was originally known as RDC1 and was cloned 
and characterised from mouse genomic DNA and the murine receptor has 90% 
amino acid similarity to the human receptor (Heesen et al., 1998). It was ‘de-
orphanised’ when the ligands CXCL11 and CXCL12 were shown to bind the 
receptor (Heesen et al., 1998). It is worth noting that CXCL12 binds ACKR3 with 
higher affinity than it binds CXCR4.  
 
ACKR3 expresses a two amino acid variation of the DRY motif and has DRYLSIT in 
its place. The functional result of this is, of course, that ligand binding by ACKR3 
does not induce a calcium flux in the cell. Chemokine receptors mainly mediate 
their signal via G-proteins upon ligand binding.  ACKR3, however, is a beta-
arrestin biased chemokine receptor (Rajagopal et al., 2010). Unlike ACKR1, 
ACKR3 has been shown to be a chemokine scavenging receptor capable of 
scavenging and therefore regulating the availability of both of its ligands (Wang 
et al., 2012). 
 
ACKR3 is not widely expressed. It has been shown on marginal zone B cells (Wang 
et al., 2012), a subset of monocytes (Infantino, Moepps and Thelen, 2006) BECs 
of the CNS (Cruz-Orengo, Holman, et al., 2011), cells of the foetal mouse liver, 
and lymphatic endothelial cells (LECs) in normal tonsil and kidneys during acute 
graft rejection. The expression of ACKR3 in the adult is very low. However it has 
been found in many tumour environments. ACKR3 is expressed both in the 
neovasculature of tumours and can be expressed by the tumour itself (Miao et 
al., 2007, Wang et al., 2008). 
 
Mice that lack ACKR3 tend to die perinatally (Sierro et al., 2007). The cause of 
this is thought to be largely due to defective heart development involving 
thickened semilunar valves and ventricular septal defects. These mice show 
normal haematopoiesis. The expression of ACKR3 in the microvessels of the 
developing heart was key to the cardiac phenotype observed by Sierro et al. To 
demonstrate this they generated mice with a specific deletion of ACKR3 in the 
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endothelium. This resulted in development of the same phenotype (Sierro et al., 
2007). 
 
Like many chemokine receptors ACKR3 has the ability to form dimers. Studies 
have shown ACKR3 to form homodimers and also heterodimers with CXCR4. 
When ACKR3 heterodimerises with CXCR4 it has a modulating effect on CXCL12 
driven responses. Binding of the heterodimer to CXCL12 causes bias in favour of 
signalling via β-arrestin and not G proteins (Décaillot et al., 2011). 
 
In a model of zebrafish embryogenesis a study found an example of CXCR4 and 
ACKR3 working together for efficient cellular migration along the lateral line. 
What was observed in this work was that a CXCL12 gradient was formed along 
the lateral line of the developing organism that triggered CXCR4 signals at the 
leading edge of the cells of the migrating primordium. This response was driving 
the migration of these essential cells. The most interesting observation here was 
that at the trailing end of the primordium there was expression of ACKR3 which 
was scavenging the CXCL12 ligands and blunting migratory responses in the 
trailing cells. This then allows ‘pockets’ of the cell to become immobile and to 
be deposited at defined points along the lateral line (Dalle Nogare et al., 2014). 
 
ACKR3 has been investigated as a potential therapeutic target. In one model of 
collagen-induced arthritis (CIA), the murine model of human rheumatoid 
arthritis, it was shown that prophylactically and therapeutically applied 
antagonists of the receptor supressed the symptoms of the disease (Watanabe et 
al., 2010). This study showed a reduction in angiogenesis in the inflamed joints 
that was considered a contributor to the reduced pathology. It is also worth 
noting that in human rheumatoid arthritis ACKR3+ blood vessels can be detected 
in the inflamed joint (Watanabe et al., 2010). Another mouse model of human 
disease in which ACKR3 has been shown to have a role is CNS disease. In the 
mouse model of experimental autoimmune encephalitis (EAE) antagonism of 
ACKR3 reduced CNS leukocyte infiltration compared to WT mice (Cruz-Orengo, 
Chen, et al., 2011). 




ACKR4 has had many names since its original discovery including CCX-CKR 
(ChemoCentryx Chemokine Receptor), CCR11 and CCRL1 (Gosling et al., 2000, 
Khoja et al., 2000, Schweickart et al., 2000). Like ACKR3, this receptor was 
originally considered to be a classical receptor and was known as CCRL11 for 
some time. It is a receptor for three of the homeostatic CC chemokines CCL19, 
CCL21 and CCL25. As previously mentioned, CCL19 and CCL21 are essential in 
the efficient migration of cells from tissue to draining lymph nodes and CCL25 
has roles in the development of thymocytes and cell-trafficking to the small 
intestine. Until the characterisation of ACKR4 it was thought that CCR9 was the 
only receptor for CCL25 (Zaballos et al., 1999).  
 
In 2002 a study by Townson and Nibbs set out to compare mouse ACKR4 to the 
human homologue. In this study they demonstrated that upon ligand binding the 
receptor failed to induce a calcium ion flux in HEK 293 cells and so confirmed it 
as a member of the atypical chemokine receptor family. In this study it was 
shown that the receptor was strongly expressed in the heart and lungs and that 
transcript was expressed in most organs. This finding was also confirmed in 
human tissue (Townson and Nibbs, 2002). Expression of the receptor has also 
been shown in the small intestine (Gosling et al., 2000). 
 
Like ACKR2 and ACKR3, ACKR4 has a scavenging function for its ligands. Upon 
binding of ligand the receptor internalises (Graham et al., 2012). This 
internalisation process has been shown to require the GTPase dynamin to induce 
endocytosis. The calveolar network is also important in this process. Other 
known mechanisms of receptor internalisation including rearrangement of β-
arrestins and clathrin-coated pit formation are not involved in this process 
(Comerford et al., 2006). A study in 2013 has suggested that ACKR4 may have 
the ability to recruit β-arrestins upon activation (Watts et al., 2013). 
Recent work by Ulvmar et al uncovered a key function for ACKR4 in the 
generation and maintenance of CCL21 gradients in lymph node margins. This was 
shown to be essential for the efficient propagation of adaptive immune 
responses (Ulvmar et al., 2014). This study showed that lymphatic endothelial 
cells that lined the roof of the subcapsular sinus of the lymph node expressed 
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ACKR4 and that these cells were key to this gradient-formation. Another study 
which relates to the last study showed that mice lacking ACKR4 had fewer 
CD11c+ MHCII+ dendritic cells in the draining lymph nodes under non-
inflammatory conditions (Heinzel, Benz and Bleul, 2007).  
 
In a separate study, the Bleul group showed that overexpression of ACKR4 on 
thymic epithelial cells resulted in a reduction in migration of haematopoietic 
thymic precursors to the embryonic anlage at embryonic day 12.5. They also 
showed that this did not seem to have an effect on the number of T cells 
developing in this mouse (Heinzel et al., 2007). 
 
ACKR4 has been shown to play a role in human pulmonary sarcoidosis. This 
disease results in the formation of granuloma in the lungs of patients and 
increased CCL19 levels (Kriegova et al., 2006). The authors harvested 
bronchoalveolar lavage cells (BAL) from both sarcoidosis patients and healthy 
controls and used real-time PCR to compare levels of ACKR4 transcripts between 
the two groups. They found that ACKR4 was upregulated in the sarcoid patients 
and, using chest X-ray, they showed that this correlated with disease stage 
(Kriegova et al., 2006). 
 
1.4.4 ACKR2 
The focus of this thesis will be on the inflammatory CC chemokine receptor 
ACKR2 which is an atypical chemokine receptor with key, non-redundant, roles 
in mammalian biology.  
 
ACKR2 was first cloned and characterised in 1997 (Nibbs, Wylie, Pragnell, et al., 
1997, Nibbs, Wylie, Yang, et al., 1997) and was shown to limit in vivo 
inflammatory responses via the scavenging activity previously mentioned 
(Jamieson et al., 2005). ACKR2 binds all of the inflammatory CC chemokines 
including CCL2, CCL3, CCL3L1, CCL4, CCL5, CCL7, CCL8, CCL11, CCL12, CCL13, 
CCL14, CCL17, CCL22, CCL23 and CCL24. ACKR2 does not bind any of the 
homeostatic chemokines nor does it bind ligands from any of the other 
chemokine subfamilies. The Ackr2 gene can be found on chromosome 3 in 
humans and chromosome 9 in mice. These chromosomal locations are major sites 
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of CC chemokine receptor encoding genes and the homology of the receptor with 
other chemokine receptors make it clear that ACKR2 has evolved from within 
this family (Nomiyama, Osada and Yoshie, 2013). The molecule was first 
reported in mice then in man. Human ACKR2 is 71% identical to mouse ACKR2 
and both of these receptors express a DKYLEIV motif instead of the conventional 
DRYLAIV equivalent (Nibbs, Wylie, Pragnell, et al., 1997). It is worth noting that 
the DKYLEIV motif seen in ACKR2 is conserved across mammals, suggesting that 
this may be functionally important (Patel, McInnes and Graham, 2009). Upon 
purification of the human protein it was shown to be 49kDa in size with an N-
terminus that is both sulphated and glycosylated (Blackburn et al., 2004). 
 
Like all chemokine receptors, the N-terminal end of the molecule is crucial for 
ligand binding. An elegant study by Hewit et al showed that the N-terminus of 
ACKR2 contains a conserved tyrosine motif that is indispensible for ligand 
binding, internalisation and scavenging. It was also demonstrated in this study 
that a staphylococcus-derived protease, Staphopain A, has the ability to cleave 
the N terminus of ACKR2 and significantly reduce its chemokine-binding ability 
(Hewit et al., 2014). 
 
Interestingly, it has been shown that the majority of ACKR2 protein in cells 
(>97%) is in intracellular vesicles including early and recycling endosomes (Weber 
et al 2004, McCulloch et al 2008)(Blackburn et al., 2004). During inflammation 
this proportion of intracellular receptors changes and more ACKR2 molecules are 
expressed on the surface of the cell (Weber et al., 2004, Bonecchi et al., 2008). 
 
1.4.4.1 Expression of ACKR2 and Regulation of Expression 
Some of the main tissue types that express ACKR2 are mucosal and barrier 
tissues. In the mouse, ACKR2 is widely expressed and has been shown in the 
lung, the liver, the skin, the ovary, the heart, the muscle, the kidney and the 
thymus (Nibbs, Wylie, Yang, et al., 1997).  
 
The cells that express ACKR2 are varied in function and anatomical location. 
Some of the particular cell-types that have been shown to express ACKR2 are the 
trophoblasts of the human and mouse placenta (Martinez de la Torre et al., 
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2007, Madigan et al., 2010) and lymphatic endothelial cells (Nibbs et al., 2001, 
McKimmie et al., 2013). Expression has been shown on astrocytes of the brain 
(Neil et al., 2005), some leukocytes including innate-like B cells, plasmacytoid 
dendritic cells (pDC) and a subset of neutrophils (McKimmie et al., 2008a). The 
study by McKimmie et al used flow cytometry and this also suggested expression 
of ACKR2 on T cells, mast cells and macrophages. Work by Hansell et al 
suggested that ACKR2 expressed on innate-like B1b cells was biologically active 
under resting conditions (Hansell et al., 2011). It is also expressed on 
keratinocytes (Singh et al., 2012). 
 
1.4.4.2 ACKR2 Signalling 
Like all of the atypical chemokine receptors, ACKR2 does not mount classical 
chemokine receptor signalling responses. In the literature it has often been 
referred to as a ‘silent’ receptor which implies an absence of signalling activity 
upon ligand binding. Whilst this is a slight misnomer, what has been shown is 
that no calcium ion flux is induced up ligand binding and therefore it can be said 
that ACKR2 is unable to convey classical signalling upon ligand binding. The 
physiological trafficking of ACKR2 to and from the cell surface is one of the 
major contributors to its function as a scavenging receptor (Weber et al., 2004). 
ACKR2 can internalise in a ligand-independent manner and no receptor 
desensitisation occurs (Weber et al., 2004, McCulloch et al., 2008). Interestingly, 
it has been shown that the vast majority of ACKR2 molecules are stored in 
vesicles within the cytosol and cell surface expression tends to be low under 
normal conditions (Blackburn et al., 2004). This is a phenomenon that is unique 
to ACKR2 as most classical chemokine receptors become desensitised upon 
binding and recycling. In fact, even upon ligand binding and recycling no 
desensitisation occurs and in the presence of high chemokine concentrations 
more ACKR2 molecules are expressed on the surface of cells (Comerford and 
Nibbs, 2005, Bonecchi et al., 2008).  
 
Internalisation of ACKR2 is mediated by clathrin-coated pits and is initiated by 
activation and re-localisation of β-arrestin molecules. The receptor becomes 
enveloped in Rab-5 positive clathrin-coated pits then Rab-4 and Rab-11 
dependent pathways target the molecule for transit in early endosomes then 
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recycling to the cell surface, respectively (Weber et al., 2004, Bonecchi et al., 
2008). The activated receptor becomes associated with clathrin-coated pits 
which drives the internalisation of the receptor from the membrane. Dynamin-
dependent fission then allows for the complete envelopment of the molecule 
and allows endocytosis to take place. At this stage the chemokine is sequestered 
from the receptor and is targeted for lysosomal degradation. At this point one of 
the unique features of ACKR2 comes into effect. The now ligand-free receptor 
recycles to the cell surface and is not desensitised. One of the key regulatory 
mechanisms of classical chemokine receptors is that when they are recycled to 
the cell surface its binding affinity for ligands is reduced. This does not seem to 
occur in the case of ACKR2 and increases its efficiency as a chemokine 
scavenger. This is depicted in figure 1.8. 
 
In 2013 a study was published that revealed a novel-signalling pathway that was 
activated when CC chemokines bind to this receptor (Borroni et al., 2013). This 
work showed that ligand binding induced the activation of the cofilin pathway 
and that this was essential for the scavenging function of the receptor. Cofilin is 
a ubiquitously expressed actin-binding protein that has been shown to reorganise 








1.4.4.3 In vivo function of ACKR2  
In vivo models, using ACKR2 null mice, have demonstrated indispensible 
physiological and pathological roles for this receptor. In a model of cutaneous 
inflammation the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) was 
used to induce inflammation on dorsal skin. In this study ACKR2 null mice 
showed increased cutaneous inflammation. Further investigation into the 
phenotype showed an increase in inflammatory chemokines within the skin of 
the ACKR2 null mice compatible with a lack of scavenging. The histological 
phenotype closely resembled that of human psoriasis (Singh et al., 2012). Wild-
type mice in this study displayed a transient and resolving inflammatory 
pathology unlike knockout mice, which displayed delayed inflammatory 
resolution (Jamieson et al., 2005). In a related model where the mutagen 7,12-
dimethylbenz(a)anthracene was applied to the skin before TPA painting, ACKR2 
null mice developed papillomas more frequently than WT mice (Nibbs et al., 




ACKR2 expression on lymphatic vessels has been an area of intense study in more 
recent years. Lymphatic endothelial cells (LEC) are the major cells expressing 
ACKR2 in tissue (Nibbs et al., 2001) which does not completely fit in with the 
anti-inflammatory function of ACKR2. In a series of experiments using wild type 
and ACKR2 null mice, it was shown that this molecule scavenges inflammatory 
chemokines that are expressed on the LECs. Chemokine ligands can be expressed 
on endothelial surfaces and presented on glycosaminoglycans (GAGs). During 
inflammation inflammatory chemokines that are not scavenged could be 
presented on LEC surfaces via GAGs as these interactions are not as specific as 
ligand/receptor interactions. Indeed fluorescently labeled chemokines injected 
into ACKR2-deficient mice accumulated around the lymphatic endothelium and 
this phenomenon was not seen in WT counterparts. It is thought that a lack of 
clearance of inflammatory CC chemokines from the LEC surface leads to 
inflammatory cells accumulating around these vessels and disrupting the 
efficient flow of APCs and fluid into the vessels. This work suggested, for the 
first time, a role for ACKR2 in the free movement of fluid and cells into the 
draining lymphatics and maintaining the efficiency of an adaptive immune 
response (Lee et al., 2011).  
Another recent finding on ACKR2 function related to lymphatic vessel formation 
and development. Work by Lee et al. suggested a reciprocal relationship 
between ACKR2 and CCR2 in the regulation of lymphatic vessel network density. 
In this work it was shown that ACKR2 null mice had a denser lymphatic vessel 
network and CCR2 null mice had a less dense network when compared to wild-
type mice. The proposed mechanism behind this phenotype relates to 
macrophages and inflammatory chemokines. The hypothesis is that in mice CCL2 
concentration in the proximity of the LEC guides CCR2-expressing 
prolymphangiogenic macrophages to the vessels thus higher CCL2 levels in ACKR2 
null mice cause increased branching and a denser network. The opposite 
phenotype occurs in CCR2KO mice. In this case the lack of CCR2 on the 
macrophages results in a reduction in the ability of these cells to respond to 
CCL2 (Lee et al., 2014). 
One of the cell types that expresses the most ACKR2 are the 
syncytiotrophoblasts of the placenta (Borroni et al., 2006, Martinez de la Torre 
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et al., 2007, Madigan et al., 2010). The functional relevance of this was 
investigated in WT and ACKR2-null pregnant mice that were treated systemically 
with an inflammatory stimulus. It was shown in this work that mice lacking the 
chemokine-scavenging molecule had a higher incidence of miscarriage upon 
inflammatory stimulation. The data from this study suggested that there was an 
increased presence of inflammatory CC chemokines in ACKR2 null when 
compared to WT counterparts. The cellular response to the increased 
inflammatory signals in the placenta included an increase in migration of 
macrophages and T cells which was ameliorated using neutralising antibodies to 
inflammatory chemokines. Interestingly, the levels of inflammatory CC 
chemokines in the placenta were similar between the two genotypes of mice 
before inflammation was induced (Martinez de la Torre et al., 2007). Madigan et 
al took these findings further using placental cell lines in an attempt to 
elucidate mechanistic details underpinning this physiological process. They 
suggested that interactions between CCL2 and ACKR2 may be responsible for the 
phenotype in the de la Torre et al study and also went to show that CCL2 and 
ACKR2 are associated in the placental tissue (Madigan et al., 2010).  
A more recent study took the findings of ACKR2 in the placenta further. This 
work provided evidence that cultured primary human trophoblasts expressed 
ACKR2 at significantly higher levels than conventional chemokine receptors. It 
was also suggested in this work that trophoblast ACKR2 was able to scavenge 
chemokines. In mice lacking ACKR2 it was shown that there was increased 
instances of neonatal death, decreased foetal weight and structural defects in 
the placenta. These phenotypes led to increased neonatal mortality (Teoh et al., 
2014). 
In a model of murine hepatic inflammation using CCI(4) induced damage it was 
shown histologically that mice-lacking ACKR2 developed more extensive liver 
damage than WT mice (Berres et al., 2009). As was also the case in the placental 
example discussed previously, the livers of the ACKR2 null mice showed 
increased leukocyte infiltration compared to WTs.  
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1.4.5 ACKR2 in Disease 
ACKR2 in Cancer 
During the development of tumours the inflammatory process is frequently key 
to the growth of the neoplasm. As inflammatory cells arrive at the tumour site 
they provide the tumour with growth factors which help develop the blood 
supply which is vital to the overall survival of the cancer. Given that 
inflammation can aid tumour survival, ACKR2 and its ability to scavenge 
inflammatory chemokines, has been shown to play a role in tumour 
development. When the skin of ACKR2-null mice were painted with a mutagen 
(7,12-dimethylbenz(a)anthracene (DMBA)) and an inflammatory agent (12-O-
tertadecanoylphorbol-13-acetate (TPA)) they developed papillomas more 
frequently than wild-type mice (Nibbs et al., 2007).  
In a clinical study of breast cancer it was shown that levels of ACKR2 expression 
had a negative correlation with metastasis to the lymph nodes (Wu et al., 2008). 
This study also showed that the transcript levels of Ackr2 in breast cancer cell 
lines negatively correlated with the invasiveness of the cancer when injected 
into mice. 
In colonic adenocarcinomas it was reported that there is a reduction in ACKR2 
expression. This study suggested that this was having an effect on inflammatory 
CC chemokine levels in the local environment and aiding the survival of the 
tumour (Langenes et al., 2013). To continue with the setting of the gut, ACKR2 
has been shown to play a role in the pathology of inflammatory bowel disease 
(IBD) and IBD-associated colon cancer (Collins et al., 2010). The results of this 
study suggested that in acute colonic inflammation the pathology could be 
controlled by ACKR2 expressed on gut lymphatic epithelial cells rather than 
haematopoietic cells (Vetrano et al., 2010). Another mucosal barrier tissue of 
high ACKR2 activity is that of the lung. 
ACKR2 in Cutaneous Disease 
ACKR2 is highly expressed in barrier tissues and has been reported to have key 
roles in multiple human pathologies. One of example of this is in the 
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inflammatory skin condition psoriasis. In this pathology it has been reported that 
ACKR2 is expressed at higher levels in the epidermis of uninvolved, or plaque-
free, skin than in lesional skin. There is also an upregulation of ACKR2 in the 
peripheral blood leukocytes of psoriasis patients (Singh et al., 2012).  
In systemic sclerosis (SSc), a chronic autoimmune disease that can cause the 
thickening of the skin and multiorgan fibrosis due to aberrant collagen 
deposition, there is involvement of ACKR2. In this condition it was shown that 
patients have increased transcript and protein levels of ACKR2 in peripheral 
blood mononuclear cells (PBMCs)(Codullo et al., 2011). In this study the levels of 
some systemic inflammatory CC-chemokines negatively correlated with the 
levels of ACKR2, suggesting a possible controlling function for ACKR2 on these 
ligands (Codullo et al., 2011). Skin is not the only barrier tissue that ACKR2 is 
involved in the pathology of however. 
ACKR2 in Cardiovascular and Pulmonary Disease 
ACKR2-null mice have also been shown to be more susceptible to cardiac rupture 
following myocardial infarction (MI) (Cochain et al., 2012). In human disease it 
was found that following MI the undamaged tissue was ACKR2-negative whilst 
area of inflamed infarcted tissue had ACKR2 expression (Cochain et al., 2012). 
In advanced chronic obstructive pulmonary disease (COPD) it has been shown 
that there is an increase in the expression of ACKR2 on local lymphatic vessels 
(Mori et al., 2013). Another finding in COPD is that there is an increase in ACKR2-
expressing alveolar macrophages. In this study, this increase in expression 
correlated with increased immune activation and functional impairment (Bazzan 
et al., 2013).  
Another ACKR2-related finding involving the lung was after infection with 
Mycobacterium tuberculosis. In this work mice lacking ACKR2 had significantly 
higher mortality rates than wild type mice (Di Liberto et al., 2008). This study 
showed a higher influx of inflammatory cells, mainly macrophages, DCs and T 
cells, to the lung tissue and higher levels of CC chemokines in the serum and 
bronchoalveolar lavage (BAL) fluid of ACKR2-null mice when compared to wild 
type animals after infection (Di Liberto et al., 2008). It was of note that the 
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bacterial load present in each genotype was similar which suggested that the 
pathology was due to an exaggerated and prolonged inflammatory response. This 
study suggested that increased concentrations of CC chemokines, due to a lack 
of ACKR2, resulted in enhanced recruitment of inflammatory cells resulting in 
increased liver and kidney damage and eventually increased mortality when 
compared to wild type mice (Di Liberto et al., 2008). 
ACKR2 in HIV-Infection 
It is not just in barrier tissue pathologies that ACKR2 has a role. It has also been 
shown that ACKR2 may be a functional co-receptor for primary isolates of dual-
tropic human immunodeficiency virus (HIV)-1 and -2 in the brain (Neil et al., 
2005). Dual-tropic HIV means that the virus can use the both CCR5 and CXCR4 as 
co-receptors. HIV-infection results in progression to acquired immune deficiency 
syndrome (AIDS) and one of the most common symptoms of this progression is 
the presence of Kaposi’s sarcoma (KS) lesions. The viral presence in these 
tumours causes an increase in the expression of the viral IL-6 homologue which 
increases the expression of ACKR2 (Nibbs et al., 2001, McKimmie et al., 2013).  
ACKR2 in Liver Disease 
Another human tissue that has been shown to express high levels of ACKR2 is the 
liver (Nibbs, Wylie, Pragnell, et al., 1997). It has been shown that single 
nucleotide polymorphisms (SNPs) of ACKR2 exist and affect the function of the 
receptor. Patients with these SNPs tended to present increased inflammation 
after hepatitis C viral infection (Wiederholt et al., 2008). 
1.5 Aims 
The overall aim of this work was to determine the role that ACKR2 plays in 
tissue-specific inflammatory responses.  Using three anatomically distinct types 
of mouse tissue this work looks at how a lack of ACKR2 can impact on a variety 
of inflammatory models. There is also an attempt to take these findings into the 
human clinical setting in order to provide some translational relevance to the 
findings presented. 
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Previous work carried-out in our lab has suggested important roles for ACKR2 in 
cutaneous inflammation. It has also been shown to have an affect on wound 
healing in the skin. The first part of the work performed in this thesis attempted 
to provide insights into how ACKR2 can affect cutaneous wound healing during 
all stages of the response. Using alternative, well-characterised, models of 
cutaneous inflammation this part of the research also looks into what other 
aspects of skin pathology ACKR2 may play a role in. 
 
The middle portion of work in this thesis studies the eye tissue. Certain tissues 
of the eye have been shown to be highly immunomodulatory and so it seemed a 
good target for ACKR2 studies. Using a model of experimental autoimmune 
uveoretinitis (EAU) mice with, and without, ACKR2 were examined for levels of 
pathology in the ocular tissue.  
 
The final body of work for this thesis was carried out to identify the potential 
role of ACKR2 in rheumatoid arthritis. Work done previously in our lab has shown 
an increase in the expression of ACKR2 on peripheral blood leukocytes harvested 
from patients diagnosed with rheumatoid arthritis. This work set out to look 
specifically at this finding in more detail.  
 
1.5.1 Linked Research Questions 
What role does the absence of ACKR2 play in inflammation brought about by the 
acute innate immune response? 
What role does the absence of ACKR2 play in the pathology of models with 
involvement of both the innate and adaptive arms of the immune system? 
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Chapter 2 Materials and Methods 
All work animal models carried out for this thesis was done in accordance with 
Home Office regulations and the principles of the 3Rs (replacement, reduction 
and refinement). The work was done under the PPL 60/4092 and the PIL 
60/11984. 
2.1 Cutaneous Inflammation 
2.1.1 Wounding Model 
Mice were shaved dorsally using an electric shaver (Wella) twenty-four hours 
before the wounds were made. They were anaesthetised with isofluorane 
(Abbott Laboratories) and cleaned using 70% ethanol (Fisher) before being 
wounded using 5mm biopsy punches (Stiefel, Brentford, UK). Mice were 
sacrificed at different time points depending on experimental requirements, 
usually days three, five, seven or twenty-one. Tissue was harvested on these 
days and stored in 10% NBF (Surgipath) until it was processed. The tissue was 
prepared for immunohistochemistry and histology according to methods listed in 
the section entitled ‘Tissue Processing, Embedding and Sectioning’. 
 
The sections were stained for MAC-2 (macrophages)(Cedarlane, Burlington, ON, 
Canada), astra blue (mast-cells)(Sigma-Aldrich), picrosirius red (total 
collagen)(Sigma-Aldrich), myeloperoxidase (neutrophils) and haematoxylin and 
eosin (general tissue architecture)(Cell Path, Powys, UK) (as seen in figure 3.3). 
Example images of MAC-2, MPO and astra blue staining can be seen in appendix 
IV). 
 
Wounds were also flash frozen in liquid nitrogen (BOC Gases). The mRNA was 
extracted from this tissue (see ‘RNA Extraction’) (2.8) and, after making cDNA 
(see ‘cDNA Synthesis’) (2.9), subsequently analysed by quantitative polymerase 
chain reaction (QPCR). For process of selection of the primers used see ‘Primer 
Design’ section (2.10.1).  
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2.1.1.1 Wound Closure Analysis 
A digital SLR camera (Fujifilm with Nikon lens, Surrey, UK) was attached to a rig 
and was set at a constant height of 40cm from the platform. The mice were 
placed atop the cage and pictures were taken at time-points to analyse wound 
closure rate. Pictures were uploaded to a PC (Dell, Berkshire, UK) for 
quantitative analysis of wound closure using Axiovision software (Zeiss, 
Cambridge, UK).  
 
The wound sections were then stained with H&E (please refer to Haematoxylin 
and Eosin Staining section for details (2.6.1)) and analysed on the Axiostar light 
microscope (Zeiss). Pictures of the wound margins were taken at 50x 
magnification and the gap between wound margins was measured using 
Axiovision software (Zeiss).  
 
2.1.1.2 Macrophage Depletion Study 
Mice were treated with clordronate liposomes (courtesy of van Rooijen) in order 
to deplete them of macrophages. Control mice were injected with liposomes 
filled with PBS. A volume of 0.2ml of liposome emulsion was injected 
intravenously (i.v.) into the tail vein. Mice were treated 48 hours before being 
wounded then every 48 hours post-wounding to ensure absence of macrophages 
before and throughout the study. The wounding model described above in 2.1.1 
was carried out. Mice were left until day 21 and wounds were harvested and 
analysed as previously described (see ‘Wounding Model’ section (2.1.2)).  
 
2.1.1.3 Analysis of Tail Pathology 
To the two groups above that were injected with liposomes, both clodronate- 
and PBS-filled, a group of WT and ACKR2-null mice were added to receive 
injections of PBS only. The animals were injected at the same time and under 
the same conditions as the other groups of mice but after injection had their tail 
girth measured. This was done using a dial micrometer (Mitutoyo, East Kilbride, 
UK) and measurements were taken at the same point on the base of each 
mouse’s tail. The tail girth was measured for mice in all four groups and the 
data collected was graphed and analysed using Graphpad (Prism, La Jolla, CA, 
USA) software. 
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2.1.1.4 Mast-Cell Degranulation Model 
The highly active mast-cell degranulator, compound 48/80 (Sigma Aldrich), was 
used for this work. 20µl of the reagent was injected intradermally into each 
mouse using a small volume syringe (Hamilton Needles, Bonaduz, Switzerland) 
and left for 48 hours. 
 
C57BL/6J mice were injected with a concentration of 10mg/ml. Drug was 
administered with PBS as a diluent. Control animals for the experiment were 
injected with diluent only. After four days a 5mm biopsy punch (Stiefel) was 
taken of the injection site and surrounding area. 
 
The mice were sacrificed and the skin was stored in 10% NBF (Surgipath) until 
processing. Once processed, sectioned and on microscope slides, the tissue was 
stained with H&E and astra blue to assess the reaction to the reagent. For more 
details on the staining protocols used please refer to the ‘Histological Staining’ 
section below (2.6). 
 
Stained sections taken from the mice were blinded and photographed for further 
analysis. Oedema was also quantified using the Axiovision software program 
(Zeiss) to measure the thickness of the tissue sections. Six randomly selected 
view fields were taken for each sample and the thickest part of tissue in the 
field of view was measured. These numbers were then averaged to give a single 
value for each mouse involved in the study. 
 
2.1.2 Allergic Contact Dermatitis Model 
Mice on the FVB background were used in this model. Before priming the 
abdomen of the mice were shaved. Priming involved the hapten 2,4- 
dinitrofluorobenzene (DNFB or Sanger’s reagent)(Sigma Aldrich) in a vehicle (1:4 
mix of acetone (Fisher Scientific) and olive oil (Bertolli, London, UK). This DNFB 
and vehicle mix was painted onto the exposed abdominal skin on day 1.  
 
Six days later, the challenge stage, the same DNFB/vehicle mix was painted onto 
the right ear of the mice. The left ear of the mice was painted with vehicle only 
as an internal control. The ears of the mice were measured using digital callipers 
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(Mitutoyo) every 24 hours. This was carried out up until 144 hours after the 
challenge.  
 
2.2  Ocular Inflammation 
2.2.1 Experimental Autoimmune Uveoretinitis (EAU) Model 
C57Bl/6J mice were injected subcutaneously with 50µg complete Freund’s 
adjuvant (CFA) (Difco from BD) and 600µg of interphotoreceptor retinoid binding 
protein (IRBP) 1-20 (New England Peptides, Gardner, MA, USA) in the dorsal skin 
(the mix of the CFA and IRBP 1-20 was sonicated until it was a thick paste-like 
consistency). This dose was split and injected into the rump at each side of the 
animal in two instalments. The mice were then injected intraperitoneally with 
500ng of pertussis toxin (Alexis Biochemicals from Enzo Life Sciences, Exeter, 
UK). Control mice were injected with a sonicated mix of PBS, CFA, and pertussis 
toxin.  
 
After twenty-eight days the mice were euthanised with CO2 and harvested eyes 
were frozen in optimal tissue cutting (OCT) (Sakura Finetek, Alphen aan den 
Rijn, Netherlands) media on dry ice. Eyes were sectioned at 8µm using a cryostat 
(Thermo Scientific) and three samples from each eye were taken in order to 
investigate pathology throughout the eye. Tissue was placed on polylysine slides 
(VWR International, Lutterworth, UK) and left to air dry. Once all of the eyes 
were cut the book housing slides (Raymond Lamb from Thermo Scientific) was 
wrapped in tin foil (Caterwrap, Shropshire, UK) and put into a -80°C freezer 
(Thermo Scientific) for storage. Ice-cold acetone (Fisher Scientific) was used for 
fixing the tissue. For the following steps taken in this protocol please refer to 
‘Haematoxylin and Eosin Staining’ (2.6.1). 
 
We repeated this model using our collaborators from the University of 
Aberdeen’s protocol. For this model 500µg of IRBP was combined with 50µg of 
CFA and also had an extra 25mg of Mycobacterium tuberculosis supplementing 
the CFA. This mixture was hand emulsified using linked syringes (Hamilton) 
rather than sonication. The mix was injected subcutaneously, as before, in two 
instalments into the rump of the mouse. An intraperitoneal injection of pertussis 
toxin (1µg) was also given immediately after the interphotoreceptor retinoid 
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binding protein (IRBP) injection. As before, control mice were injected with PBS 
in place of IRBP. 
 
For one study in section 4.2.1.4 the B10.BRIII mouse strain was used as opposed 
to C57BL/6 as per all other studies in this chapter. This particular study was 
carried out by our collaborators at The University of Aberdeen and we were sent 
the laser-captured tissue for analysis. This model was also carried out over 70 
days rather than 28 as per other studies in this section. 
 
2.2.2 Histopathological Grading 
Once the eyes were stained they were analysed using a customised 
histopathological grading system shown below:  




Table 2.1-Customised Histopathological Grading System for EAU- The table above details the 
factors taken into consideration for quantifying the pathology presented by the animals in the 
EAU model (Xu et al. 2008). 
 
2.2.3 EAU QPCR 
Mice were culled using carbon dioxide (BOC Gases) and eyes were removed from 
5 C57/BL6J mice using forceps (Fisher Scientific). The eye structure was to be 
Customised histopathological grading of EAU  
Cellular infiltration   Structural/morphological changes  
Anterior segment   Posterior segment   
Iris Infiltrating cells 1 Rod outer segments Cell infiltrate 1 
 Thickening of iris 2  Partial loss 2 
Anterior chamber Cells<= 20 1  Moderate loss 3 
 Cells >20 2  Subtotal loss 4 
Cornea Infiltrating cell/ 
thickening 
1  Total loss 5 
Posterior segment   Neuronal layers Cell infiltrate 1 
Ciliary body Cell infiltrate <5 cells 1  Partial loss 2 
 Mild thickening 2  Moderate loss 3 
 moderate thickening 3  Subtotal loss 4 
 Gross thickening 4  Total loss 5 
Vitreous Cells <5 1 Retinal morphology Folds 1 
 Cells 5--25 2  Focal 
detachment 
2 
 Cells 25--50 3  Subtotal 
detachment 
3 
 Cells 50--100 4  Total 
detachment 
4 
 Cells >100 5 SRNVM (SRNVM: 







1  >3 2 
extravascular 
cells) 
10--25% 2 TOTAL   
 25--50% 3 Infiltrative 35  
 50--75% 4 Structural 16  
 >75% 5 Grading: Infiltrative   
 Cells in or around wall 1 1 1--4  
 Mild perivascular 
cuffing 
2 2 5--9  
 Moderate cuffing 3 3 10--14  
 Gross cuffing 4 4 15--19  
Rod outer 
segments 
<10% involved 1 5 20--24  
Cell infiltrate 10-25% 2 6 25--29  
 25-50%e  3 7 >=30  
 50-75% 4 Grading: Structural   
 >75% 5 1 1--3  
Choroid Cell infiltrate 1 2 4--6  
 Mild thickening 2 3 7--9  
 Moderate thickening 3 4 10--12  
 Gross thickening 4 5 13--16  
 Granulomas 1 1    
 Granulomas 2--5 2    
 Granulomas >5 3    
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analysed for ACKR2 transcript levels. RLT buffer (Life Technologies) was added 
to the eyes and the TissueRuptor (Qiagen, Crawley, UK) was used to homogenise 
the sample. The homogenate was spun at 17,000g (Fisher Scientific) for 3 
minutes and the supernatant was harvested. The process of RNA extraction is 
listed below in the ‘RNA Extraction’ section, for more protocol details please 
refer to this.  
 
To a tube of PCR master mix (Rovalab, Teltow, Germany) 3µl of template (cDNA 
from the remaining eye structure sample) with was added along with 0.5µl of 
both forward and reverse primers (IDT DNA, Interleuvenlaan, Belgium). Once this 
assay had been completed a 50ml 2% agarose gel (Roche, West Sussex, UK) with 
5µl ethidium bromide (Sigma Aldrich). The gel was run at 100V (BioRad, Hemel 
Hempstead, UK) for 45 minutes. A molecular weight ladder (Hyper Ladder IV 
(Bioline, London, UK)) was included on the gel.  
 
2.2.4 Western Blot of ARPE-19 Cell Line for ACKR2 Expression 
ARPE-19 cells were lysed for western blot analysis (for details on the cell line 
please refer to section 2.11.2). Cells were lifted from the flask (Corning) with 
trypsin-EDTA (Life Technologies) and resuspended. After being resuspended in 
fresh medium (Life Technologies/Sigma) the cells were centrifuged (Thermo 
Scientific) and the cell pellet was resuspended in sterile PBS (Life Technologies) 
and re-centrifuged. The cell pellet was then resuspended in Mammalian Protein 
Extraction Reagent (MPER) Lysis Buffer (Pierce from Thermo Scientific) to lyse 
the cells. Originally 400µL of MPER was used to prepare the cell lysate, however 
after carrying out the western blot this created a lysate that was too dilute. As a 
result, 200µL of the lysis buffer was used to create the second lysate. The 
lysates were stored at -80°C (Thermo Scientific). 
 
2.5µL of sample buffer (NuPAGE LDS Sample Buffer (4x)(Life Technologies)) was 
added to 7.5µL of cell lysates. This was carried-out in accordance with 
Blackburn et al (Weber et al., 2004) This was incubated at room temperature for 
around 10 minutes, after this, 2µL of NuPAGE sample reducing agent (10x)(Life 
Technologies) was added to the lysates. Along with the cell lysate of ARPE-19 
cells, Human Embryonic Kidney (HEK)-293 cell lysates were used as a negative 
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control and ACKR2-transfected HEK-293 cells as a positive control (all cell lines 
from ATCC, Manassas, VA, USA). The lysates were added to a NuPAGE 12 well 4-
12% Bis-Tris gel (Life Technologies) electrophoresed at 100V in NuPAGE MES SDS 
running buffer (20x) (Life Technologies) for an hour and a half. A pre-stained 
protein ladder was used to estimate the size of the proteins on the gel (Life 
Technologies). 
 
Electrophoresed proteins were transferred onto a nitrocellulose membrane (Life 
Technologies) using the iBlot system (Life Technologies). The transfer took 7 
minutes. After transfer the membrane was washed in phosphate buffered saline 
with tween 20 (PBST) (Life Technologies/Sigma) (0.05%) 3 times for 5 minutes 
per wash. Once washed the membrane was blocked using 10% milk (Marvel, 
Dublin, Ireland) in PBST for 1 hour at room temperature.  
 
After blocking, the primary antibody was added. The mouse anti-human ACKR2 
antibody (made in-house) was applied at a dilution of 1:5 in the PBST/milk 
solution. The primary antibody was incubated on the membrane overnight at 4°C 
on a shaker. After this incubation the antibody solution was removed and the 
membrane washed 3 times in PBST for 5 minutes each.  
 
The secondary antibody (HRP-conjugated sheep anti-mouse IgG) (GE Healthcare) 
was then added at a dilution of 1:10,000 in 5% milk PBST and incubated at room 
temperature for 1 hour. After this the membrane was washed in PBST 4 times for 
15 minutes. The development reagent, WestFemto (Pierce) was prepared by 
adding equal amounts of solutions 1 and 2 contained in the kit for a total volume 
of 1.5mL.  
 
X-ray film (Kodak, Geneva, Switzerland) was placed over the membrane and 
exposure allowed to proceed for various times. They were then developed using 
an XOmat developing machine (Konica-Minolta, Banbury, UK). 
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2.3 ACKR2 in Rheumatoid Arthritis 
2.3.1 In vivo Study Sample Collection 
2.3.1.1 Patient Criteria 
After receiving ethical approval (see Appendix II) from the relevant bodies, this 
experiment was undertaken. Patients were selected by checking medical notes 
for a positive diagnosis. They were then consented before seeing the clinician. 
This involved a brief interview in which the project was explained and the 
necessary paperwork completed. Three groups of patients were used in this 
study along with healthy controls: 
 
Clinic 1- Escalating RA: Patients whose current therapy regimen is no longer 
effective with disease diagnosed over 12 months before sample collection 
 
Clinic 2- Established RA: Well-managed disease diagnosed over 12 months before 
sample collection 
 
Clinic 3- Early RA: Diagnosed within 12 months of sample collection 
 
Patients were ineligible for the study if they were undergoing any biological 
based therapies. 
 
2.3.1.2 Blood Collection 
18ml of blood (2 x 9 ml) was taken from participants and stored in EDTA 
Vacuettes (Grenier Bio-One, Stonehouse, UK). 
 
2.3.1.3 Patient Data 




Disease Activity Score (DAS) 
Erythrocyte Sedimentation Rate (ESR) 
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C-Reactive Protein (CRP) 
Rheumatoid Factor (RF) 
 
2.3.1.4 Plasma and Cell Collection 
Blood was pooled (approximately 18ml) in a 50ml centrifuge tube (BD) and 
centrifuged at 600g for 5 minutes (Thermo Scientific). Supernatant was 
aliquoted into 1.5ml tubes and spun at 17,000 g for 5 minutes. Supernatant was 
aliquoted into 1.5ml tubes and stored at -80°C. Cell pellet was resuspended in 
PBS (Life Technologies) with ethylenediaminetetraacetic acid (EDTA) (Life 
Technologies) and foetal calf serum (FCS) (PAA from GE Healthcare) and added 
to remaining blood.  
 
Blood sample minus plasma was diluted 1:1 with PBS-EDTA-FCS (PEF) and layered 
carefully onto 5ml of Ficoll (GE Healthcare). It was then centrifuged at 600 g for 
25 minutes. 
 
The peripheral blood mononuclear cell (PBMC) layer was removed and placed in 
an RNase-free 1.5ml tube (StarLab) and centrifuged for 10 minutes at 200g. 
Supernatant was removed and the pellet was resuspended in PEF. This 
suspension was spun again at 200g for 5 minutes. 
 
PBMCs were counted using trypan blue (Sigma Aldrich) and a haemocytometer 
(VWR International).  
 
2.3.2 Patient Sample Analysis 
2.3.2.1 QPCR 
Cells were lysed in RLT lysis buffer (Qiagen) and placed a Qiashredder (Qiagen) 
and centrifuged at 13000 x g for 2 minutes. After this, steps were taken in 
accordance with sections 2.8 ‘RNA Extraction’, 2.9 ‘cDNA Synthesis’ and 2.10 
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2.3.2.2 Multiplex ELISA 
A 30-plex ELISA (Life Technologies) was used with the plasma samples collected 
from patient peripheral blood samples. The targets of this assay are listed 
below: 
 




IL-1β Cytokine Pro-inflammatory 




IL-4 Cytokine Anti-inflammatory 
IL-5 Cytokine Anti-inflammatory 
IL-6 Cytokine Pro-inflammatory 
IL-7 Cytokine Pro-inflammatory 
IL-10 Cytokine Anti-inflammatory 
IL-12 Cytokine Pro-inflammatory 
IL-13 Cytokine Anti-inflammatory 
IL-15 Cytokine Pro-inflammatory 
IL-17 Cytokine Pro-inflammatory 
IFN-α Cytokine Pro-inflammatory 
IFN-γ Cytokine Pro-inflammatory 
TNF-α Cytokine Pro-inflammatory 
G-CSF Cytokine Pro-inflammatory 
GM-CSF Cytokine Pro-inflammatory 
CCL2 Chemokine Pro-inflammatory 
CCL3 Chemokine Pro-inflammatory 
CCL4 Chemokine Pro-inflammatory 
CCL5 Chemokine Pro-inflammatory 
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CXCL9 Chemokine Pro-inflammatory 
CXCL10 Chemokine Pro-inflammatory 
VEGF Chemokine Pro-inflammatory 
FGF-basic Growth Factor Angiogenic 
 Growth Factor Angiogenic 
EGF Growth Factor Angiogenic 
HGF Growth Factor Angiogenic 
 
Table 2.2- Analytes on 30-plex plate- The table above lists the molecules analysed using the 
multiplex ELISA kit for the patient plasma samples. 
 
The assay was carried out in accordance with product literature. However as a 
quick overview, the wells were pre-wet with wash buffer and antibody-coated 
beads added. Samples and standards were added with incubation buffer and 
assay diluent. The plate was incubated and shaken for two hours then washed 
twice. Secondary/detector antibodies were then added to the wells and the 
same incubation, shaking and washing step was repeated. A 
streptavidin/phycoerythrin complex was added to the wells and the plate was 
incubated and shaken for 30 minutes. After three washes the plate was read 
using the xMap™ System (Luminex Corp). 
 
2.4  Rheumatoid Arthritis and ACKR2- In vitro Studies 
2.4.1 ACKR2 vs. Hypoxia QPCR 
2x106 cells were seeded onto two 60mm dishes. These were then either placed 
in a hypoxia chamber filled with carbon dioxide or placed in a normal incubator. 
They were each incubated for 24 hours in their respective conditions. Once this 
was done the medium was removed from the plate, the plate was washed with 
PBS and cells lysed using RLT Buffer (Qiagen). Lysate was removed from the 
plate and taken for transcriptional analysis. QPCR was carried out in accordance 
with the previous section entitled ‘QPCR Assays’ (2.10). 
 
   
 
75 
2.4.2 Disease Modifying Anti-Rheumatic Drugs (DMARDs) vs. 
ACKR2 
Peripheral blood mononuclear cells (PBMCs) were obtained from a buffy coat. 
The blood was separated using a Ficoll-Pacque (GE Healthcare) gradient and 
PBMCs harvested. The monocyte fraction of the cells was isolated using CD14+ 
cell sorting. 
 
From the cells obtained, half were used to generate dendritic cells (DC) and for 
macrophages. Cells were incubated in complete media with added growth 
factors in order to drive lineage commitment. DC and macrophage medium was 
made up of RPMI buffer was supplemented with 5% human AB serum (Life 
Technologies) and gentamicin (Sigma).  
 
Both populations of cells had granulocyte macrophage colony-stimulating factor 
(GM-CSF) added to them (macrophages received 125 ng/ml and DC were treated 
with 50 ng/ml). Differentiated DC also required interleukin (IL)-4 (15 ng/ml). 
 
The cells were incubated for ten days then were placed into two 12-well plates 
(one for macrophages and one for DCs) and given more growth medium 
(containing the appropriate growth factors). At this point the cells were treated 
with disease modifying anti-rheumatic drugs (DMARDs) methotrexate (20nM) 
(Nesher, Moore and Dorner, 1991, Thomas et al. 2011), dexamethasone (1µM) 
(Verhoef et al. 1999), or acitretin (100nM) (Papadimou et al. 1998). Doses were 
taken from publications. 
 
Cells were incubated for six or twenty-four hours at 37°C then lysed with RLT 
buffer (Qiagen). Samples were then taken through the steps mentioned in the 
section entitled ‘RNA Extraction’ (2.8). Finally, a QPCR assay was carried out. 
 
2.5 Tissue Processing, Embedding and Sectioning 
2.5.1 Tissue Storage 
Once harvested the skin was spread out dorsal side down on filter paper to help 
keep its shape and stored until it could be processed. This was done by placing 
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the sample in 10% neutral buffered formalin (NBF) (Surgipath) immediately after 
harvest. 
  
2.5.2 Tissue Processing 
Fixed tissue was placed in a tissue cassette (Simport from CamLab, Cambridge, 
UK) for treatment in a tissue processor (Thermo Scientific) using the following 
programme: 
 
Station  Solution  Time 
1 10% NBF 30 mins 
2 70% Alcohol 1hour 
3 90% Alcohol 1hour 
4 95% Alcohol 1hour 
5 100% Alcohol 1 hour 
6 100% Alcohol 2 hour 
7 100% Alcohol  2.5 hours 
8 Xylene 1 hour 
9 Xylene 1 hour  
10 Xylene 1.5 hours 
11 Wax 4 hours  
12 Wax  5 Hours  
 
Table 2.3- Programme for Tissue Processing- The table above gives details of the steps taken in 
the tissue processing machine to prepare samples for histology. 
 
2.5.3 Embedding Tissue 
Once processed the tissue was embedded (an embedding suite (Thermo 
Scientific) was used). This involved orienting the sample in a tissue mould 
(Surgipath) in the way it was to be cut then surrounding it in liquid wax (VWR 
International).  
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2.5.4 Sectioning Tissue 
Blocks of wax containing samples (Simport) were left on ice until cooled. Blocks 
were kept on ice during the process. Sections were cut, using a C35 blade 
(Feather from Cell Path), at 4-6µm on a microtome (Thermo Scientific) and 
floated in a water bath (Thermo Scientific). The water bath was kept at 40°C 
and sections were collected onto polylysine coated microscope slides (VWR 
International). Slides were left on a heating block (Thermo Scientific) at 60°C 
overnight. 
 
2.6 Histological Staining 
2.6.1 Haematoxylin and Eosin 
This histological technique was used for both formalin fixed paraffin embedded 
(FFPE) and frozen tissue sections. As a result two slightly different protocols 
were required. 
 
FFPE sections were dewaxed with xylene (VWR International) and rehydrated in 
100%, then 70% ethanol (VWR International), then water. Frozen sections, on the 
other hand, were removed from storage at -80°C (Thermo Scientific) and brought 
to room temperature before being fixed in ice-cold acetone for five minutes 
(Fisher Scientific) then air-dried for twenty minutes. 
 
After these stages the protocols became the same for both. Slides were stained 
with haematoxylin ‘Z’ stain (Cell Path) (seven minutes) and put in running water 
to remove excess stain. After this, 1% acid alcohol (Fisher Scientific) and Scott’s 
tap water substitute (Cell Path) were used (two minutes incubation in each) for 
differentiation and were separated by rinsing in running water. 1% Eosin (Cell 
Path) in water was then used (four minute incubation) as the counter stain and 
slides were again rinsed to remove excess stain. Slides were dehydrated in 70%, 
90% then 100% ethanol (Fisher Scientific), further cleared in xylene (VWR 
International and finally mounted using xylene containing DPX mountant (VWR 
International)). 
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2.6.2 Picrosirius Red 
Picrosirius red is a mix of Sirius red (Sigma) and saturated picric acid (Sigma) and 
stains collagen fibrils. Slides were dewaxed in xylene (VWR International) and 
rehydrated in 100%, 90% and 70% ethanol (Fisher Scientific) then water. After 
this slides were placed in picrosirius red solution (Sigma Aldrich) and left until 
the stain saturated the tissues (not less than one hour). Acidified water (5ml 
glacial acetic (Fisher Scientific) acid in 995ml water) was then used to prevent 
loss of stain intensity over time (ten minute incubation). Slides were dehydrated 
in three changes of 100% ethanol (Fisher Scientific) and cleared in xylene (VWR 
International) before being mounted with DPX (VWR International). 
 
2.6.3 Astra Blue 
Tissue was cleared in xylene (VWR International) and rehydrated in 100% and 95% 
ethanol (Fisher Scientific) and water before the astra blue stain (Sigma Aldrich) 
was added to the tissue. After removing the excess stain with water, 1% aqueous 
safranin (Sigma Aldrich) was added as a counter stain. This counterstain was 
removed with tap water and tissues were dehydrated in 70% and 100% ethanol 
(Fisher Scientific) before being cleared in three changes of xylene (VWR 
International) and mounted in DPX (VWR International). 
 
2.6.4 MAC-2 
For this immunocytochemical stain slides were cleared in xylene (VWR 
International), and rehydrated in 100% and 70% ethanol (Fisher Scientific) and 
running water. After this they were placed in distilled water (Triple Red, Bucks, 
UK) then rinsed with PBS (made in-house). 3% H2O2 (Fisher Scientific) was used 
as a peroxidase block and was rinsed off with PBS (Life Technologies). A 20% 
goat serum (Vector Labs)/PBS (in-house) solution was applied as block then the 
primary rat anti-mouse mac-2 antibody (1/6000 dilution) (Cedarlane) was 
applied in a 1% BSA (Sigma)/PBS (Life Technologies) blocking solution. The 
isotype control antibody was IgG2a (BD). This was added to slides and incubated 
overnight at 4°C prior to be removed with PBS washes (Life Technologies).  
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The secondary antibody used was a goat anti-rat IgG (Vector Labs, Peterborough, 
UK) that was suspended in blocking solution as mentioned above. This was 
removed with PBS as before and replaced with a tertiary antibody solution. 
Extravadin-peroxidase (Sigma) was then applied, diluted in blocking solution 
(Dako, Ely, UK). 
 
A diaminobenzidine (DAB) substrate (Vector Labs) was left on the samples in the 
dark until sufficient time had passed to give appropriate levels of staining 
intensity. Sections were checked periodically for intensity using a light 
microscope (Zeiss). Slides were then soaked in tap water in order to quench the 
reaction. This was the substrate used for all MAC-2 staining except in the case of 
figure 4.6 in section 4.2.1.2. where red alkaline phosphatase (Vector Labs) had 
to be used instead. This was carried out as above for DAB but gave a red stain 
for positive staining instead of brown. 
 
Haematoxylin was used as a counterstain and after this step slides were 
dehydrated in 70%, 90% and 100% ethanol (Fisher Scientific) and cleared in 
xylene (VWR International) before being mounted in DPX (VWR International) and 
covered (Menzel-Glasser, Braunschweig, Germany). 
 
2.7 Microscopy 
An Axiostar or AxioImager (both Zeiss) microscope with Axiovision or ZEN (both 
Zeiss) software, respectively, was used for this. During all microscopy work, 
where possible, images and analysis were carried out blind. Six random fields of 
view at 400x magnification were taken and cell types were counted within these 
fields. These counts were used to gain a percentage value for each cell type 
over total leukocytes. 
 
For the wounding model the view fields were taken around the wound margin or 
the local cells just out-with the margin. Tissue sections were taken at different 
time-points throughout the healing process.  
 
In the compound 48/80 model it was important to ascertain any differences in 
tissue integrity as well as cell numbers. Cell number figures were obtained using 
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methods described above and the area of interest, in this model, were the layers 
of skin just below the injection site. Measuring the area of broken epidermis and 
the extent of this breach of the top skin layer also assessed tissue integrity. 
Oedema in the tissue was also measured and this was carried out using 
Axiovision software (Zeiss) again. As described previously multiple measurements 
were made and a mean value was calculated from these figures. 
 
The Experimental Autoimmune Uveoretinitis (EAU) model analysis had to adopt a 
very different approach, as required. The whole eye was assessed for 
inflammation and pathology. A customised grading guide was used during 
analysis of the eye tissue as mentioned earlier (section 1.2.2). The pathology of 
this condition has many varying outcomes/symptoms and so using this system 
allowed a fairer and qualitative` way to analyse different animals in the 
experiment.  
 
2.8 RNA Extraction 
Samples that were to be analysed by QPCR were stored in RNA Later (Qiagen) at 
4°C. They were then flash frozen in liquid nitrogen (BOC Gases) and crushed 
down to a fine powder using an RNase free pestle and mortar (Sigma Aldrich). 
The pestle and mortar was cleaned between samples and before use with 70% 
ethanol and RNase Zap (Ambion). The fine powder was placed into 1.5ml RNase 
free microcentrifuge tubes (Ambion) and RLT buffer (Qiagen) was added. The 
suspension was then passed through a blunt ended 20-gauge needle (BD). 
 
The newly lysed tissue/RLT buffer suspension was filtered through an RNeasy 
mini-kit (Qiagen) column. An optional DNase (Qiagen) digest was carried out. 
The adherent RNA was cleaned using the wash buffers provided and eluted using 
an elution buffer also in the kit. For more details please refer to commercial 
product guidelines. 
 
2.9 cDNA Synthesis 
Using a commercial kit (Stratagene, Cambridge, UK) complimentary (c)DNA was 
made from the RNA extracted using the columns. 3µg of the total RNA 
(template) was added to 1µl of primers and RNase-free water was used to make 
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up the reaction volume of 15.7µl. This reaction mix was heated to 65°C to 
denature the poly(A) tail and cooled back to room temperature to allow the 
primers to anneal to the template. 
 
This mix includes 0.8µl/sample of dNTP mix, 1µl/sample of reverse 
transcriptase, 2µl/sample of reverse transcriptase buffer, and 0.5µl/sample of 
an RNase block that, in conjunction with controlled temperature changes for 
DNA denaturing, annealing, and elongation of sequences, produces cDNA. For 
more details please read commercial product literature. 
 
The reaction mix was placed into a thermal cycler (Applied Biosystems, Paisley, 
UK) at 25°C for 10 minutes then 55°C for 60 minutes. It was then heated to 72°C 
for 15 minutes to elongate the newly synthesised strands of DNA. Once the 
programme was complete the samples were cooled to 4°C to preserve the PCR 
products. 
 
2.10 QPCR Assays 
2.10.1 Primer Design 
Sequences of genes of interest were obtained using Ensembl software 
(www.ensembl.org). In order to design and select optimal primer pairs for the 
QPCR assays ‘Primer 3’ computer software (http://frodo.wi.mit.edu/) was used. 
 
For these assays two sets of primers were designed and used. The outer primers 
produce a large product to provide a target for the inner primers essential for 
the generation of a standard curve. The smaller inner primers are designed from 
sequence of the product produced by outer primers. The specifications for 
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Specification Optimal Value Acceptable Range 
GC content 50% 40-65% 
Sequence length N/A 18-23 base pairs 
Melting Temperature (Tm) 60°C 59.5-61°C 




Amplified Product Size (Inner) 150 base pairs <150 base pairs 
Amplified Product Size (Outer) >300 base pairs >300 base pairs 
 
Table 2.4 Criteria for QPCR Primer Design. The table above shows the attributes used to design 
primers for the QPCR assays throughout the work in this thesis. 
 
Other key criteria: sequences cannot contain more than three consecutive G or C 
bases, and two or more G or C bases must be avoided within the final five bases 
at the 3’ end (‘GC clamp’).  
 
Although the above criteria are important for optimal primer design some 
attributes can be altered if primers cannot be found. As an example, GC content 
can be relaxed to 35-70% and melting temperature range can be slightly 
extended to take in 58-62°C. Making these changes allow more difficult primers 
to be designed. Once primers had been selected using the software they were 
verified using the Basic Local Alignment Search Tool (BLAST) from NIH PubMed 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 
2.10.2 Generation of a Standard Curve 
To generate a standard curve we used cDNA from a positive control sample. 2µl 
of this cell lysate was added to a pre-made PCR master mix (Rovalab) along with 
1µl of forward/reverse outer primer mix (IDT DNA). The PCR reaction was 











1 95 3 minutes 
2 95 15 seconds 
3 60 20 seconds 
4 72 40 seconds 
Repeat 2-4 for 40 cycles   
5 72 7 minutes 
6 4 Indefinitely 
 
Table 2.5 End-point PCR Run Method. This table shows the timing and steps used during standard 
end-point PCR reactions. 
 
The products of the reaction were separated out on a 2% agarose gel. Gel was 
made by adding 2g of agarose (Roche) to 100ml of tris-acetate-
ethylenediaminetetraacetic acid (TAE) buffer to which 7µl of ethidium bromide 
(Sigma) was added. A DNA ladder (type IV hyperladder (Bioline)) was added to 
the gel to allow estimation of product band size. The gel was run with 100V 
(BioRad) through it for around one hour. 
 
The gel was observed under ultraviolet light and the band representing the 
specific PCR product was cut out with a scalpel (Swann-Morton, Sheffield, UK). 
This gel portion was then stored in a nuclease-free microcentrifuge tube 
(Ambion) and extraction of the product from the gel was carried out using a 
commercial kit (Qiagen). For full protocol details please refer to the product 
manual. In brief, however, the gel was dissolved in ‘buffer QG’ (provided in the 
kit) at 50°C for 10 minutes. Isopropanol (Fisher Scientific) was added at this 
stage then this mix was added to a QIAquick® (Qiagen) column provided in the 
kit which binds the DNA. This was spun (Thermo Scientific) and the flow-through 
was discarded. After a cleaning process to enhance the quality of the final 
product, the DNA was obtained using elution buffer supplied in the kit (Qiagen). 
 
2.10.3 TOPO Cloning 
Again, this method was carried out using a commercially available kit and full 
details can be obtained from manufacturer’s literature. To briefly outline the 
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protocol, 1µl of TOPO® vector (Life Technologies) was added to 1µl of salt 
solution, a 3 times Molar excess of insert, plus nuclease-free water (Ambion) to 
make a total volume of 20µl. 
This reaction mix was left for 5 minutes at room temperature then 3µl of the 
mix was added to the chemically competent TOP10F’ One Shot® Escherichia coli 
(Life Technologies) and left on ice for 30 minutes. The bacterial mixture was 
then incubated at 42°C for 30 seconds, to heat-shock the bacteria, then placed 
on ice for 5 minutes. 200µl of super-optimal broth with catabolite repression 
(S.O.C.) media  (Life Technologies) was added to the mix and incubated for one 
hour in a shaking incubator at 37.5°C (New Brunswick Scientific, Enfield, CT, 
USA). At the same time Luria broth (LB) agar plates (made in-house) were placed 
in an incubator cabinet to pre-warm. 
After the incubation, the bacterial mixture in the S.O.C. media (Life 
Technologies) was spread onto the pre-warmed LB agar ampicillin (Sigma 
Aldrich) (50µg/ml) plates at 37°C overnight. The next day a suitable colony was 
selected with a pipette tip (Starlab, Milton Keynes, UK) and added to 5ml of LB 
plus ampicillin (Sigma Aldrich) (50µg/ml) and incubated overnight at 37°C to 
allow bacteria to proliferate. 
 
2.10.3.1 Purification of DNA from the Bacterial Vector 
The following protocol was carried out using reagents from a commercial kit 
(Life Technologies) and full details can be obtained from product literature. 
Following on from the section 2.10.3, the E. coli culture was centrifuged and 
pelleted bacteria were resuspended in buffer plus lysis buffer added. 
The next buffer that was added precipitates the genomic DNA but leaves the 
plasmid DNA in suspension, as a result when the suspension and precipitate is 
centrifuged the supernatant was carried forward and the pellet was discarded. 
This supernatant is added to a spin column to purify the plasmid DNA. It was 
spun at 13000 x g and the flow-through was discarded. The column was cleaned, 
using buffers provided, then spun again to remove any residual wash buffer. The 
plasmid DNA was harvested using elution buffer and the final product was then 
ready to be used in QPCR assays. 
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The above protocols results in a solution of plasmid DNA that, after a set of 
serial dilutions, gives a series of standards that can be quantified. A 1:100 
dilution, 5µl of the pure solution was added to 495µl of elution buffer (Qiagen), 
gives a 10-2 solution. This process is repeated giving 10-4 and then 1:10 dilutions- 
50µl into 450µl were repeated until a concentration as low as 10-9 is made. To 
quantify the absolute copy number in each of the dilutions the optical density 
(O.D.) was be measured using a nanodrop (Thermo Scientific). 
 
2.10.4 Standard Verification 
2.10.4.1 Verification by PCR 
Once standards had been produced and cloned the inner primer pair had to be 
tested. This was done by regular polymerase chain reaction (PCR). The standard, 
at a concentration of 10-5, was used routinely as a template for this test. The 
standards were added as template (3µl) and the inner primer mix (0.5µl of each) 
was added to a pre-made master-mix (Rovalab). The reaction was carried out 





1 95 3 minutes 
2 95 15 seconds 
3 60 20 seconds 
4 72 40 seconds 
Repeat 2-4 for 40 cycles   
5 72 7 minutes 
6 4 Indefinitely 
 
Table 2.6- End-point PCR Run for Standard Verification. The table above shows the details for 
the end-point PCR run that was used to confirm the standards designed for the QPCR were 
appropriate for the final assay. 
 
A 2% agarose (Roche) gel was made up (2g of agarose to 100ml of TAE buffer) 
with 7µl of ethidium bromide (Sigma Aldrich). Once the PCR was complete 20µl 
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of the reaction product was added each well of the gel. A DNA ladder (type IV 
hyperladder (BioLine)) was also added to determine the size of the PCR product. 
 
The gel was run at 100V (BioRad) for 30-40 minutes. Once the gel had run for a 
sufficient length of time it was imaged under UV light (AlphaImager, East Sussex, 
UK).  
 
2.10.5 QPCR Assay Proper 
Following the verification of the standards and inner primers the formal QPCR 
assay can go ahead (section 2.10.4). The cDNA preparations were generated as 
described earlier in the section entitled ‘cDNA Synthesis’ (2.9). Master mix was 
made up as described earlier and are listed below: 
 
Ingredient Volume (µl/well) 
SYBR© Green Fast Mix (VWR) 10 
Nuclease Free Water 
(Ambion) 
8.2  
Primer Mix (IDT) 0.4 
  
Table 2.7- Ingredients of QPCR Master Mix- The table above lists the reagents and volumes used 
to make a master mix for the QPCR assay. The values given are per well as stated. 
 
An example of the quantities and working for the make-up of this master mix are 
listed below: 
 
26 templates in triplicate= 78 wells 
 
78 x 15%    = 89.7 
 
10µl/well of SYBR© Green Fast Mix (VWR) x 89.7 = 897µl  
8.2µl/well of Nuclease Free Water x 89.7= 735.54µl 
0.4µl/well of primer mix x 89.7= 35.88µl 
 
Total volume of Master Mix made up= 1668.42µl 




6µl of template (cDNA sample) was added to 54.5µl of the master mix per well 
of the set-up plate. The well contents of the set-up plate were mixed thoroughly 
to ensure consistency between replicates. After mixing, 19.6µl of this template 
and master mix was added to the QPCR plate (Applied Biosystems). In this 
example the plate was set up with 18 samples, 1 control, 6 standards, and 1 
non-template control (NTC) all in triplicate. The plate was covered with a 
plastic film (Applied Biosystems), spun down in a refrigerated centrifuge, at 
400g for 15 seconds and run in the QPCR (Applied Biosystems) machine. The 





1. 95 20 
2. 95 3 
3. 30 30 
Repeat 2-3 40 times   
4. 95 15 
5. 60 15 
6. 95 15 
 
Table 2.8 Run Details for QPCR Assay. The table above gives the timings and temperatures for 
each step of the QPCR assays used throughout the work presented in this thesis. 
 
2.10.5.1 QPCR Primers 
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Gene of Interest Forward Primer (5’ > 3’) Reverse Primer (5’>3’) 
Mouse 
ACKR2  TTCTCCCACTGCTGCTTCAC  TGCCATCTCAACATCACAGA 
α-SMA CCTGAAGAGCATCCGACAC  AGAGGCATAGAGGGACAGCA 
Collagen I GACTGGCAACCTCAAGAAGG ATGACTGTCTTGCCCCAA 
 
 







Collagen Ivα TGCTACCCTGCTGTTCCTTC GTGCCCAAAATACTCCTCCA 
 
Human 





Table 2.9 Primer Details for QPCR. The specific sequences used for QPCR analysis during this 
thesis are listed above. 
 
2.10.5.2 Analysis of QPCR Data 
The data from the QPCR assay were exported into a Microsoft Excel spreadsheet. 
The data generated from the reference gene assay were analysed first on the 
spreadsheet. The optical densities of the standard generating wells were used to 
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27.8 ng/µl = 2.78x10-8 g  
 
2.78x10-8 g x 6.02x1023 (Avogadro’s Constant)/ 68640 (molecular weight of target 
product) = 2.44x1011 copies/µl  
 
2.10.5.3 QPCR Quality Control 
In order to ensure the reliability of the results gained through QPCR assays for 
this thesis a systematic quality control approach was taken. This included 
thoroughly testing standard curves (as listed in 2.10.4), removing reverse 
transcriptase from random test samples during cDNA synthesis to ensure no 
genomic DNA was being amplified, addition of non-template controls (samples 
with QPCR master mix but with water instead of cDNA) and by running and 
examining the melt curve generated after the assay. 
2.11 Cell Culture 
Cell lines were incubated at 37°C in an atmosphere containing 5% CO2 (Thermo 
Scientific) unless otherwise stated. All cell lines used for the work done here 
were tested for mycoplasma infection prior to work being undertaken. This was 
done with a luminescence assay using a commercial kit (MycoAlertTM (Lonza)) and 
read using a fluorometer (Fluoroskan AscentTM FL (Thermo) cells were verified as 
being mycoplasma-free using this system. 
 
2.11.1 Culture of Human Embryonic Kidney (HEK) 293 Cells 
This adhesive cell line required cell dissociation buffer (Sigma) to remove cells 
from the flask. The spent medium was removed from the cells and the 
dissociation buffer was added to the flask. This was incubated for up to 10 
minutes at 37°C. Cells were removed from the flask, placed in a 50ml tube (BD) 
and centrifuged (Thermo Scientific) at 200 x g for 5 minutes.  
 
HEK 293 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) plus 
sodium pyruvate, L-glutamine, Penicillin/Streptomycin and 10% foetal bovine 
serum (all Life Technologies). Once the cells had been spun, the supernatant 
was removed and the pellet was re-suspended in 10 ml of fresh medium. 1ml of 
this cell suspension was added to 29ml of fresh medium to give a ‘split’ of 1:10. 
This new suspension was added to a T75 flask (Corning). 
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2.11.2 Subculture of ARPE-19 Cells 
The ARPE-19 cell-line was grown in a 1:1 mix of Dulbecco’s Modified Eagle 
Medium (DMEM) (Life Technologies) and Hank’s F12 medium (Sigma Aldrich). To 
this mix L-glutamine, Penicillin/Streptomycin and 10% foetal bovine serum (all 
Life Technologies) was added. The cells were incubated as previously stated and 
required to be ‘split’ every 48 hours. 
 
When ‘splitting’ these cells 3.0mL of (0.05% w/v) trypsin-0.53 mM EDTA solution 
(Life Technologies) was added to the cells after discarding the growth medium. 
Cells were rinsed with trypsin-EDTA solution. After this 3.0ml of trypsin-EDTA 
was added again and the cells were placed in the incubator for 5-10 minutes and 
monitored for cell dissociation using an inverted microscope (Zeiss). 8.0mL of 
growth medium (Life Technologies/Sigma) was then added to the cell solution, 
to remove the cells. This was then harvested and placed in a 50mL centrifuge 
tube (BD). Cells were spun down (Thermo Scientific) at 125 x g for 10 minutes. 
 
After centrifugation, supernatant was removed and the cell pellet was 
resuspended in 9mL of fresh growth medium (Life Technologies/Sigma). 3mL of 
the fresh cell suspension was then added to a 50mL centrifuge tube (BD) 
containing 27mL of fresh growth medium (Life Technologies/Sigma) to give a 1 in 
3 split of the cells.  
 
2.11.3 HDLEC Cell Culture 
Human dermal lymphatic endothelial cells (HDLEC) were bought in (Promocell 
(Heidelberg, Germany)) and grown in a T25 culture flask (Corning). These 
primary human cells were grown to confluency in endothelial growth medium 
(Promocell) with added supplements provided (basic Fibroblast Growth Factor, 
Insulin-like Growth Factor (Long R3 IGF-1), and Vascular Endothelial Growth 
Factor). The medium was also supplemented with penicillin/streptomycin 
(Sigma) and gentamycin (Sigma). HDLECs were then transferred into a T75 flask. 
2.12 Flow Cytometry 
ARPE-19 cells were removed from the tissue culture flask using a non-enzymatic 
cell dissociation buffer (Life Technologies) and washed in PEF before being 
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centrifuged and resuspended in PEF. Using a haemocytometer (VWR 
International) approximately 1 x 10
7 
freshly isolated cells were harvested by 
centrifugation at 300 x g for 5 minutes at 4
o
C then washed three times with PEF 
buffer and re-suspended in chilled PEF. In order to stain intracellular ACKR2 the 
cells had to be fixed and permeablised. This was achieved using a commercially 
available kit (Cytofix/CytopermTM (BD)). Cells were incubated with 
Cytofix/CytopermTM buffer (BD) for 20 minutes at 4
o
C then cells were washed 
twice in 1x Perm/WashTM buffer (BD). The samples used for intracellular analysis 
were washed in 1x Perm/WashTM buffer (BD) from this point onwards, antibodies 
were also diluted in the same buffer for these samples. 
Primary antibodies (in-house made mouse anti-human ACKR2 (clone 4A5)) or 
isotype control (mouse anti-human IgG2a (Dako)) were then diluted in chilled 
PEF and added to the cells and left to incubate for 15 minutes with occasional 
gentle agitation. Samples were washed twice with 2ml chilled PEF before being 
incubated with fluorescently-labelled secondary antibodies (anti-mouse FITC 
(R&D Systems)) in PEF on ice for 15 minutes with occasional gentle agitation. 
Cells were washed twice more with 2ml chilled PEF and re-suspended in 200µl 
PEF. A live/dead cell discriminator-Viaprobe (BD Biosciences, San Jose, CA, 
USA)- was used to identify viable and non-viable cells, respectively. Samples 
were analysed on the MACSquant analyser (Miltenyi Biotec).  
Both stained cells and cells from the competition assays were analysed using a 
MACsquant
TM 
analyser. Parameters for acquisition and data collection were 
established using unstained cells. Data was analysed subsequent to acquisition 
using MACSquantify
TM 
software (Miltenyi Biotec), using unstained samples to 
ascertain a gating strategy.  
2.13 Statistical Analyses 
Throughout all of the models shown in this thesis the Graphpad (Prism) 
statistical analysis software was used. The test(s) carried out for each piece of 
data, along with the relevant statistical information, is listed in the figure 
legend of each figure in the coming results chapters. In all figures error bars 
represent standard deviation (SD). 
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Chapter 3- The Role of ACKR2 in 
Cutaneous Inflammation 
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Chapter 3 The Role of ACKR2 in Cutaneous 
Inflammation 
3.1 Introduction 
3.1.1 Skin: An Overview 
To paraphrase Henderson’s Dictionary of Biology, an organ is a part or structure 
within an organism that serves a specialised function (Lawrence, 2008). This, by 
definition, makes the skin the largest organ in the human body. Skin is a multi-
layered tissue that differs in architecture and structure depending on anatomical 
location and function. 
 
The constitutive layers of human and murine skin are the epidermis, dermis, and 
sub/hypodermis. In humans the epidermis is made up of the stratum corneum, 
stratum lucidum, stratum granulosum, stratum spinosum, and stratum basale 
(Martini, Nath and Bartholomew, 2012), however in mice this layer is 
considerably less complex with only four layers. Another feature that separates 
mouse skin from human is that the murine hypodermis contains a layer of 
striated muscular tissue which human skin lacks (Treuting et al., 2012). 
 
Skin carries out many specialised functions including, amongst others: providing 
a crude barrier to prevent entry of pathogens into an organism; maintaining 
homeostasis by helping regulate temperature; protecting our organs from 
harmful UV radiation and from physical damage (Martini, Nath and Bartholomew, 
2012). Considering the aforementioned functions of the skin, it becomes clear 
that any breaches, or trauma, in this tissue require rapid and efficient 
resolution. A perfect healing process would result in the newly formed skin being 
identical to the tissue it replaced. In reality, the damage is never resolved to its 
previous structure and strength, and fibrotic scar tissue forms at the site 
instead. It is thought that the process of scar formation is the result of an 
evolutionary push towards rapid repair (Bayat, McGrouther and Ferguson, 2003). 
It seems logical that, due to the unhygienic conditions we may have lived in 
many years ago, rapid repair would be highly advantageous. As a result of this, 
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our wound healing process is more focused on rapid repair over perfect 
regeneration. As a consequence scars form.   
 
Damage to the skin causes the induction of the inflammatory mechanisms 
discussed in the introductory chapter to this thesis (section 1.1.1). Chemokines 
play an indispensible role in the propagation, maintenance and resolution of 
these processes. During inflammation, immune cells are recruited to areas of 
trauma and danger. Local cells at the damaged or infected site release 
chemokines and cytokines to signal trauma and that, in turn, initiates the body’s 
defence mechanisms. 
 
3.1.1.1 The Cutaneous Environment 
The skin is an amazingly adaptable organ and, under resting conditions, consists 
of both resident tissue/stromal and immune sentinel cells (Igyártó et al., 2011). 
These developmentally distinct cells work together to carry out surveillance of 
the tissue and react to signs of infection and damage. The skin is the main 
interface between the host and the outside world and so is constantly exposed 
to potentially immunogenic mediators. The skin harbours trillions of commensal 
bacteria and it has been shown that these play a role in tissue homeostasis and 
shaping the cutaneous immune response (Naik et al., 2012, Sanford and Gallo, 
2013). It has been suggested that resident dendritic cells of the skin present the 
peptides from these commensals to CD8+ T cells and in turn this bolsters the 
barrier function of this tissue. A paper by Naik et al suggested that this process 
exquisitely shapes the immune response of the skin (Naik et al., 2015). This 
would suggest that, under physiological conditions, these microorganisms have a 
protective role to play for the host. However, this may not be the full story. 
 
A study by Canesso et al in 2014 showed evidence from germ-free mice that 
suggested a detrimental effect of the skin microbiota during the repair of 
excisional wounds. They showed that in the absence of these commensals the 
wound repaired more rapidly, with a scar-free phenotype and with a significant 
reduction in infiltrating immune cells. The main immune cell that they reported 
to be reduced was neutrophils (Canesso et al., 2014). It has also been shown 
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that by removing cells that express the transcription factor PU.1, a regulator of 
myeloid cells, results in a ‘scar-free’ repair phenotype (Martin et al., 2003). 
 
Another unique feature of the skin is the presence of the follicular stem cells 
that populate it. Hair follicles of the epidermis have been suggested to be 
immune-specialised as well as being sites of frequent immune cell interaction. 
Macrophages and mast cells of the skin have been shown to interact with these 
structures. It has also been suggested that the follicles may act as a ‘portal’ for 
epidermal entry of effector cells (Chou et al., 2013).  
 
3.1.1.2 Chemokines and Receptors in the Skin 
One of the key roles of chemokines is to attract cells to discrete anatomical 
locations and to retain them there. In this regard the skin is no exception. 
Stromal cells of the skin release chemokine ligands that recruit cells bearing 
cognate receptors under both inflammatory and physiological conditions. Three 
molecules have been shown to help regulate skin homing in both mice and 
humans, these are CCR4, CCR10 and the cutaneous lymphocyte antigen (CLA) 
(Reiss et al., 2001). It has been shown that interactions between CLA and E-
selectin mediate the exit of lymphocytes from the cutaneous venules in much 
the same way as described for neutrophil extravasation in the introductory 
chapter (Santamaria Babi et al., 1995). 
 
Keratinocytes of the basal epidermis secrete the chemokine CCL27 which binds 
to the receptor CCR10 (Homey et al., 2000) in an axis that is responsible for the 
recruitment of T cells to the skin (Homey et al., 2002). This is a constitutive 
process that allows for the positioning of skin-resident memory T cells, also 
known as peripheral tissue immune surveillance T (TPS) cells (Sigmundsdottir et 
al., 2007). An interesting process that imprints skin-homing specificity on these 
T cells involves ultraviolet (UV) light from the sun. As the skin is exposed to UV 
light, vitamin D3 is metabolised into its active form 1,25(OH)2D3  by dendritic 
cells. In a process known as ‘imprinting’ these specialised DCs induce the 
expression of CCR10 on T cells in the local lymph node (Sigmundsdottir et al., 
2007). 
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The other key chemokine receptor for lymphocyte recruitment to the skin under 
physiological conditions is CCR4 (Reiss et al., 2001, Gehad et al., 2012). The two 
ligands for CCR4 are CCL17 and CCL22 and, of these, CCL22 has a higher affinity 
for the receptor. Interestingly it has been shown that there is an accumulation 
of these ligands associated with lesions of cutaneous T cell lymphoma (Ferenczi 
et al., 2002) and that antibody-mediated interference with the receptor is of 
therapeutic benefit to the patient (Han et al., 2012). This axis is also involved in 
atopic responses in the skin (Gehad et al., 2012). 
 
3.2 Wound Healing 
Since as early as 1500 BC the subject of wound healing has been investigated. 
Research into the care of wounds can be traced all the way back to ancient 
Egypt (Sipos et al., 2004, Majno, 1975). This was of interest to ancient 
civilisations as modern medicine was not available and so efficient healing was 
essential to prevent infection. It is still an area of active research, thankfully for 
different reasons, within the scientific and medical communities. The purpose of 
research in this area is now to optimise the way our bodies heal after trauma so 
that we can prevent chronic wounds or hypertrophic scar formation. 
 
Wound healing is, after birth, one of the most complex biological processes that 
the body can go through (Gurtner et al., 2008). The inevitable product of wound 
healing is scar formation, as mentioned, and it is thought that this may be a 
product of evolutionary pressure to rapidly close off denuded tissue at the 
expense of perfect regeneration. Both humans (Colwell, Longaker and Lorenz, 
2003) and mice (Adzick and Longaker, 1991) in the foetal stage of development 
seem to recover from wounds without the formation of scar tissue. Many 
questions have been raised about the underlying mechanisms of this process.  
 
Some postulated (Block, 1960) that it might be a product of the sterility, local 
proteins and growth factors in the foetal environment. To address this 
hypothesis experiments were carried out using marsupials. The thinking behind 
this was that when these animals are born they are still anatomically and 
physiologically in a foetal state. The offspring then survive in a maternal pouch 
until fully developed; this pouch is free of any sort of placental nourishment 
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and, importantly, is a non-sterile environment. Work in these studies found that 
wounding the developing opossum in the maternal pouch did not result in a scar 
until a particular time-point of development. Wounds inflicted six days or more 
before leaving the pouch healed in a scar-free process, any wounding after this 
time-point resulted in the formation of a scar (Armstrong and Ferguson, 1995). 
Interestingly it is at this time in development that the opossum begins to 
develop an innate immune system (Armstrong and Ferguson, 1995). This work 
suggested that the placental milieu was not the key mediator of foetal scar-free 
wound healing and that the developing immune system is more causative of scar 
production. 
 
The classical model of skin repair involves three or four phases. The first step, 
according to some, is haemostasis. This is a platelet-driven phase where these 
vasoactive particles become activated and form a fibrin clot to stop 
haemorrhage (Coller, 2011). The α-granules of the platelets also release a 
plethora of mediators such as cytokines, chemokines and growth factors to 
induce repair processes and recruit immune cells (Hundelshausen et al., 2005). 
The inflammatory phase follows on from this and involves the influx of cells such 
as neutrophils and monocytes/macrophages which phagocytose cellular debris 
and neutralise invading pathogens at the wound site (Gurtner et al., 2008). 
Following this the proliferation stage commences. The main feature of this 
phase is the formation of granulation tissue and, during this, angiogenesis and 
collagen deposition also occur. This is the early-repair portion of the response 
where fibroblasts produce a provisional extracellular matrix and epithelial cells 
proliferate and migrate to the surface of the wound to create a covering of new 
tissue (Gurtner et al., 2008). The final phase of this model is the maturation 
stage. This is the late-repair phase where the new tissue, laid down in the 
previous stage, is strengthened and reinforced. The newly synthesised collagen 
is remodelled and unneeded cells undergo apoptosis. It takes up to two years for 
this process to be completed in humans (Gurtner et al., 2008). 
 
3.2.1 Healing Processes 
Three forms of wound healing have been described and they depend on the form 
that the original wound takes. Healing by Primary Intention is probably the most 
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common form of wound healing. This occurs when the two leading edges of the 
epithelium are in close proximity. This process would occur following a 
laceration or incisional wound (Standring, n.d.). This healing reduces scarring as 
less new tissue synthesis is required and is far less traumatic for the local tissue. 
Healing by Secondary Intention occurs after an excisional wound- i.e. removal of 
an area of skin leaving a large open wound needing repaired. This process 
involves the synthesis of granulation tissue- puffy red looking skin that is very 
well vascularised- and can result in extensive scarring (Standring, n.d.). During 
this wound healing process, large amounts of new tissue have to be synthesised 
in order to repair the wound fully. This type of healing would occur in large 
surgical wounds for example. Finally, healing by Tertiary Intention involves 
clearing and debridement of the tissue and the wound is left open purposely and 
would only really occur during procedures like tissue grafting (Standring, n.d.). 
The work in this thesis focuses mainly on excisional wounding and so healing in 
these models is by Secondary Intention. That being said many of the process, 
cells and factors involved are essential in all types of wound healing regardless 
of healing method and wound type. 
 
The healing process of cutaneous tissue, after a wound, is a complex one and 
needs to be tightly regulated as ‘under-aggressive healing’ could lead to a 
chronic wound, or ‘over-aggressive healing’ could lead to a hypertrophic or 
keloid scar (Yang et al., 2003). The key to wound healing is to replace damaged 
tissue with new skin that is as structurally similar, high in tensile strength, and 
elasticity as its predecessor. As mentioned earlier, the inevitable result of this is 
the formation of scar tissue. A scar will never reach the full tensile strength of 
normal unaffected skin but it should recover the vast majority of this original 
strength (Standring, n.d.). At around three-weeks post wounding in humans, 
collagen deposition peaks in the scar. Tensile strength at this time, however, is 
a mere 15% of local unaffected skin (Hardy, 1989). Interestingly research has 
shown that wounds that repair under increased tension repair with scars of a 
higher tensile strength (Pickett et al., 1996). This has lead to the development 
of some dressings that apply tension over the healing wound to increase scar 
tensile strength. 
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Hypertrophic scars are a result of uncontrolled fibrosis of the skin and follow a 
similar pathophysiology as other fibrotic disorders in the body (Mori et al., 
2001). The cells, growth factors, and processes involved in pathologies such as 
pulmonary fibrosis and renal fibrosis are very similar to those involved in 
cutaneous fibrosis (Mori et al., 2001). From wound to fully formed scar is 
thought to take around one hundred days in humans (Gurtner et al., 2008). For 
the first three weeks or so the local stromal cells are laying down new collagen 
and repairing nearby damaged areas under the influence of immune, stromal, 
and mesenchymal cells (Gurtner et al., 2008). From here until the process is 
finished the main objective for the skin cells is scar maturation. This is when the 
scar tissue gains tensile strength (Standring, n.d.). This process is highly 
dependent on growth factors and cells to achieve these goals. 
  
The result of an over-healed wound is a hypertrophic scar. The result of an 
under-healed wound is a chronic wound. For one or more of many reasons 
wounds can fail to heal appropriately and fall into one of these two categories. 
Some groups are more susceptible to this than others including obese, diabetic 
(Nguyen et al., 2013), and genetically predisposed patients. 
 
3.2.1.1 The Monocyte/Macrophage Axis and Beyond 
Of all the immune cells involved in wound repair the monocyte/macrophage 
system seems to play one of the most pivotal roles and is involved in all stages of 
the repair process (Rodero and Khosrotehrani, 2010). Macrophages have a 
dichotomous role in wound healing both as immune cells and as tissue growth 
promoting cells (Brancato and Albina, 2011). During the early stages of the 
wound repair response blood monocytes are recruited to the damaged site and 
these mature into tissue macrophages (Brancato and Albina, 2011). As discussed 
in the introduction section of the thesis (1.1.1.4), there are multiple subsets of 
monocytes and it has become apparent that the macrophage population in 
wounds reflect this (Daley et al., 2010).  
 
One of the key roles of macrophages as they invade the wound bed is to 
phagocytose debris and apoptotic neutrophils, a process known as efferocytosis 
(Brancato and Albina, 2011). The idea of macrophages engulfing neutrophils was 
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proposed by the man who discovered the cells, Metchnikoff (Metchnikoff, 1893). 
In a process that aids in the control of inflammation, macrophages can directly 
induce apoptosis of neutrophils through interactions between CD36 and the β3 
integrin in the presence of membrane-bound TNF-α (Meszaros, Reichner and 
Albina, 2000). It is proposed that macrophages that are derived from CCR2+ 
monocytes in mice are able to carry out this apoptotic induction however, in a 
two-part mechanism; it is then that the CX3CR1+ monocyte-derived macrophages 
phagocytose the dead neutrophil (Brancato and Albina, 2011). The phagocytosis 
of apoptotic neutrophils induces a profibrotic phenotype in macrophages and 
stimulates the release of key mediators such as TGF-β1 and VEGF (Savill and 
Fadok, 2000).  
 
To add to this, wounding models carried out in CX3CR1 null mice show reduced 
wound closure capacity. These wounds contain fewer macrophages and 
myofibroblasts, a cell key to wound contraction (Hinz et al., 2007). There are 
also decreased levels of VEGF and TGF-β1 (Ishida, Gao and Murphy, 2008). More 
details on these two key mediators in wound repair will be provided later on in 
this Chapter.  
 
At the subsequent restorative phase more macrophages are recruited, but in this 
stage they are there to serve a more reparative function (Lucas et al., 2010). In 
the final stage of repair where the purpose is to aid in the maturation of the 
developing scar macrophages are also present. It has been shown that 
macrophage numbers increase during the inflammatory stage, reach a pinnacle 
during the early repair phase and then decline during the later repair phase 
(Martin and Leibovich, 2005).  
 
A possible reason for these cells seeming to be of such high importance is that 
they have an effect on the healing process at every key stage (Brancato and 
Albina, 2011). In 2010 Lucas et al (Lucas et al., 2010) set-out to define the 
specific roles played by macrophages at each phase of the wounding response by 
selectively knocking them out at specific times. This elegant study showed that 
depletion of macrophages before/during the initial inflammatory response 
resulted in a delay in the formation of granulation tissue and epithelialisation in 
the latter early stages of the repair response. They proposed that this was down 
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to a failure to recruit alternatively activated macrophages that have a key role 
in repair. The group also showed in this study that macrophages recruited during 
the mid-stage of the response were important in aiding the stability of newly 
forming blood vessels and granulation tissue. The macrophage-depleted mice 
had such unstable new vessels that they suffered haemorrhage. Finally, they 
suggested that depletion of macrophages in the final maturation phase of the 
response had a minimal affect (Lucas et al., 2010). 
 
What may not be so intuitive is that, as mentioned above, many of the growth 
factors that these cells can produce and secrete also play a part in the 
production of new tissue in the proliferation stage of the healing process. 
Macrophages secrete factors such as TGF-β1, fibroblast growth factor (FGF), and 
vascular endothelial growth factor (VEGF) to initiate the process of re-
epithelialisation (Brancato and Albina, 2011). This step in the course of healing 
commences just hours after the trauma and these macrophage-derived growth 
factors act on tissue cells such as fibroblasts, endothelial cells and keratinocytes 
to produce new tissue. Keratinocyte migration ceases when the epidermal 
barrier is restored (Raja et al., 2007).  
 
3.2.1.2 Mast Cells 
Mast cells (MC) are involved in multiple stages of the healing response (Noli and 
Miolo, 2001). They are abundant in barrier tissues and the dermis is a site of 
fairly high mast cell presence (Noli and Miolo, 2001). It has been shown that 
mechanical damage is enough to activate these cells and, as a result, they are 
activated very early in response to a wound (Egozi et al., 2003).  
 
Activation leads to the release of mediators like histamine and vascular 
endothelial growth factor (VEGF), which cause vasodilation to aid the acute 
response and the recruitment of effector cells (Canesso et al., 2014). Chymase, 
an enzyme released by MC, has been shown to play a role in neutrophil 
recruitment. Histamine can also stimulate the release and production of pro-
inflammatory cytokines by keratinocytes. Human keratinocytes express the H1 
histamine receptor (Giustizieri et al., 2004) and activation of this results in the 
release of CCL2, CCL5, CCL20 and CXCL10 from the cells.  




MC also aid in the proliferation stage of the healing response (Succar et al., 
2014).  Mice that lacked some key proteases of murine MC showed much reduced 
blood vessel formation in the second stage of wound healing (Succar et al., 
2014). The stimulation of keratinocytes, mentioned above, also induces the 
release of growth factors and cytokines that aid the re-epithelialisation process. 
Through some of the many active mediators that mast cells release they can aid 
angiogenesis indirectly and they can activate fibroblasts directly. They produce 
keratinocyte growth factor (KGF) and epidermal growth factor (EGF) both key 
growth factors in the repair process that will be discussed in more detail in 
section 3.2.3.  
 
A number of studies in MC null mice have suggested that these cells are 
dispensable in wound repair. Although subtle differences were noticed, such as 
collagen remodelling (Iba et al., 2004) differences between the models, the 
general consensus was that these were not vital cells  (Antsiferova et al., 2013, 
Nauta et al., 2013). Some studies have shown the opposite of this though and 
suggested a key role for MC in repair (Weller et al., 2006). 
 
Reports have suggested that MC can also affect scar formation in mice and 
humans. Studies have shown a negative correlation between MC 
number/activation state and levels of scarring (Canesso et al., 2014). Oral 
wounds heal with minimal scarring and oral mucosa contains fewer MC during 
wounding than cutaneous tissue. However the levels of moisture in the oral 
mucosa may also have a profound effect on the healing process (Costa et al., 
2011). Some studies suggest a role for MC in collagen/scar maturation (Iba et al., 
2004). The increased presence of MC has also been shown in other fibrotic 
diseases such as systemic sclerosis where auto-IgE antibodies have been shown 
to activate these potent cells (Akimoto et al., 1998). 
 
3.2.1.3 Neutrophils 
Neutrophils are involved in wound healing arriving earlier than recruited 
macrophages although their action does not last as long- their role ending at 
around day five during a normal response (Gurtner et al., 2008). It is now 
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thought that these cells can carry out almost all of the functions of macrophages 
including antigen presentation- they have been shown to upregulate class II 
major histocompatibility complex (MHC-II) in inflamed lesions (Geng et al., 
2013). The trauma of the injury suffered during wounding to the local tissue 
causes CXCL8 production (Roupé et al., 2010). This chemokine is highly 
chemotactic for neutrophils. Work by Lammermann et al suggested that once 
neutrophils had left the circulation the signal from chemokines was less 
important for movement in the interstitium (Lammermann et al., 2013). This 
paper described an essential role for the lipid mediator leukotriene B4 (LTB4) in 
the ‘swarming’ phenomenon attributed to these cells. They also showed that the 
death of these cells catalyses this response (Lammermann et al., 2013). When 
the effect of phagocytosis of neutrophils is considered this positive-feedback 
situation has potential to be an important factor in appropriate wound healing 
responses. 
 
The key role for these cells during wound healing is probably to quickly and 
efficiently phagocytose any opportunistic pathogen or foreign debris that may 
have entered the host at the wound site. It is then the role of the macrophages 
or other neutrophils (Martin and Leibovich, 2005) to phagocytose the dead or 
dying neutrophils.  
 
3.2.1.4 Platelets 
Platelets are defined as non-nucleated small disc-shaped cell fragments that are 
involved in blood clotting, which gather at sites of damage and release clotting 
factors (Gurtner et al., 2008). When skin is wounded, a fibrin clot is produced. 
This is achieved by the cross-linking of fibrin polymers that act as a temporary 
barrier to protect the host where the tissue has been breached. Platelets 
contain granules that are released when the platelet is activated. Of these 
granules, the alpha (α)-granules are the most abundant (Blair and Flaumenhaft, 
2009) and can single-handedly aid the wound healing processes in several tissues 
(Anitua et al., 2005, Nagai et al., 2005, Moulin et al., 1998).  
 
It has been shown that, from α-granules, platelets are capable of releasing the 
chemokine CCL5 which is responsible for inflammatory cell recruitment 
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(Kameyoshi et al., 1992). This suggests that these cell fragments are more than 
just players in the blood-clotting cascade. Platelets have also been implicated in 
cutaneous pathologies such as psoriasis with an aggregation of these fragments 
being seen around psoriatic lesions (Hayashi et al., 1985). It is now widely 
thought that these cell fragments are key to repair downstream of the 
coagulation of microvessels in the injured locale. In wound healing the blood 
clot formed by, and rich in, platelets, acts as a reservoir of chemokines and 
growth factors that are released to enhance the reparatory process. 
 
The important role of platelets in wound healing is highlighted by platelet-
associated treatments that are being increasingly employed in patients with 
chronic wounds such as diabetic ulcers (Margolis et al., 2001). One treatment 
involves the topical application of platelet rich plasma (PRP) to the wounded 
tissue. PRP can increase the levels of local growth factors such as TGF-β1, 
platelet-derived growth factor (PDGF), EGF, insulin-like growth factor (IGF) and 
VEGF. The importance of these growth factors will be discussed later but 
increasing the levels in the local milieu appears to be advantageous to the 
patient.  
 
The other treatment is known as platelet-derived wound healing factor (PDWHF) 
and is the releasate of thrombin-activated platelets (Knighton et al., 1986). 
Although the mechanism by which this treatment works is not completely 
understood, in some studies it showed significantly accelerated wound healing 
when compared to placebo treatments (Steed et al., 1992, Margolis et al., 
2001). However other studies have shown no real effect (Senet et al., 2003). 
 
3.2.2 Stromal Cells in Repair 
Cells of the immune system are of the highest importance at the early stages of 
repair. Later on, once any potential infection has been cleared and during the 
re-epithelialisation and remodelling phases, the stromal cells play the key roles 
in repair, mainly under the influence of growth factors. Stromal cells are cells 
that produce new elements of tissue and extracellular matrix. Fibroblasts, 
myofibroblasts, keratinocytes and endothelial cells are all examples of this cell 
type that are involved in wound healing (Stappenbeck and Miyoshi, 2009). 




Dermal fibroblasts are key cells in the wound repair response (Wong, McGrath 
and Navsaria, 2007). These cells are important for the synthesis and deposition 
of extracellular matrix (ECM) and they have been shown to proliferate and 
migrate in response to cutaneous damage (Wong, McGrath and Navsaria, 2007). 
Fibroblasts commence migration towards the wounded tissue around five days 
post-injury and are capable of synthesising new collagen fibres (Musyoka et al., 
2013). Growth factors such as fibroblast growth factor (FGF) and transforming 
growth factor (TGF)-β1 are responsible for activating this cell type to produce 
molecules such as collagen (Colwell et al., 2005).  
 
In vitro work on these cells has suggested that under the influence of TGF-β1, 
endothelin-1, and IL-1 released from keratinocytes, fibroblasts undergo 
differentiation into proto-myofibroblasts. From here, with further TGF-β1 and 
IL-1 influence, these cells become myofibroblasts (Shephard et al., 2004a, 
Shephard et al., 2004b). These differentiated cells are equipped with properties 
of both fibroblasts and of smooth muscle cells, hence the name. They express 
alpha-smooth muscle actin and, during wound healing, are important in the 
contraction of the wound edges for closure. As mentioned previously, healing 
under tension is required to provide the resulting scar with tensile strength; 
these cells provide much of this. During both incisional wounding and healing by 
Second Intention, these cells are vital to repair.  
 
Keratinocytes are a key stromal cell of the skin. One of the most essential events 
in wound healing is re-epithelialisation and the migration and proliferation of 
these cells is key to this (Werner, Krieg and Smola, 2007). Despite this, the 
details of the migration of these cells to the site of the wound bed are still 
poorly defined. Keratinocytes express the LTB4 receptor BLT2 (Liu et al., 
2014a). Agonism of this receptor with another of its ligands, 12(S)-
hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT), has been shown to increase 
the efficiency of wound repair in mice by accelerating the migration of 
keratinocytes (Liu et al., 2014b). Once they have reached the wound, 
keratinocytes release factors that can act in both autocrine and paracrine 
fashions. One such growth factor is TGF-α (Beyeler et al., 2014). In vitro work 
has shown a role for this factor in the repair of wounds by increasing fibroblast 
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migration to the wound site (Beyeler et al., 2014). Interestingly in the early 
stages after wounding, it has been demonstrated that these cells release TGF-α 
(Antoniades et al., 1993) Keratinocytes from keloid scars have been shown to be 
more effective at inducing fibroblast proliferation (Xia et al., 2004). Another 
group showed that keloid keratinocytes released increased levels of TGF-β1, 
which would in turn cause local fibroblasts to produce more type I collagen 
(Machesney et al., 1998).   
 
3.2.3 Growth Factors 
Growth factors are molecules that cause cell activation and/or cell growth 
(Lawrence, 2008) and as a result, these molecules are indispensable to the 
process of wound repair. Growth factors are tightly regulated during the healing 
process and any disregulation in this network can lead to the development of a 
chronic wound or a hypertrophic scar. There are a large number of growth 
factors involved in the healing of a wound and they all have to strike a delicate 
balance to ensure appropriate repair. 
 
Epidermal Growth Factor (EGF) family members, such as the already discussed, 
Transforming Growth Factor (TGF) -α and EGF, are vital to the process. These 
two factors are secreted by platelets, macrophages and fibroblasts and both 
have an activating effect on keratinocytes (Schultz et al., 1991, Barrientos et 
al., 2008). The key function of EGF is re-epithelialisation and this is achieved by 
accelerating migration and activation of keratinocytes (Jiang et al., 1993). 
 
TGF -β1 is an important growth factor for wound healing (Roberts, 1995) but has 
been found to increase the instance of keloid or hypertrophic scars (Niessen et 
al., 2001)(Wang et al., 2013). It is suggested in the literature that a reduction of 
TGF-β1 signalling during the wound repair process results in an accelerated 
healing phenotype (Flanders et al., 2003, Ashcroft et al., 1999). Work on foetal 
wounding models has also shown that in the local tissue surrounding the wound 
there is reduced expression of TGF-β1 (Bullard et al., 2003).  
 
Platelet derived growth factor (PDGF) is a protein that is important during all 
phases of the wound healing process. It has been shown to aid angiogenesis and 
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re-epithelialisation as well as to be chemotactic for innate immune cells in the 
early stages of the response (Eppley et al., 2004, Hosgood, 1993).  
 
Osteopontin has been shown in many studies to have a significant role to play in 
wound healing. This highly phosphorylated sialoprotein has been shown to be up-
regulated during the inflammatory phase of the wound healing response and is 
expressed by fibroblasts (Mori, Shaw and Martin, 2008).  
 
3.2.4 Collagen 
Members of the collagen family make-up around thirty percent of proteins within 
the human body and twenty-nine different forms of collagen have been 
described (Myllyharju and Kivirikko, 2001). These molecules are structural 
proteins with considerable mechanical strength, properties that are key to a vast 
array of biological processes including the repair of wounded tissue.  
 
The vast majority of the collagen in the body is of types I-IV. Type I collagen was 
first discovered in skin, bone and tendon and is the most abundant collagen in 
the human body being present in almost all tissues (Epstein and Munderloh, 
1978). It makes up over 80% of skin collagen (Jinnin, 2010) and exists in a 
fibrillar form. Type II collagen is a unique molecule that is found in the 
cartilaginous tissues of the body (Epstein and Munderloh, 1978) and the vitreous 
body of the eye (Hardy, 1989). Type III collagen is another very abundant 
collagen that can be found in many different tissues in the body. It is thought to 
be expressed in the epidermis and surrounding dermal appendages (Epstein, 
1974). This makes up about 10% of skin collagen (Jinnin, 2010). Type IV collagen 
is present in the basal lamina of the skin during normal physiological conditions 
and, during wound healing, at the leading edge of the epithelial tongue. The 
importance of this collagen is observed when matrix metalloproteinase (MMP)-9 
is over-expressed. MMP-9 is a type IV collagenase and over-expression causes 
delayed wound healing as it removes this type of collagen (Reiss et al., 2010). 
Type V collagen is present in the skin but makes up only a small percentage of 
fibrils (Jinnin, 2010). It is also expressed at low levels during the process of 
wound repair (Inkinen et al., 1999). Replacing wounded skin with new tissue is a 
complex and highly regulated process and collagen synthesis is key to 
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biomechanical strength. Both over, and under, production of collagen during this 
process can lead to many clinical, pathological and cosmetic complications. The 
quantity and formation of newly synthesised collagen during wound repair are 
key areas this research will address.  
 
3.3 Cutaneous Inflammation 
Wound healing is just one example of inflammation in cutaneous tissue. As 
cutaneous tissue is constantly exposed to the outside environment, skin is often 
exposed to pro-inflammatory agents. The work in this thesis also used chemical 
reagents to induce models of inflammatory states and investigate the role of 
ACKR2 in other forms of skin trauma. 
 
3.3.1 Compound 48/80 
Burn-type inflammation was simulated using the potent mast-cell activator, 
compound 48/80 (Paton, 1951). As described above, the granules of mast cells 
contain many potent immunomodulators such as histamine, heparin, 
prostaglandins, leukotriennes, cytokines and chemokines. The potency of the 
contents of these cells is most evident during anaphylaxis; this process is driven 
by the release of mast-cell contents and causes severe acute symptoms in the 
patient. Symptoms include widespread vasodilation, rapid heart rate, severe 
drop in blood pressure, and dyspnoea (breathing difficulty) all of which are 
caused by a catastrophic release in histamine.  
 
Compound 48/80 causes mast cells to degranulate and, in turn, results in a 
massive release of the immunomodulators mentioned previously. This then 
causes local cells to present an active/inflammatory phenotype. During 
inflammation induced by this reagent, an accumulation of inflammatory cells 
such as neutrophils and macrophages occurs, and these cells secrete further 
inflammatory cytokines, chemokines and other factors. If these signals are not 
regulated a hyper-response will be observed and an increase in local tissue 
damage will occur. The degranulation process is independent of Fcε receptor 
binding in the case of compound 48/80 mediated activation, as it would be in a 
burn-type wound. Degranulation of mast cells is caused by an opening of the 
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calcium ion channels on the mast cell surface membranes and results in the 
release of cell contents (Walsh et al., 2009). As previously mentioned, mast-cells 
have been shown to express moderate levels of ACKR2 (McKimmie et al., 2008b) 
and so this work could give a direct insight into the role played by this receptor 
during the process of mast-cell degranulation. 
 
3.3.2 Allergic Contact Dermatitis 
Allergic contact dermatitis reactions are a common form of skin response to 
materials like nickel in susceptible individuals. People who suffer from nickel 
sensitivity, for example, present oedema, redness, and itching at the site of 
contact with the metal. This is a delayed response as it is an adaptive immune 
driven process. Reagents such as 2,4-dinitrofluorobenzene (DNFB) can be applied 
in a two stage process involving priming and challenging to mimic a similar 
response. DNFB is a molecule known as a hapten; these are small immunogenic 
molecules. The priming stage involves painting the abdomen of the mouse with a 
mix of the hapten and a vehicle to aid its absorption. This mix of hapten and 
vehicle causes mild inflammation at the site of contact. The priming agent is 
picked up by tissue dendritic cells and/or macrophages (both cells are known as 
APCs) and taken to a local draining lymph node.  As mentioned in the 
introductory chapter this leads to specific T cells that respond to this agent upon 
any subsequent encounters. 
 
Then after around six days the same animal is challenged on another tissue. The 
ear is a commonly used challenge site. At this time, the same solution used to 
prime the animal’s immune system is used to challenge it. The effector memory 
cells, set-up during the priming response, proliferate rapidly and migrate to the 
site of the challenge. Here they react against the antigen for which they have a 
specific receptor. They induce inflammation and activate innate immune cells 
also. The degree of immune reaction is measured in the oedema presented in 
that tissue. It is the easiest site to measure swelling and as there are two, the 
untreated ear acts as an internal control specific to each animal. 
 
All of these models are designed to provide us with an insight into the role of 
ACKR2 in many arms and facets of the immune system. Using the techniques 
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detailed above we can investigate how ACKR2 affects the innate and adaptive 
immune systems, and how it affects the response to both chemical and 
mechanical injury in the cutaneous tissue. 
 
3.4 Results 
3.4.1 Wound Healing Model 
3.4.1.1 Wound Closure 
We began our investigation by looking at wound closure over time in wild type 
and ACKR2 null mice. This involved making a full skin thickness wound and taking 
photographs of the wounds at time points until closure had occurred. To ensure 
a full thickness wound was made without damaging subcutaneous tissue, a skin 
fold was taken and a biopsy punch made through the entire fold. This method 
resulted in two wound sites. A representative set of images is shown below, in 
figure 3.1, to illustrate our findings. 
 
 
The first clear and consistent observation across all of these studies was that the 
healing kinetics of each genotype were very similar. The images collected in this 
process are more of an objective observation and they consistently suggested 
that a lack of ACKR2 resulted in no change to temporal healing kinetics. In order 
to gain quantifiable data from these images we used computer software to 
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measure the wound circumference. The graph shown in figure 3.2 below 
summarises data from multiple studies. The average for each time point in each 
study is taken to generate the graph below. 
 
 
In keeping with the macroscopic images these data show little difference in 
temporal resolution between wild-type and ACKR2-null mice. Measurements 
taken to the point of wound closure are comparable despite the presence or 
absence of ACKR2. This graph in figure 3.2 suggests that the ACKR2 receptor has 
a minimal role in the closure of wounds at the early stages of healing. Given this 
we wanted to investigate the wounds further to see if there were any less 
obvious phenotypic changes in the recovering wound tissues. 
 
3.4.1.2 Wound Histology and Immunohistochemistry 
The local and recruited cells at the site of the wound shape the efficiency and 
ultimate success of the healing process. It was important to investigate any 
changes in cellular profile of the wounded tissue at different time-points 
throughout the wound healing process. We did this by quantitative histology, 
immunocytochemistry and brightfield microscopy. The first stain we carried out 
was haematoxylin and eosin and this can be seen in figure 3.3. 





The images in figure 3.3 indicate that there was an increase in the number of 
infiltrating cells to the ACKR2-null wounds (fig 3.3B) at day 3 (i) post-wounding 
compared to that seen in WT mice (fig 3.3A). It is worth noting that this 
disparity between the genotypes seems to have disappeared by the next time 
point which was day 5 (ii). Images from WT and ACKR2-null mice at day 5 look 
similar in terms of cellular recruitment. We wanted to look into this in more 
detail by investigating more specifically at individual leukocyte populations to 
see if they were any changes in specific cell recruitment. 







Figure 3.4 shows counts of individual leukocyte populations infiltrating the 
wound site. The specific cells investigated were neutrophils (3.4A), macrophages 
(3.4B) and mast cells (3.4C). As can be observed in figure 3.4A there is a 
significantly higher number of neutrophils arriving at the wound site and this 
appears to remain the case throughout the three time points examined, although 
this difference lessens with time. Macrophages, shown in figure 3.4B are also 
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present in higher numbers in ACKR2 null mice when compared to WT mice. 
Interestingly, the rate at which the presence of these cells declines is very 
similar between ACKR2 null and WT mice; there is simply a higher number of 
these cells at every point in the ACKR2 null mice. Finally, mast cells (figure 
3.4C) are also present in greater numbers in ACKR2 null wounds throughout the 
model. 
 
Given the literature surrounding wound healing (Daley et al., 2010), we decided 
on the basis of these data to further investigate the roles for macrophages (3.4B) 
in wound healing in wild type and ACKR2 null mice. One of the key roles 
macrophages play in wound healing is in releasing factors that contribute to 
collagen synthesis (Rohani et al., 2015). Given the significant increase in 
macrophage numbers in ACKR2 null mice throughout the model, we decided to 
assess the collagen content and organisation in the mature and developing scars 
of ACKR2 null and WT mice. 
 
3.4.1.3 Collagen Staining 
During the repair process newly synthesised collagen fibres are laid down in the 
recovering tissue. This is the beginning of the formation of what will eventually 
become scar tissue. To assess any possible contributions that ACKR2 was making 
to this process we stained developing scar tissue with picrosirius red (PR). This 
histological technique stains type I and type III collagen fibres both of which are 
vital in wound repair. 
 
 





Figure 3.5 shows the developing collagen fibres through time as the wound 
heals. It can be seen that at day 3 in WT (3.5Ai) and ACKR2 null mice (3.5Bi) 
there is no discernable difference in collagen profile. As one looks at images 
from day 5, 3.5Aii and 3.5Bii, there appears to be a phenotype emerging. The 
ACKR2 null mice appear to have a higher number of larger collagen fibres. By 
day 8 (iii) it can be observed that the ACKR2 null wound (3.5Biii) clearly has a 
greater number of collagen fibres than WT (3.5Aiii). These data suggest that a 
greater number of collagen fibres are being produced in ACKR2 null mice during 
the wound healing response and that this, at least in part, contributes to the 
disorganisation phenotype shown in these mice when compared to WT mice. 
 
3.4.2 Scarring Phenotype in ACKR2-Null Mice 
We carried out the same wounding protocol as discussed earlier but allowed the 
wounds to heal until day 21. By this time the wound was healed and the 
epidermal barrier had been restored. The images below in figure 3.6 show a 
representation of the picrosirius red stained tissue from this assay. 




By looking at the tissue at a later time point a phenotype was apparent in the 
ACKR2-null mice. At day 21 of repair the collagen fibres in the scar tissue 
seemed to be less organised in the absence of ACKR2 (highlighted by the black 
triangle) than in wild type mice. This could be due to a greater number of 
collagen fibres being synthesised or it could be purely down to lack of 
organisation as they are synthesised. The data shown here did not allow us to 
reach any conclusion on this. As a result we wanted to attempt to elucidate the 
cause of this phenotype. In order to do this we first carried out PR staining of 
wounds at earlier time-points to observe the development of the collagen fibres 
over time. 
We wanted to look into the possible causes of this hypercollagenous response. 
We did this using QPCR assays on samples of skin from each of the time points to 
ascertain if any particular changes in transcription of key genes were 
contributing to the phenotype. 
 
3.4.2.1 Wounding Model Quantitative-PCR 
We analysed expression of five different genes to assess differing facets of the 
wound healing response. This technique allowed us to address the changes that 
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ACKR2 was making on the transcription of certain genes that appear to be 









In the first graph displayed above in figure 3.7A, α-SMA, the copy number seen 
at day 3 is lower than the untreated control skin; this suggests an active 
reduction in transcription at this time-point. This phenomenon seems to hold 
true regardless of the absence of the Ackr2 gene. The transcription of α-SMA is 
significantly increased in ACKR2 null mice compared to wild type mice at day 5. 
At day 7 one can see a large divergence in the transcription levels of α-SMA, the 
presence of Ackr2 is associated with a major drop in transcription but the 
absence seeing a large rise in transcription, this difference is statistically 
significant. 
 
Figure 3.7B shows data for the type-I collagen QPCR. In wild-type mice a steady 
increase in transcription can be observed with time. This holds true for the 
Ackr2 null mice in that, from day 3 to 5, expression follows a very similar 
progression to the wild-type counterparts. It is between days 5 and 7 that a 
dramatic rise in collagen transcription is seen in Ackr2 null mice compared to WT 
mice. There is around a five-fold increase in Ackr2 null mice transcription 
between these days and significantly more transcripts in ACKR2 null mice 
compared to wild type mice. 
 
The osteopontin graph in figure 3.7C reveals a similar pattern to the type-I 
collagen graph; however at each time point here there is significantly more 
osteopontin transcription in ACKR2 null mice compared to wild type mice. Again 
the WT samples show a steady increase in transcription with time, as do the 
Ackr2 null mice up until day 7 again. In this graph there is a three-fold increase 
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in gene copy number between day 5 and day 7 in the Ackr2 null mice compared 
to WT mice.  
 
The penultimate graph (figure 3.7D) shows transcription levels of transforming 
growth factor (TGF)-β1. In Ackr2-null mice expression appears erratic. On day 3 
there are significantly more TGF-β1 transcripts in Ackr2 null mice than in WT 
mice. This phenotype then appears to be reversed as the next time-point of day 
5 where there is significantly more TGF-β1 transcription in the wild type mice 
compared to ACKR2 counterparts. The transcription levels of TGF-β1 at day 7 are 
almost double those observed at day 3. At all time-points there is a relative 
increase in gene copy number when compared to the control sample. 
 
Finally, figure 3.7E shows the expression of collagen type-IVα. At day 3 the wild 
type mice show only a small increase in transcription compared to the control 
sample. The equivalent Ackr2 null sample is showing significantly greater 
transcription than the wild type sample. At day 5 wild type mice have 
significantly increased levels of transcription of this gene compared to ACKR2 
null mice and have even reversed the transcription levels of day 3. By the 
seventh day the two groups are transcribing the gene at similar levels. 
 
3.4.3 Wounding Model with Macrophage Depletion 
In an attempt to understand the mechanism of action of ACKR2 in the scarring 
phenotype we decided to target phagocytic cells, namely macrophages. The 
data presented so far seemed to suggest a role for an increased macrophage 
response in the absence of ACKR2. We wanted to address if the scarring 
phenotype observed between ACKR2 null and WT mice was due to the 
recruitment of these cells as it has been shown that they can affect scar 
formation (Rohani et al., 2015). We did this by depleting macrophages using 
clodronated liposomes and carrying out the previously used wounding model. 
 
Our hypothesis here was that a lack of ACKR2 was driving an increase in 
macrophage recruitment to the wound site. This was resulting in an increase in 
pro-fibrotic factors such as TGF-β1, and by reducing the number of these cells 
the phenotype could be reversed. As described in detail in the ‘Materials and 
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Methods’ section we injected the mice with clodronated liposomes to deplete 
phagocyte numbers.  
 
When this emulsion is injected into the animal, phagocytes engulf the liposome. 
Once inside the cell this degradation leads to the release of the drug. The drug, 
clodronate, induces apoptosis in the cell and so depletes the numbers of any cell 
that phagocytoses the liposomes. For this work the control mice received 
liposome injections but these liposomes were filled with PBS rather than the 
drug. 
 
3.4.3.1 Wound Healing Kinetics in Macrophage Depleted Mice 
We collected images of the wounds, as before (see figure 3.1), every second day 
during the healing process to investigate any changes in repair kinetics brought 
about by the lack of phagocytes. The circumferences of the wounds were then 




The graph shows an interesting phenotype brought about by the lack of 
phagocytic cells. The data show that, in the absence of macrophages, ACKR2 
null mice have significantly delayed wound closure when compared to wild-type 
mice with and without these cells and ACKR2 null mice with macrophages.  




After leaving the wounds for twenty-one days to fully heal and form mature 
scars the animals were culled and the skin harvested. We then took this skin and 
stained the scar tissue with picrosirius red. As before we were analysing the 




The staining shows that whilst in PBS treated mice the ACKR2 null mice display 
disorganised collagen within the skin this phenotype is reversed by depletion of 
phagocytic cells. This suggests that by depleting these cells the wound can heal 
normally and produce a scar of wild type-like quality. The converse of this of 
course is that during normal wound healing, i.e. in the presence of phagocytic 
cells, the ACKR2 receptor has an important effect in the mechanism of the 
phenotype by normalising the magnitude of phagocyte recruitment. 




Our results here suggest that the difference observed in the formation of scar 
tissue between wild type and ACKR2 null mice is down to the inflammatory cells 
that are accumulating at the damage site. We postulate that in the presence of 
ACKR2 fewer phagocytes, probably mostly macrophages, are being recruited. 
This, in turn, results in a more appropriate level of macrophage-derived growth 
factors in the local area and prevents a hyper-response from stromal cells. 
 
The results above suggest that whilst a lack of ACKR2 seems to play no role in 
the kinetics of wound closure, it does, through a macrophage-mediated process, 
have an effect on the eventual scar tissue. 
 
3.4.3.2 Tail Pathology in the Macrophage Depletion Wounding Model  
During the frequent injections needed for this work we noticed that the mice 
displayed inflammation in the tail and that this was more pronounced in the 
ACKR2 knockout mice. In 3.10A one can see that the tails of clordronate-injected 
mice both of wild type and ACKR2 null backgrounds were thickened when 
compared to PBS treated counterparts. It can also be seen that the clordronate 
treated ACKR2 null tails have an increased diameter compared with clordronate 
treated wild type tails although this is not significant. Microscopic analysis 
showed that the pathology resembled psoriasis with lesions of hyperproliferative 
epidermis including hyperkeratosis in 3.10B (highlighted by the white triangle). 
Increased leukocyte infiltration could also be seen (black triangle) in ACKR2 null 
tails treated with clordronate. Neither of these findings were seen in 
clordronate treated wild type tails. In addition to this the ACKR2 null tails were 
becoming grossly inflamed towards the end of the time-course of the 
experiment. Interestingly, these lesions were only present in knockout animals 
whereas the wild type counterparts showed some oedema but little else. 
 
We next considered the possible cause. Obviously the tails of these mice were 
subject to mechanical trauma with injections every forty-eight hours but we 
were unsure how much the drug was contributing to this tissue damage. We 
wanted to look more closely at this phenomenon. 
 






Two groups (one wild type and one ACKR2 null) received the same liposome 
injections as before, and the other mice received injections of PBS, as discussed. 
As can be observed in the figure 3.10A, the tail girth of the mice receiving the 
PBS injections remained at a constant diameter throughout the protocol. Both 
WT and ACKR2 null mice receiving injections with clordronate had a clear 
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inflammation of the tail with ACKR2 null mice showing increased oedema when 
compared to WT mice. This suggests that the inflammatory reaction is related to 
chemically induced trauma rather than the mechanical damage caused by the 
injections. However, after analysis, the difference in girth between wild type 
and ACKR2 null mice was not significant.  
 
3.4.4 Compound 48/80 Experiment 
The potent mast cell degranulator compound 48/80 was used to induce a wound 
similar to that of a burn in the dorsum of the mice. This experiment was 
designed to give insight into the role of ACKR2 during this form of trauma. Mice 
were injected intradermally with 20µl of the reagent at 10mg/ml at two sites on 
the dorsal skin using a small volume syringe. The mice were left for four days to 
allow the action of the compound 48/80 to cause cutaneous pathology. After this 
time the mice were culled and 5mm biopsy punches of the injection site and 
surrounding areas were harvested for histological examination.  
 
Macroscopically it was obvious that the ACKR2 null mice were showing increased 
inflammation as lesions were visible on the dorsal epidermises that were not 
present in wild type mice. However, by staining the tissue biopsies for H&E it 
was clear how extensive this increased response was. This is highlighted by the 
white triangle in figure 3.11Aii showing the marked deposits of invading 
leukocytes. 





Figure 3.11A depicts the damage caused by the mast cell degranulation in WT 
and ACKR2 null mice. The figure suggests that the increased accumulation of 
leukocytes has lead to massive tissue damage at the injection site in the ACKR2 
null mice (3.11Aii). There is degradation of the epidermis in both genotypes 
associated with this degranulation. There is a major accumulation of immune 
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cells gathering at the dermal-epidermal margin (black arrow) and deeper down 
in the dermis and the epidermis is disrupted in ACKR2 null mice (white triangle). 
In the mice lacking ACKR2 it is clear that the degradation of tissue is spreading 
deeper than the epidermis and starting to affect lower levels of tissue. The 
tissue architecture in the two pictures is very different. The inflammation in the 
WT mice is tightly regulated (3.11Ai) whereas, in comparison, in the mice 
lacking ACKR2 a hyper-inflammation is seen. Figure 3.11B shows that oedema 
was increased in ACKR2 null mice at the compound 48/80 injection site when 
compared to wild type mice. 
 
The results above demonstrate that, without ACKR2, mice are unable to clear 
the inflammatory signals caused by release of histamine. This could imply that 
ACKR2 could have a protective role in the reaction to a cutaneous burn. 
 
3.4.5 Allergic Contact Dermatitis 
The hapten 2,4-dinitrofluorobenzene (DNFB) was used in a model of allergic 
contact dermatitis. Mice were primed with DNFB in an acetone and olive oil mix 
(vehicle), which was painted onto the ventral skin. This was followed with a 
challenge, seven days later, to the right ear. The left ear received vehicle only 
as an internal control. 
 
The reason for doing this was to determine the role of ACKR2 in the induction of 
an adaptive response to a cutaneous antigen. All work presented thus far has 
focused mainly on the innate arm of the immune system. This also allowed us to 
look at the role ACKR2 is playing in a different anatomical cutaneous location.  




The graph of ear thickness vs. time in figure 3.12 shows a clear inflammatory 
response in the treated (right) ear compared to that of the control (left) ear. 
The treated ears of the ACKR2 null mice were, in general, thicker than their 
wild-type counterparts however this only reached statistical significance at the 
forty-eight-hour time-point. This significance is not thought to be of any 
biological relevance as it was not a consistent finding across repeated studies. 
Both genotypic groups showed the same levels of inflammation after challenge, 
although a pattern of slightly increased inflammation in the ACKR2 null mice can 
be seen throughout the time points shown in figure 3.12.  
 
3.5 Discussion 
3.5.1 Wound Healing 
The wound-healing model that was carried out for this thesis gave intriguing 
results. We initially investigated the differences in the temporal healing kinetics 
involved in the repair of wounds in wild type and ACKR2 null mice. The results 
we obtained from this work implied that a lack of ACKR2 does not result in any 
significant change in wound closure times.  
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We next decided to look at the key outcome of the wound healing process and 
investigated scar structure and quality. To do this we looked at the scar tissue 
three weeks after the wound induction. We noticed that a lack of the ACKR2 
receptor resulted in a disorganisation of collagen structure in the newly formed 
scar. We then tried to identify the mechanism whereby ACKR2 was contributing 
to this phenotype by ablating phagocytes in the wound model.  
 
Removal of these cells reversed the scarring phenotype in the ACKR2 null mice 
and resulted in well-structured collagen fibrils in the scar tissue, equivalent to 
those seen in wild-type animals. These results make sense as an over-expression 
of macrophage-produced growth factors have been shown to lead to 
hypertrophic scar production. During the last stage of the wound repair 
response, remodelling, the collagen fibres laid down at earlier stages are re-
aligned and shaped to provide the highest quality scar possible. 
 
A key question that now needs to be answered about this work is how the 
absence of ACKR2 affects the functionality of this scar tissue. The tensile 
strength of a scar is a key aspect of its functionality as a new barrier. Skin has to 
be tough and able to withstand mechanical stresses, the extent of which 
depends upon anatomical location. As mentioned previously, scar tissue does not 
achieve the same level of tensile strength of unaffected healthy skin, however it 
can display over 90% of this strength during optimal healing (Hardy, 1989). Any 
healing process that reduces this further would be a problem for the host. The 
disorganisation of the collagen fibrils in the ACKR2 null scar tissue may lend 
itself to reduced tensile strength but this has not been formally tested.  
 
It also has to be assessed whether these scars are cosmetically different to wild 
type scars. Hypertrophic or keloid scars can be unsightly and can distress 
patients that are unfortunate enough to have them. Both of these factors are yet 
to be assessed. 
 
An excellent next step would be to test the effect of over-expression of the 
ACKR2 receptor during the wound healing process. An improvement in scar 
generation would be an important clinical finding. Transfection with an ACKR2 
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expressing lentivirus, for example, into local cells could be another possible 
avenue to explore for over-expression studies.  
 
Although the work we have presented so far suggests that an absence of ACKR2 
expression in the system may play a role in the resultant scar, we would like to 
identify the separate contributions of this absence made by immune cells and 
stromal cells. We could achieve this by setting up bone marrow chimeras. This 
would involve transplanting ACKR2 null mice with wild type bone marrow- giving 
ACKR2 null stroma and ACKR2 positive immune cells- and a wild type mouse with 
ACKR2 null bone marrow- giving ACKR2 positive stroma and ACKR2 null immune 
cells. This would allow us to assess the individual contributions of ACKR2 from 
these two cell-types. 
 
Macrophages are key to the process and a lack of ACKR2 could be causing an 
increased recruitment of these cells to the wounded tissue, then downstream of 
this there are more growth factors being released by these cells. This is just a 
hypothesis but it is, however, logical when taking current literature into 
account. 
 
3.5.2 Compound 48/80 
It would seem from our results that mast cell degranulation in ACKR2 null mice is 
causing local inflammation that is not being controlled when compared to wild 
type mice. The animals lacking ACKR2 are unable to scavenge, to the same 
extent, the inflammatory chemokines being released by local tissue cells 
subsequently increasing the extent of cellular influx. In a positively regulated 
loop type mechanism this is then causing an increase in inflammatory markers in 
the local area and therefore an increase in tissue damage. The extent of this 
damage was so great that the epidermis had almost been completely lost and 
lesions had formed on the dorsal skin of the mice. This was not the case with the 
wild type mice. 
 
3.5.3 Allergic Contact Dermatitis 
The allergic contact dermatitis model carried out on wild type and ACKR2 null 
mice gave us inconclusive results. They did, however, show that there was a 
   
 
130 
possible trend towards increased inflammation in the ACKR2 null mice although, 
apart from 48-hours post challenge, this was not significant. It would be worth 
repeating this model with larger groups of mice in order to confirm if this was a 
biologically relevant trend or not. 
One could also repeat this model and add histological analysis to the data as 
well as the ear thickness measurements. It would be interesting to see if there 
were any differences in the amount of leukocytes being recruited to the 
challenged ear. Finally, given the work done by Lee et al, looking at the 
cellularity of the local draining lymph node would be of interest (Lee et al., 
2011). This paper suggested that a lack of ACKR2 results in leukocytes binding to 
the lymphatic vessels and preventing the efficient transit of fluid and cells out 
of the tissue and into the lymphatics (Lee et al., 2011). There is a chance that 
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Chapter 4 Experimental Autoimmune Uveitis 
4.1  Introduction 
4.1.1  The Eye 
The eye is a sensory organ and during embryonic development the optic nerve 
and the retina are outgrowths of the brain. For this reason the eye is considered 
part of the central nervous system (Standring, n.d.). The anatomy of the 
anterior (the part of the eye that faces the outside world) of the eye has evolved 
to both control and manipulate light to optimise the amount that ultimately hits 
the retina, the site at which light signals are converted into nerve impulses. The 
cornea (the exposed tissue of the eye) has both a protective and lens-like role as 
light first hits the eye at this site. After this the components of the eye that are 
most recognisable such as the iris, the pupil and the sclera (the white of the 
eye) play their parts. The pigmented epithelium of the iris (which gives colour to 
eyes), and the pupil sizes, vary to control the amount of light the eye is letting 
in. When the light passes through the pupil and into the eye itself it passes 
through the lens. Like any lens the purpose of this tissue is to help focus the 
incoming light onto the retina. The only thing between the lens and the retina is 
the vitreous humour. The word vitreous is Latin for ‘glass-like’ which accurately 
describes the gelatinous mass that aids the transit of the light form the lens to 
the back wall of the eye. The retina is located at the posterior of the eye and is 
neural tissue. The location of these tissues can be seen in figure 4.1. 
 






The retina is a complex and multi-layered tissue that contains photoreceptor 
cells (Lens, Nemeth and Ledford, 2008). It is, in fact made up of ten discrete 
layers including the retinal pigmented epithelium which will be discussed in 
more detail later in this chapter. The two most abundant of the photoreceptor 
cells are the rods and the cones. Rods contain rhodopsin and are responsible for 
collecting information in low light; in fact they are almost entirely responsible 
for night vision (Remington, 2012). They are expressed more in the peripheral 
retina than the central retina and also have a significant role to play in 
peripheral vision. The cells responsible for distinguishing colour are the cones. In 
bright light the rods quickly become saturated by light signals and this is when 
the cone cells begin to work. There are three different types of cone in the 
human eye. One can receive long wavelength light (red), one medium (green) 
and one short (blue). The medium wavelength cones are the most abundant, a 
fact that is illustrated by the human eye’s ability to distinguish more shades of 
green than any other colour (Remington, 2012). Photons that hit the retina are 
converted into neural signals by the resident ganglion cells and relayed to the 
   
 
134 
brain via the optic nerve. The retina has a high metabolic demand and as such 
receives a blood supply from both the central retinal artery and choroidal blood 
vessels (Remington, 2012).  
 
4.1.2  Immunology of the Eye 
 
The importance of sight needs no explanation and it is due to this that the eye 
has a unique immunological environment. It is said that the eye is an 
immunomodulating tissue, with particular activity in the pigmented cells of the 
iris and the retina (Caspi, 2010). It was Peter Medawar, the pioneer of 
transplantation, who first described the unique properties of corneal transplant 
and the fact that rejection was very rare in this tissue. Medawar placed skin 
explants into the anterior chamber of the eye and noticed this phenomenon, 
furthermore when he transplanted tumours into the same place he observed that 
they were able to grow almost unperturbed (Medawar, 1948). With further 
research the mechanism behind this became clearer and was named anterior 
chamber associated immune deviation (ACAID) by Streilein (Streilein, 2003). 
Continued work done by Kaplan and Streilein was key in defining this 
phenomenon. It was once thought that ocular immune privilege was due to an 
inability of the immune system to come into contact with retinal antigens. This 
is now known to be untrue as ocular peptides, including those explanted into the 
anterior chamber are presented to the immune system. In fact the peptides are 
presented by resident F4/80+ macrophages to B cells, NKT cells, CD4 and CD8 
cells in the spleen (Caspi, 2010). This leads to peripheral tolerance to these 
peptides. 
 
The uvea lies beneath the sclera (the white of the eye) in the middle of three 
layers that make up the outer portion of the eye. Its name comes from the Latin 
word for grape and is one of the main sites for resident ocular immune cells such 
as macrophages, dendritic cells and mast cells. This layer provides much of the 
blood supply to the eye and helps in the formation of the image on the retina by 
reducing reflection of light within the eye (Lens, Nemeth and Ledford, 2008). As 
previously discussed, the cornea is a highly specialised tissue. It is a so-called 
barrier tissue as it faces the outside world and will very frequently experience 
potential inflammatory situations but due to its functional role needs to be 
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completely transparent. The cornea has a fixed lens function and refracts light 
into the eye so any opacity will reduce the efficiency of this. The transparency 
of the cornea is so important that it has no direct blood supply. This tissue 
becomes oxygenated through its direct contact with the atmosphere (Lens, 
Nemeth and Ledford, 2008). 
 
4.1.2.1  Pigmented Epithelium 
 
The pigmented epithelium of the iris uses contact dependent interactions with 
inflammatory cells to modulate their action whereas the more posterior, retinal 
pigmented epithelium uses soluble factors (Gregerson et al., 2007). In the iris 
pigmented epithelium molecules such as CTLA-4 bind active T cells and prevent 
activation (Gregerson et al., 2007). The intraocular environment is highly 
immunosuppressive under physiological conditions. TGF-β1 is expressed at 
relatively high concentrations in the fluid of the eye (Streilein, 2003). This 
cytokine also has a role to play in the other pigmented epithelium of the eye, 
namely that of the retina. Retina pigmented epithelium (RPE) serves many 
functions in the retina. The main role of RPE is to absorb scattered light and 
improve the function of the eye, it also provides nutrients to photoreceptor cells 
as well as phagocytosing them when damaged or dying. Finally, and most 
relevant to this work, the RPE uses soluble factors, like TGF to aid in the 
immunomodulation of the eye (Vega et al., 2010). 
 
This cytokine has multiple roles and has been shown to enhance the conversion 
of conventional T cells into regulatory T (TREG) cells (Jonuleit et al., 2002). 
Animal models of human uveitis have provided important insights into the 
molecular and cellular mechanisms that are in place to protect the eye from 
damage and what ultimately overcomes these processes during inflammation.  
 
A small population of natural TREG (nTREG) cells has been shown to reside in the 
eye and it is thought that these aid the resistance to inflammation in this tissue 
(Grajewski et al., 2006). nTREG cells are formed and exposed to retinal antigens 
in the thymus in a process known as central tolerance (Avichezer et al., 2003). 
During this process developing thymocytes, the precursors of T cells, are 
exposed to self-antigens expressed by medullary epithelial cells of the thymus 
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under the control of the transcription factor AIRE (Gotter et al., 2004). 
Deficiencies in this gene have been shown to result in multi-organ autoimmunity 
(Mathis and Benoist, 2009). It has also been shown that it is during this process 
that these developing cells encounter retinal peptides for the first time 
(Avichezer et al., 2003). If the antigen receptor (TcR) of a thymocyte reacts too 
strongly to a peptide it is deleted from the developing cellular pool in a process 
known as negative selection (Zhang et al., 2003). It is thought that in the case of 
nTREG cells their TcR responds strongly to a given peptide but not strongly enough 
to bring about deletion (Zhang et al., 2003). These cells have been shown to play 
important roles in the control of inflammation and autoimmunity (Sakaguchi and 
Sakaguchi, 2005). 
 
The nTREG cells account for some of the immunomodulatory capability of the eye 
but when ‘committed’ effector T cells enter the tissue under inflammatory 
signals they are able to overwhelm the quelling action of these cells. It has been 
shown that within hours of the induction of antigen-induced uveitis, retinal-
antigen specific lymphocytes are present in the eye. In these models, utilising 
adoptive transfer of antigen-specific T cells, the remaining injected cells tend to 
migrate to the spleen. The cells then proliferate in the spleen before migrating 
to the eye along with inflammatory leukocytes slightly later in the model. It is at 
this point that the pathology of these models start to become observable. It has 
also been shown that if uveitis is induced and allowed to take its course it is a 
self-limiting pathology in wild-type animals (Klaska and Forrester, 2015). Also, 
once the pathology has subsided, there is an increase in the number of resident 
TREG cells in the eye compared to pre-inflammation levels (Silver et al., 2015). 
This makes the tissue even more anti-inflammatory and able to convert active T 
cells into a regulatory phenotype (Silver et al., 2015).  
 
4.1.3 Experimental Autoimmune Uveoretinitis 
4.1.3.1 Cellular response to the model 
One of the most interesting findings from work on rodent models of uveitis has 
been the subtlety of the pathology that can result depending on the way in 
which the model is induced and the strain of mouse used (Klaska and Forrester, 
2015). The inflammatory pathology of uveitis models has, in the past, been 
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attributed to a TH1 response. However, more recently, the TH17 cell has become 
implicated (Amadi-Obi et al., 2007). Specifically the cytokine, IL-17, that these 
cells produce has been implicated in the pathology (Sun et al., 2015). In fact 
what has been shown is that how the inflammation is induced skews the T cell 
response and is a defining factor in what the uveitogenic T cell population is. In 
models where dendritic cells are pulsed with retinal antigens then injected into 
a recipient mouse the resulting pathology appears to be of a TH1 phenotype 
(Caspi, 2010). In immunisation-based models, such as the injection of IRBP with 
CFA, the resulting damage is attributed to TH17 cells (Caspi, 2010). Another 
counter-intuitive finding from work in these models is that, in the eye, the 
highly inflammatory cytokine interferon-γ may have anti-inflammatory and 
immunomodulatory properties. This conclusion has been reached as neutralizing 
this cytokine exacerbates disease (Caspi et al., 1994). 
 
4.1.3.2 Translational value of the model 
Experimental autoimmune uveoretinitis (EAU) is an animal model of posterior 
uveoretinitis in humans (Klaska and Forrester, 2015). The purpose of this model 
is to simulate the pathology and mechanisms involved in human uveitis in order 
to gain insight into the aetiology of the damage. Humans with this pathology can 
present symptoms ranging from redness of the eye through to loss of vision and 
pain. It is a pathology that presents as a comorbidity in a variety of conditions 
and can be observed in systemic disorders like multiple sclerosis, Behçet's 
syndrome, or infectious diseases like Lyme’s disease (Forrester, 1991). 
Uveoretinitis is, by definition, inflammation affecting the uveal and retinal 
tissue which consists of the choroid, the ciliary body, the iris, the sclera, and 
the retina. This inflammatory pathology can be anterior, intermediate, or 
posterior depending on what section of the uvea the inflammation is affecting. 
As has already been discussed, the eye has multiple mechanisms in place to 
prevent inflammation in the tissue. During the induction of this pathology the 
blood retina barrier (BRB) is seemingly broken down allowing for the 
accumulation of inflammatory leukocytes in the eye (Forrester, 1991).  
 
Autoimmune uveitis is a chronic inflammatory disease and the treatment 
regimen is similar to other diseases of this type such as rheumatoid arthritis (RA) 
and psoriasis. One of the pathological contributors in uveitis is overproduction of 
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the potent cell activating cytokine TNFα which, when blocked, can provide 
symptomatic relief to patients (Gardner et al., 2015). Some of the key cells 
which produce and release this cytokine are CD4+ cells which have been shown 
to drive the inflammation during this pathology along with neutrophils, 
macrophages and NK cells (Grivennikov et al., 2005, Gardner et al., 2015). 
Another treatment strategy used by clinicians in the treatment of uveitis that 
has commonality with RA is that of glucocorticoids (LeHoang, 2012). Drugs from 
this family, such as dexamethasone, have been shown to limit the TH1 response 
and limit the damage induced by pro-inflammatory cytokines released by these 
cells (Guo et al., 2007). To add to this, drugs such as dexamethasone 
significantly reduce the amount of TNFα produced in the retinal tissue (Yossuck 
et al., 2001). 
 
4.1.3.3 Methods of EAU induction and associated-pathology 
EAU can be induced by various methods, as already mentioned, and this has an 
effect on the overall pathology. For the work presented here a retinal peptide, 
inter-photoreceptor retinoid binding peptide (IRBP) 1-20, was injected with an 
immunological danger signal (Complete Freund’s Adjuvant (CFA)) to induce an 
immune response. CFA contains inactive Mycobacterium tuberculosis emulsified 
in mineral oil and is used to boost the immune system. In the literature other 
retinal peptides can be used to immunise the mouse and each is effective. Our 
model was carried out over twenty-eight days before samples were harvested, 
more details are provided in section 2.2.1.  
Given that this is an immunisation-based inflammatory induction model it can be 
assumed that the pathology here is a TH17 and macrophage/monocyte driven 
inflammatory process. Eyes are known as immuno-specialised organs, this means 
that retinal peptides are treated differently during development but when given 
with an immunological danger signal can induce inflammation. This means that 
during the ‘priming’ phase of an EAU model an eye peptide specific to the uvea 
is injected subcutaneously into the dorsal skin of the mouse along with a ‘danger 
signal’ and an adjuvant that will both alert and enhance the immune system 
respectively (Klaska and Forrester, 2015).  
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4.1.4 Chemokines and the Eye 
Literature in this field supports an essential role for chemokines and their 
receptors in the initiation, induction and maintenance of the inflammation 
associated with uveitis (Adamus, Manczak and Machnicki, 2001, Crane et al., 
2006, Zhao, Chen and Xu, 2014). Two pathways for tissue damage have been 
described in the clinic; patients can be diagnosed as having granulomatous or 
non-granulomatous uveitis. The former is associated with an influx of the 
monocyte/macrophage cell type whereas the latter is a neutrophil driven 
process. Interestingly the extent of tissue damage appears to be similar in both 
diagnoses.  
 
A study by Forrester et al has shown a need for CCR5 to enable the transition of 
TH1 cells across the blood retinal barrier. In this study uveitogenic T cells were 
isolated from the spleens of mice and treated with CCR5-blocking antibodies. 
This was shown to significantly reduce the number of cells able to breach the 
barrier. The study suggested that CCR5 was required for crossing the blood 
retina barrier, and not rolling or adhesion in the local endothelium as previously 
thought (Crane et al., 2006).  
 
The CCR5Δ32 mutation, discussed in the main introduction (section 1.3.2.1), has 
been studied in cohorts of patients with Behçets Disease (BD). As already 
discussed, this disease includes retinitis and almost all studies involving the 
CCR5Δ32 mutation show that it lessens inflammatory pathologies. One study, in 
fact, found that this mutation was non-protective in a cohort of Italian BD 
patients (Atzeni et al., 2012) whereas another study found that in Portuguese 
patients it has no significant effect on pathology (Bettencourt et al., 2014). 
Finally, a meta-study found that the mutation brought about increased risk of BD 
if the patient was of the HLA-B51 antigen-type (Song, Kim and Lee, 2014). One 
study of single nucleotide polymorphisms (SNP) in the genes of ACKR2-related 
ligands and receptors found that these mutations had altering effects on the 
development and progression of idiopathic immune-mediated posterior segment 
uveitis (Ahad et al., 2007) 
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Another study of patients with uveitis found expression of chemokines in the 
conjunctival epithelium. Almost paradoxically, there was a significant increase 
in the expression of the TH2-associated chemokine receptor CCR4 in patients 
with uveitis and just weak expression of the TH1-associated chemokine receptor 
CCR5 (Trinh et al., 2007). The pathophysiological relevance of this is unknown 
but it may be reasonable to postulate that the eye is attempting to quell 
damage brought about by the inflammatory state caused by incoming cells. 
 
Work on CCR2 knockout mice showed an absence of infiltrating macrophages 
resulting in a more neutrophil driven inflammation (Sonoda et al., 2011). The 
classical leukocyte response in this model is dominated by macrophages and a 
small number of neutrophils. The lack of CCR2 brought about an almost 
complete reversal of this. Interestingly, there was no significant difference in 
the number of recruited T cells between the two genotypes. There was also no 
significant difference in the eventual pathology resulting in either strain. These 
studies, and others, provide good evidence to suggest a possible involvement of 
ACKR2-related classical chemokine receptors in the chemotaxis of inflammatory 
cells to the eye (Diedrichs-Möhring et al., 2005, Crane et al., 2006). Other 
studies provide evidence of the role of ACKR2 ligands accelerating the pathology 
of EAU (Crane et al., 2001) (Zhao, Chen and Xu, 2014). 
 
Another recent study has shown that, in mice lacking CCL2 and CX3CR1, the 
tissue damage caused in the EAU model is reduced. The findings of this work 
showed a reduction in the number of CD45+ cells infiltrating the eyes of the 
knockout mice at 25 days post-immunisation. Again, in this model there were 
fewer F4/80+ macrophages but an increase in the number of neutrophils 
infiltrating the eye. Zhao et al went on to show that at 60 days post-
immunisation there was a reduction in macrophages and myeloid-derived 
suppressor cells in the knockout mice but a significant increase in recruited 
lymphocytes (Zhao, Chen and Xu, 2014). The findings in this more recent study 
correlate nicely with those in the Sonada paper which showed that a lack of 
CCR2 resulted in a neutrophil-dominant EAU pathology (Sonoda et al., 2011).  
 
Taken together, the findings in these publications provide a reasonable basis for 
a possible role of ACKR2 in regulating the inflammatory pathways causing the 
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pathology associated with EAU. Our aim was to test the hypothesis that a lack of 
ACKR2 would ameliorate/alter the pathology associated with the IRBP 1-20 
immunisation model of EAU. We also ultimately wanted to draw some relevance 
from this to the human disease of uveoretinitis. 
 
4.2 Results 
4.2.1 The Role of ACKR2 in EAU 
4.2.1.1 Histology 
Increased inflammation in ACKR2-null mice during EAU model 
 
After immunisation (section 2.2.1) to induce inflammation we checked for 
differences in pathology between wild-type (WT) and ACKR2 null mice using 
standard histological methods. As mentioned in the materials and methods, the 
retinal peptide IRBP 1-20, Complete Freund’s Adjuvant and Pertussis toxin were 
injected into WT and ACKR2-KO C57BL/6 mice. Figure 4.2 shows the gross 
pathology of the eyes. It can be seen in figure 4.2B that there is mild 
inflammation in treated wild type mice including leukocyte infiltration (1), 
granuloma formation (2), and folding of the retina due to oedema (3). The 
histology in 4.2C showed a marked increase in cellular influx to the inflamed eye 
in the mice lacking the ACKR2 compared to WT mice. In 4.2C one can see 
thickening of the retina and choroid layers (4 and 5, respectively), leukocyte 
infiltration into the photoreceptor rod outer segment layer (6) and retinal 











Using a customised histopathological scale (see Materials and Methods section 
2.2.2) we were able to quantify the tissue damage caused. H&E stained slides 
were blinded before being analysed according to the scale. It is a complex 
system that takes into account information on a range of pathological 
contributors such as discrete sites of inflammation, cellular influx and tissue 
degradation in order to get an objective score for the pathology. From the 
examples above, using the system the scores would be as follows: A would score 
a 0 as the architecture of the tissue look to be normal and healthy. B would be 
given a score of 0.5, as although there are signs of inflammation, all layers of 
the retina are discernable and intact. The example in C is highly inflamed with a 
great deal of tissue damage. The retina is detached/detaching, the layers of the 
retina are both difficult to determine and hyperplasic too. This would give this 
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The above figure suggests that across the whole retina, and in different tissue 
layers of the eye, there was inflammation in the ACKR2-null mice. It is unclear if 
wild-type mice had already gone through this inflammatory process and 
recovered or whether this would be apparent throughout the model. The 
histology images in figure 4.2 B (WT) and C (KO) illustrate this finding. One can 
clearly see swelling in all layers of the eye in the ACKR2 null mice but figure 4.3 
summarises the findings across the whole model as well as showing statistical 
analysis of the data. 
 
Here we show that ACKR2 provides a protective effect during the EAU model. We 
show that in the absence of this receptor there is an increase in leukocyte 
recruitment to the eye and an increase in tissue damage. 
Increased collagen accumulation in ACKR2-null mice during EAU model 
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When we did our work on inflammation of the skin, presented in chapter 3, we 
noticed an increase in collagen formation in the ACKR2 null mice (section 
3.5.1.2). Within our group this is a finding that has been present across 
numerous ACKR2 null models (data not shown). With this in mind we stained the 
eyes with picrosirius red to investigate any changes in collagen distribution 




Figure 4.4 shows the optic nerve region of the eye (denoted by the triangle) and 
it can be seen that there is an accumulation of collagen fibres around this area 
of the eye. The most obvious region of increased collagen accumulation is the 
choroidal uveal tract layer (denoted by the white arrow). As shown in A, this 
layer is barely visible in resting mice, in B it is a distinct and obvious layer, 
whilst in C there is profound thickening of this layer. As leukocytes arrive at the 
inflamed eye they may be accumulating and causing this fibrosis. We wanted to 
investigate the possible cause of both the increased inflammation and the 
collagen accumulation in the ACKR2 null mice so carried out immunostain for 








Increased CD45+ cell accumulation in ACKR2-null eyes during the EAU model 
 
Having shown that ACKR2-null mice were presenting increased uveal pathology 
we wanted to investigate the cellular profile of the immune infiltrates to the 
eye. Specifically we investigated if the disparity in tissue damage was as a result 
of a larger leukocyte influx or if there was an altered cellular profile. To achieve 
this we performed immunohistochemistry with CD45 and MAC-2 as targets. CD45 
is also known as the leukocyte common antigen and is expressed by all 
haematopoietic cells. MAC-2 is a lectin which is expressed by macrophages and 
some dendritic cells. The conclusion from the work done for Chapter 3 was that 
in ACKR2-deficient mice there was a change in the influx of macrophages to sites 
of cutaneous inflammation. Therefore we wanted to investigate if this was also 

















As can be seen in figure 4.5, there is a clear infiltration of leukocytes to the eyes 
of the mice during the EAU model. These representative images show that in WT 
mice (A) there is a mild influx of CD45+ cells to the subretinal tissue with some 
leukocytes infiltrating further into the retina itself. In (B), the ACKR2-null mice, 
one can see a greater number of CD45+ cells including increased retinal 
infiltration and deeper retinal infiltration. Part C of the figure shows the 
enumeration of these positive cells across the cohort and demonstrates that the 
data is statistically significant. 
 
Having observed the significantly increased influx of CD45+ cells to the inflamed 
eye of the ACKR2 null mice we wanted to gain further information as to the 
possible cell-types responsible for this disparity. To do this we studied 
macrophages as, from previous work in this thesis, we had observed a marked 
difference in the recruitment of these cells in the absence of ACKR2. We used 
the MAC-2 stain described previously along with brightfield microscopy in order 
to quantify the number of cells arriving and to gain information as to where they 
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The results shown in the above figure suggest that although there is a greater 
influx of total leukocytes arriving into the eyes of ACKR2 null mice (4.6B) there 
is a decrease in the recruitment of MAC-2+ cells. Figure 4.6C suggests a reduction 
in the accumulation of macrophages to the ACKR2-null eyes. The MAC-2+ cells 
that are recruited in this process are probably macrophages and due to the 
resulting pathology of the knockout mice it is reasonable to suggest that WT 
mice may be preferentially recruiting alternatively activated macrophages. Due 
to the colour of the retinal pigmented epithelial (RPE) cell layer and the fact 
that pigment picked-up by cells phagocytosing RPE cells can look like positive 
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DAB staining, red alkaline phosphatase was used as a substrate for this work to 
give a red colour (see section 2.6.4). 
 
4.2.1.3 ‘Glasgow Model’ vs. ‘Aberdeen Model’ of EAU 
This work was performed in collaboration with the Forrester group from the 
University of Aberdeen. We provided them with ACKR2 null mice allowing them 
to parallel our analysis at their facility. Surprisingly the results from their model 
suggested no significant difference in inflammation between the genotypes 
(personal communication). As a result of this we compared the protocols used 
during the immunisation of the mice. Table 4.1 shows the concentrations of the 




Table 4.1- The above table shows the reagents used to make up the 
immunisations that each mouse received during the EAU models. On the left is 
the protocol we used and on the left is the protocol that the University of 
Aberdeen use for the same model. 
 
 
As can be seen, there are a few discrepancies between the protocols. The 
Aberdeen protocol uses less of the retinal peptide but is, in general, more 
inflammatory. It contains double the pertussis toxin, and the literature suggests 
that this aids in the breakdown of the blood-retina-barrier. Although the same 
volume of complete Freund’s adjuvant was used they added extra 
Mycobacterium tuberculosis which would provide more of a ‘danger signal’ to 
the immune system. As a result of the discrepancies between our results and our 
protocols we decided to swap protocols and see if protocol differences explain 
the discrepant results or the animal units housing the mice were effecting the 
phenotypes. The results from the two models we ran are shown below in figure 
4.6. As can be observed, we were able to recapitulate the results that the 
Aberdeen group had when we used their protocol. It is also worth noting that the 
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group in Aberdeen also found the same phenotype as we did when they used our 
method (personal communication).  
 
 
It is clear from these results that in both protocols there is increased pathology 
in the eyes of ACKR2-null mice. Interestingly, using the ‘Aberdeen protocol’ 
seems to cause an increase in inflammation in the WT mice (as shown by the 
increase in histology grading) but this is not as pronounced in the knock-out mice 
although not significant. This may suggest that using the more inflammatory 
protocol of our collaborators is ‘overwhelming’ the protective action of the 
ACKR2 present in the WT mice and contributing to this increased damage. 
 
We wanted to quantify the level of ACKR2 expression in naïve and EAU treated 
WT mice to see if any transcriptional changes were being induced by the model. 
We removed the vitreous humour from the eye as this is largely acellular and 
may have had a diluting effect on the transcriptional signal of ACKR2.  
4.2.1.4 Transcriptional Analysis of Ackr2 in EAU 
We wanted to look in more detail at expression in the two tissues that contain 
pigmented epithelium namely the iris and the retina along with whole eye 
samples. The pigmented epithelium of the eye, present in both the iris and the 
retina, is a highly immunomodulatory tissue and as such may be a site of ACKR2 
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activity (discussed in more detail in section 4.1.2). Laser-capture microdissected 
tissue from the eyes of mice was harvested by our collaborators at the University 
of Aberdeen. They had immunised B10.BRIII mice, using the same peptide as we 
used but with a slightly altered inoculum (as per table 4.1), and allowed the EAU 
model to progress to seventy days. At the termination of the model the eyes 
were harvested and tissue laser-captured to yield RNA from the whole eye, the 
retina and the iris. We had been given naïve and inflamed eyes so we could also 
investigate the ACKR2 transcriptional profile of these tissues before, and after, 
the induction of inflammation. With these data we could now identify any 
change in regulation of transcription of the receptor during the EAU pathology 
and at separate anatomical locations.  
 
As discussed in the Materials and Methods section (2.2.1), this particular 
experiment was carried out on a different strain of mouse, the B10.BRIII as 




The results in figure 4.8 show an increased expression of Ackr2 transcription in 
the whole eye compared to iris and retinal tissue at seventy days post-
immunisation. Interestingly there seems to be higher Ackr2 transcriptional 
activity in the inflamed retina than in the naïve retina the functional 
significance of this was not tested and is unknown. One possible reason for this 
is that EAU is a model of posterior uveoretinitis and, by definition, affects more 
tissues than just the retina. This model should induce a minimal response in the 
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iris and the data above even suggest a downregulation of Ackr2 transcription in 
this tissue. This result is in-keeping with previous findings form other models 
that ACKR2 is upregulated during inflammation (Singh et al., 2012). 
 
The results presented above suggest that ACKR2 expression may be increased 
slightly at the site of pathology but that there could be a more widespread 
response to inflammation in the eye. These data also suggest that ACKR2 may 
play a protective role in the mouse eye during the EAU model. Mice lacking the 
receptor had a significant increase in ocular tissue damage and a markedly 
larger leukocyte infiltration to the eye. As this work was a model of human 
disease the next step for this was to investigate the possible relevance of these 
findings for the human eye. 
 
4.2.2 ARPE-19 Cell Line Characterisation 
4.2.2.1 Transcriptional Analysis 
As discussed in the introduction to this chapter (section 4.1.2.1), it is the 
retinal-pigmented epithelium of the eye that has some of the greatest 
immunomodulatory capacity. In order to ascertain if ACKR2 was expressed in the 
human eye we purchased a human retinal pigmented epithelial cell line. This 
seemed like a likely place for ACKR2 to be expressed in the retina and 
contribute to the phenotype observed in vivo. We investigated a human retinal-
pigmented epithelium cell line (ARPE-19). This allowed us to characterise ACKR2 
expression in this cell line and further investigate how the levels of this receptor 
change with inflammatory stimulation. We carried out protein and 
transcriptional analysis of Ackr2 on these cells. We started the characterisation 
of this cell line with QPCR to assess the levels of transcription of this gene. We 
used another human cell line, human embryonic kidney (HEK) 293 cells, that do 
not express Ackr2, as a negative control. As a positive control in this assay we 
used HEK293 cells that had been transfected with human Ackr2. 
 




Data from the PCR analysis are shown in figure 4.9. The above data suggest that, 
in a resting state, the ARPE-19 cell line is able to transcribe Ackr2 at a 
detectable but low level. Once this had been shown we went on to investigate, 
and quantify, protein expression levels using various techniques. Much like 
starting with transcription, we utilised the more sensitive techniques first. 
ACKR2 molecules, as mentioned in the introduction to this thesis, are much more 
abundant in cytoplasmic vesicles of the cell with a low level of expression on the 
cell surface. As a result of this a total protein analysis was required to assess the 
level of, ACKR2 protein expression in the ARPE-19 line. 
 
4.2.2.2 Western Blot 
Results were controlled using both positive (HEK293 cells transfected with 
ACKR2) and negative (HEK293 cells) controls. Monolayers of cells were grown and 
equal numbers of cells were lysed before analysis by western blotting.  The 











The results from the western blot suggested that this cell line does express 
ACKR2 at the protein level and at higher levels than the transcriptional data in 
figure 4.9 would suggest. One of the possible reasons for this is that ACKR2 
protein is very stable and has a long half-life (Weber et al., 2004). As a result it 
can have a low level of transcription but relatively high levels of protein 
expression. However, it can be observed that there is a size difference between 
the bands from the ARPE-19 cells and the bands from the HEK-293-ACKR2 cells. 
This is probably a result of a post-translational modification like, for example, 
glycosylation. We did not test this formally however so this remains speculation.  
 
We went on to use flow cytometry and immunocytochemistry to see if this 
expression displayed the same intracellular predominance as seen in other cells. 
By permeablising the cell membranes flow cytometry allowed us to quantify the 
expression on the cell surface against the expression within the cell and 
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compare it to other cells of known expression levels. The immunocytochemistry 
allowed us to visualise the expression on the cells more precisely. 
 
4.2.2.3 Flow Cytometry 
 
In order to truly quantify the levels of ACKR2 in the cytosol, versus that on the 
cell surface, we utilised a flow cytometry-based analysis method. Having shown 
that the cells express ACKR2 protein the next step was to accurately quantify 
the levels of surface versus intracellular expression. This assay provided us with 
a baseline reading for ACKR2 expression in these cells. The idea here was to 




The data in figure 4.11 above show that the ARPE-19 cells express high levels of 
ACKR2 in the cytosol, however levels of the protein on the cell surface were low 
in comparison. This is a normal expression pattern for ACKR2. These results, 
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taken along with the data from the western blot assay, suggests that the ARPE-
19 expresses the ACKR2 receptor in a manner not unlike many other cells our 
group have characterised in the past with most ACKR2 in intracellular stores. 
Having shown that these cells can transcribe the gene and express the ACKR2 
protein we wanted to show the functionality of the protein.  
 
4.2.2.4  ARPE-19 Cell Chemokine Uptake Assay 
 
Again this was achieved using a flow cytometry based approach. We used a  
competitive uptake assay to determine this. This was a technique developed in 
our group by Dr Chris Hansell (Hansell et al., 2011) and one that can be used for 
multiple chemokine receptors. By taking a fluorescent ligand for ACKR2 (CCL22 
in this case), and incubating the cells with it, binding is allowed to take place 
and is assessed by flow cytometry. CCL22 can bind more than just ACKR2 though. 
In order to determine the chemokine binding that is ACKR2-specific a non-
fluorescent competitor (CCL2 in this case) is added in excess. Only ACKR2 binds 
both CCL2 and CCL22. As a result the mean fluorescent intensity (MFI) of the 
sample will drop in relation to the amount of ACKR2 present on the cells. The 
results below (figure 4.13) show the data obtained from this assay. 





It is clear from figure 4.12, that as the non-fluorescent chemokine is added to 
the ARPE-19 cell line the MFI of the sample drops considerably. Using the 
relevant controls, as shown, we can take from these results that the ARPE-19 
cells express ACKR2 and it is functional. Although this is an experimental model 
using a cell-line, it does suggest that the equivalent cell-type in the human body 




Once we had established that these cells expressed ACKR2 at the total protein 
level we wanted to use immunocytochemistry to visualise the expression of the 
protein within the cell. The images below were taken using an epifluorescent 
microscope. It is important to point out that the cells were permeablised before 
staining to detect both surface and intracellular protein as described above.  
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   A        B 
 
 
The images show a high level of ACKR2 positive cells within the ARPE-19 
monolayer. These results further confirm ACKR2 protein expression by ARPE-19 
cells. Taken together our results suggest that ACKR2 may play a considerable 
role in the anti-inflammatory response in the eye. They also suggest that the RPE 




Our findings show that ACKR2 has a protective role to play in the IRBP 1-20 
immunisation EAU model in C57BL/6 mice. The results we have obtained from 
this model are in agreement with current literature surrounding EAU and 
chemokines. Published work (Crane et al., 2001) on this model has shown that 
ACKR2 ligands and ACKR2-related receptors can alter, and drive, the 
inflammation associated with EAU. The data presented in our models show that 
the presence of the ACKR2 receptor confers a protective advantage.  
 
The EAU model we used is one of a number of possibilities for studying 
uveoretinitis and it would be very interesting to see if this phenotype was 
repeated if other models were used. Like C57BL/6J mice, the B10.BRIII 
background is also susceptible to EAU and breeding ACKR2 null mice onto this 
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background would be useful to test the pathology they present. Different strains 
of mice mount different immune responses to models of inflammation and it 
would be interesting to see if there is any change in the pathology in B10.BRIII-
ACKR2-null mice compared to C57BL6/J-ACKR2-null mice. It has also been 
discussed, in section 4.1.3, that the way in which the model is induced can 
affect the resulting pathology. In all of the models presented in this section the 
pathology was induced by immunising the mice. It would be worth investigating 
the pathology that results from pulsing DCs with retinal antigens before 
transferring them back into the animal. This would drive a more TH1-type model 
and so may alter the pathology slightly; it would be intriguing to see if ACKR2 
conferred more or less protection in this setting. 
 
The models carried out for this work went to an end-point of 28 days after 
immunisation and the results were obtained from the eyes at this point. What 
our results have not been able to show is the progression of the pathology with 
time and this would be of great importance to investigate. There is a reasonable 
chance that the ACKR2-null mice have a delayed recovery from the inflammation 
in the model and that the peak pathology in the two genotypes are similar. As 
mentioned in the introduction to this section, the EAU model is self-limiting 
(Caspi, 2010) in wild-type mice so there is a chance that these mice may have 
had a similar level of inflammation at one point and that this has resolved.  
Another possibility is that the pathology could continue to develop and worsen. 
To look into this one could use the fundus imaging technology that many labs 
working in ocular research employ (Crane et al., 2006). This allows the 
investigator to look at the inflammation in the eye without culling the mouse 
and so progression of pathology can be quantified throughout the development 
of the model rather than at an end-point as per our work. 
 
In addition to the general histopathology of the condition we also investigated 
the individual cell types that could be contributing to the inflammation. The 
cell-based work presented revealed a stronger inflammatory profile during EAU 
in mice lacking the ACKR2 receptor. Interestingly, the WT animals show a more 
extensive influx of macrophages, assessed by MAC-2 staining, to the eye during 
the model and we would like to investigate whether these are alternatively 
activated macrophages.  As macrophages are often thought of as inflammatory 
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cells this does not seem to fit with the pathological phenotype. This is why it 
would be reasonable to suggest that this increase in macrophage recruitment 
could, in fact, be the anti-inflammatory alternatively activated macrophages. It 
would also be worthwhile investigating other leukocyte populations such as 
neutrophils and monocytes to see what cells account for the increased CD45+ 
cell accumulation in the ACKR2-null eyes. Studies on chemokines in EAU have 
shown that alterations in chemokine ligand and receptor levels have significant 
effects on the incoming cellular infiltrate (Crane et al., 2001, 2006). We would 
postulate that the population of recruited cells in the ACKR2 null mice during 
EAU is different to that of the wild-type. This is something that should be looked 
into in more detail possibly through a CD45 separation of inflamed eye lysates by 
flow cytometry to add to the immunohistochemistry shown in figure 4.5. This 
would allow us to see exact percentages of key leukocyte subtypes arriving at 
the site of pathology during this model.  
 
One of the most interesting findings of our study was the differing results from 
our model compared to those of our collaborators. Upon swapping protocols and 
emulating each other’s results this raised questions as to the possible 
mechanisms behind the discrepancies. The data suggested that when mice are 
immunised along with a more potent adjuvant and immunological danger signal 
the protective effects of ACKR2 are lost or reduced. It would seem reasonable to 
postulate that, like the immunomodulatory capacity of the eye, the protective 
effects of the atypical chemokine receptor are lost when the inflammatory 
signal becomes too great. Again further research into the kinetics of these 
findings would be welcome and fundus imaging would be key to this. It would 
also be interesting to investigate if the profile of the recruited cells was changed 
in any way using this more potent immunisation protocol. A paper from Lee et al 
in 2011 showed that ACKR2 plays an essential role in the process of lymphatic 
drainage. This paper showed that without ACKR2 expression on LECs 
inflammatory leukocytes interact with non-cleared inflammatory chemokines. 
This results in a disruption to the drainage of fluids and cells to local lymph 
nodes (Lee et al., 2011). This is, of course, something that should be considered 
during the EAU model in ACKR2-null mice.  
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Having shown the effect of a lack of ACKR2 on the pathology of EAU we wanted 
to look into the transcription of the gene under resting conditions and during the 
development of the pathology. QPCR of RNA from normal eye tissues, versus EAU 
day 70 eye tissues, revealed a shift of ACKR2 transcription from the iris, under 
naïve conditions, to the retina. This could be explained by the fact that ACKR2 is 
found, for the most part, on barrier tissues. The iris would be more likely to 
encounter inflammatory insult under normal conditions than the retina would. 
However, as the model of EAU used here targets the posterior segment of the 
eye it seems reasonable that transcriptional activity of this gene would be 
slightly increased in the retina. In a paper by Singh et al investigating ACKR2 in 
psoriasis an interesting finding was noted which might be of relevance to this. In 
this work it was suggested that in psoriatic lesions there is an increase in the 
transcription of ACKR2 in non-lesional skin (Singh et al., 2012). This, it has been 
suggested, may be a response to limit the spread of lesions in the skin by local 
cells and that trauma caused a drop in this activity of ACKR2 which allowed 
‘opportunistic inflammation’ (Singh et al., 2012). It is reasonable to postulate 
that a similar mechanism may be at play here.  
 
Reliable anti-human ACKR2 antibodies are available so we wanted to look at 
human cells to see if they expressed ACKR2. Our work on the human cell line, 
ARPE-19, has given a great deal of hope that our findings in the murine model 
can be extrapolated to human uveitis. Upon receiving the cells we rigorously 
tested them for expression of ACKR2. Our findings were promising and it 
appeared that they are able to transcribe the gene and express the functional 
protein. Unfortunately we did not get round to adding inflammatory stimuli to 
these cells to investigate any effect that had on ACKR2 expression but this would 
be important to investigate. 
 
As the ARPE-19 cells express ACKR2 it suggests that the receptor may be 
expressed on primary human retinal-pigmented epithelial cells. We are currently 
working to gain access to human eye tissue as this would provide more validity 
to our findings on the human cell line. With this we would be able to stain for 
ACKR2 using immunohistochemistry and, if the receptor were expressed in 
human tissue, it would be logical to predict that our findings in the mouse 
models may translate to human pathophysiology and that ACKR2 may help lessen 
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inflammatory processes in the eye. Importantly having this tissue, and the 
expression data to match it, would allow us to visualise where in the eye ACKR2 
is expressed and any possible functional significance of this. If it were the case 
that ACKR2 is expressed at these sites in the human eye then ACKR2-based 
therapeutic interventions could be designed to improve human disease. 
 
To summarise, the findings presented in this chapter provide evidence of a role 
for the atypical chemokine receptor ACKR2 in the maintenance of the anti-
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Chapter 5- The Role of ACKR2 in 
Rheumatoid Arthritis   
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Chapter 5 Rheumatoid Arthritis 
5.1 Introduction 
5.1.1 Symptoms and Pathology 
Rheumatoid arthritis (RA) is a progressive chronic inflammatory disorder that 
affects the synovial joints. It is the most prevalent of the inflammatory 
arthritides (Scott et al 2010). According to the World Health Organisation (WHO) 
around 1% of the Caucasian populations of America and Europe are affected by 
RA (Symmons, Mathers and Pfleger, 2003). This is a disease which can be 
incredibly debilitating and as such comes with a high socioeconomic cost 
(Firestein, 2003). It has long been established that women have a greater risk of 
developing RA than men and there is also evidence that the onset of symptoms 
can be associated with negative life events (McInnes and Schett, 2011).  
 
The primary symptom of RA is symmetrical inflammatory polyarthritis that 
affects the synovium. The synovial membrane is made up of connective tissue 
that lines the movable part of a joint and secretes proteins to lubricate 
movement (Lawrence, 2008). Other clinical manifestations include synovial 
hyperplasia, neoangiogenesis and local immune cell infiltration (McInnes and 
Schett, 2011). Local symptoms include excruciating joint pain, synovitis 
(inflammation of the lining of the joint), loss of cartilage and bone 
remodelling/erosion (Majithia and Geraci, 2007). The synovium also becomes 
hyperplastic with an infiltration of inflammatory leukocytes and proliferation of 
local fibroblast-like synoviocytes (FLS) (Sweeney and Firestein, 2004). A new 
mass of tissue, known as the pannus, forms as the synovium invades the 
cartilage and this plays a key role in bone erosion (Ainola et al., 2008). The 
formation of this pathological tissue happens so rapidly that it out-paces the 
neoangiogenic processes in the local area. The result of this is a hypoxic 
environment in the arthritic joint (Strehl et al., 2014). 
 
RA is associated with a large array of co-morbidities. Due to the patient’s 
increased systemic inflammatory state, the person can become far more 
susceptible to myocardial infarction, stroke, and even depression (Dougados et 
al., 2014, Kawada, 2014, Solomon et al., 2015). Cardiovascular disease is a 
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frequent comorbidity in RA and conditions such as artherosclerosis are far more 
common in RA patients than in the general population (Dougados et al., 2014). 
Patients with RA also have a reduced life expectancy compared to the average 
population (Pincus, Sokka and Wolfe, 2001). 
 
Great lengths have been taken by clinicians to work out the stages that patients 
progress through during this disease. The European League of Associations for 
Rheumatology (formerly the European League Against Rheumatism)(EULAR) 
recently published a set of criteria for the phases of the disease path (Gerlag et 
al., 2012). What has become clear is that this described clinical ‘pathway’ is far 
from a linear progression. Patients can go both back and forth through the 
phases of the disease (Jutley, Raza and Buckley, 2015). 
 
The cytokine TNF-α plays a key role in the inflammation of RA and beyond. It has 
been shown than TNF-α can have neuropsychiatric effects on patients (Wolfe 
and Michaud, 2004). The cytokine can bind the serotonin receptor and affect the 
hypothalamo-pituitary-adrenocortical (HPA) axis leading to conditions such as 
depression (Tillmann et al., 2013). This axis has emerged as an important player 
in the onset, maintenance and co-morbidity of RA (Capellino et al., 2010). The 
onset of RA can be associated with stressful life events and it is thought that this 
is due to involvement of the HPA axis (Tillmann et al., 2013). It has also been 
shown that the degree of stress positively correlates with the severity of the 
resulting pathology (Capellino et al., 2010). RA patients who are positive for 
rheumatoid factor (RF) tend to be diagnosed faster and have lower levels of 
depression than RF-negative patients (Tillmann et al., 2013). 
 
For some time now rheumatologists have suggested that RA has such variable 
pathology that it is more than likely a number of different conditions that have 
been crudely gathered under one name. RA can be thought of clinically as a 
syndrome that involves the activation of multiple inflammatory pathways of the 
body. These pathways eventually converge and cooperate to cause the joint 
pathology seen in the disease (van der Helm-van Mil and Huizinga, 2008, Scott, 
Wolfe and Huizinga, 2010). The full pathogenesis of the disease remains to be 
completely elucidated, but this disease is a sizeable contributor to disability and 
absence from work in the industrialised world (Majithia and Geraci, 2007). 




Due to chronic nature of RA patients tend to have to live with the condition for 
many years. This can have profound effects on the productivity of patients in the 
workplace along with increased absenteeism leading to cessation of paid work 
(Filipovic et al., 2011). Patients suffer from fatigue and malaise during RA 
(Wolfe and Michaud, 2004).  
 
What is becoming apparent in the literature is that the early classification and 
initiation of treatment is key to patient outcome (Raza et al., 2006, van der 
Linden et al., 2010). There are three factors that have reached widespread 
agreement in creating increased susceptibility to disease and these are being 
female, smoking and certain genetic subtypes (Aho and Heliövaara, 2004). Other 
factors such as oral inflammation and the microbiome of the gut have been 
implicated, along with smoking, in creating epigenetic modification which leads 
to a breakdown in immunological tolerance to self (McInnes and Schett, 2011).  
 
5.1.2 Epidemiology 
In the United Kingdom RA affects about 1% of the population and women are 
three times more likely to be diagnosed with this condition than men (Symmons 
et al., 2002). Although not impossible, the occurrence of being diagnosed with 
RA before the age of 15 is very uncommon but the chance of a positive diagnosis 
increases year on year from then until the age of 80 (Majithia and Geraci, 2007). 
Interestingly, it has been shown that autoantibodies such as rheumatoid factor 
(RF) and anti-citrullinated peptide antibody (ACPA) can sometimes be detected 
in patients many years before the positive diagnosis of arthritis (Rantapää-
Dahlqvist et al., 2003). 
 
There have been many advances in the epidemiology of RA and it is now 
apparent that certain major histocompatibility complex (MHC) haplotypes make 
patients susceptible to the development of disease (Klareskog et al., 2006). 
Certain HLA alleles leave patients more susceptible to developing RA. HLA-DRB01 
has been shown to be particularly susceptible to production of auto-antibodies 
following post-translational modification of self-peptide (Klareskog et al., 2006). 
Citrullination of self-peptides can trigger the cascade towards pathology. 
Citrullination is a process where the amino acid arginine is modified to citrulline. 
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Smoking can cause the citrullination of self-peptides and that this, in turn, can 
lead to the development and production of ACPA (Willemze et al., 2011). Studies 
on twins further implicate genetic factors in the susceptibility of RA. There is a 
15-30% chance of monozygotic twins both being affected by the disease whilst 
dizygotic twins have a 5% concordance rate (MacGregor et al., 2000). 
 
5.1.3 Diagnosis and Progression 
The diagnosis of RA can be complex and there is no single-test that confirms a 
patient is suffering from this condition. As a result of this patients are classified 
by many pathological criteria in order to stratify them. These criteria include 
the levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and 
autoantibodies. The American College of Rheumatology (ACR) and the EULAR 
jointly devised this system (Aletaha et al 2010). A summary of this system can be 
seen in Table 5.1. 
 
 
Table 5.1- The above table summarises the symptomatic factors that are used by clinicians to 
stratify the patient in terms of what form the RA is taking. (Aletaha et al. 2010). 




When it comes to monitoring the progression of a patient’s disease state, and 
their response to treatment, the Disease Activity Score of 28 joints (DAS28) 
system is used. This system looks at joints of the hands, feet, shoulders, knees 
and wrists and attempts to gain information on tenderness and swollenness (van 
Gestel et al., 1996). To this score details are added from other clinical markers 
of inflammation such as ESR and the patient is asked for a self-assessment of 
their symptoms over the seven days before the interview with the clinician 
(Prevoo et al., 1995). This allows the clinician to make informed decisions as to 
whether the patient should have a change in treatment strategy or continue on 
the clinical path that they are currently on. If a patient scores above 5.1 on the 
DAS28 scale they would be judged to have ‘very active’ disease and a change to 
their treatment would be required. 
 
5.1.4 Therapy 
The goal of therapy is to achieve a state of clinical remission and, upon a 
positive diagnosis of RA, patients are rapidly put onto an aggressive treatment 
regimen. Current therapy for RA patients is often centred on drugs known as 
DMARDs (disease modifying anti-rheumatic drugs). The most commonly 
prescribed DMARD is methotrexate (MTX), which is used as a first-line therapy 
(van der Linden et al., 2010). The drug was originally used as a 
chemotherapeutic agent in high doses but at low doses had efficacy in the 
treatment of rheumatoid arthritis (CRESS and DEAVER, 1964). The complete 
mechanistic action of MTX is not fully known. In vivo studies show little effect of 
MTX on cytokine production but do show reduces RF production and 
neovascularization (Hansen et al., 2006). 
 
Biological therapy has been heralded as one of the most significant advances in 
treatment of RA patients in recent years (McInnes and Schett, 2011). These 
therapies are given to patients, when conventional DMARDs are no longer 
effective, and provide both symptomatic and pathological relief. The most 
common type of biological agents, used in the clinic, target the potent 
inflammatory cytokine TNF-α. Drugs are either neutralising monoclonal 
antibodies against the cytokine (such as Infliximab or Adulimumab) or soluble 
TNF receptors (such as Etanercept).  




Another biological therapeutic agent that has been shown to have great efficacy 
as a treatment in RA is Abatacept (ABA) (trade name Orencia)(Conaghan et al., 
2013).  This molecule targets the immune system by exploiting regulatory 
mechanisms that are in place for the control of activation of T cells. ABA is a 
fusion protein with the FC portion of human IgG1 and the FAB region of cytotoxic 
T lymphocyte-associated antigen (CTLA)- 4. CTLA-4 (inhibitory of T cell 
activation) binds to the costimulatory molecules CD80/86 with a higher affinity 
than CD28 (key in the costimulation and activation of T cells). The result of a 
lack of costimulation in T cell activation is T cell anergy and this also reduces 
the amount of IL-2 that T cells produce which is essential for their proliferation 
(Brunner et al., 1999). The mechanism of action goes beyond this primary 
function of T cell regulation and plays a role in B cell biology also (Ballesteros-
Tato et al., 2012). CD4+ T-helper (TH) cells are required to activate B cells in 
order to induce antibody production (Calvo et al., 1986). It has been shown that 
a secondary effect of ABA treatment is the reduction of B cell activation which 
can lead to a reduction in titres of autoantibodies in seropositive patients (Scarsi 
et al., 2014). 
 
The pathogenic contribution of B cell activation in RA can be targeted more 
directly by treatment with another biologic agent known as Rituximab (RTX) 
(trade name mAbThera). This molecule is a monoclonal anti-CD20 antibody that 
causes death in both activated, and memory, B cells and is accompanied by a 
reduction in autoantibody production (Shaw, Quan and Totoritis, 2003). It is 
worth noting that upon the withdrawal of treatment this reduction is lost 
(Lopez-Olivo et al., 2015). 
 
Interestingly the state of clinical remission is very rarely achieved during therapy 
and, if achieved, is lost upon the removal of therapeutic intervention (Jutley, 
Raza and Buckley, 2015). This suggests that there is something else at play here 
that could be targeted to bring about a more permanent and less drug-
dependent remission in patients. 
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5.1.5 Immune System Involvement 
Although this is an inflammatory autoimmune disease and there is clearly 
hyperactivation of multiple immune pathways, there is a breakdown in 
regulatory mechanisms of the immune system too. The new wave of biologic 
therapies, discussed above, illustrate some of the ways in which the immune 
system is involved in the pathogenesis of RA. Genome-wide association studies 
have implicated the breakdown of immune system regulatory factors as having a 
key role to play in the pathology of RA (Wellcome Trust Case Control 
Consortium, 2007). So it seems that there is a hyperactivation of the immune 
system that is complimented by a reduction in regulation creating a 
multiplicative effect.  
 
5.1.6 Cells and Cytokines 
RA is an autoimmune condition with involvement from both the innate and 
adaptive arms of the immune system. Synovitis, one of key pathological 
features, is caused by an influx of leukocytes to the synovial tissue (Sweeney and 
Firestein, 2004). Cellular involvement includes recruitment of 
monocytes/macrophages, dendritic cells, T and B cells, NK cells, and neutrophils 
(McInnes and Schett, 2011). There is also involvement from activated resident 
stromal cells in the inflamed joint milieu (Jutley, Raza and Buckley, 2015). Some 
of the main contributors to the pro-inflammatory state are fibroblast-like 
synoviocytes and macrophage-like synoviocytes (Jutley, Raza and Buckley, 
2015). Studies suggest that the increase in cell number in the synovium is due to 
cellular influx as opposed to proliferation at the site (Talbot, et al., 2015).  
 
It is worth noting though that local tissue cells also perpetuate the inflammation 
in this pathology. Chondrocytes are cells that synthesise, release and maintain 
the cartilaginous extracellular matrix (ECM) factors that make up the joint 
(Standring, n.d.). During RA inflammatory cytokines such as IL-17, IL-1β, and TNF 
act on chondrocytes and cause them to release damaging matrix 
metalloproteinases (MMPs) (Moran et al., 2009). These enzymes are responsible 
for building and degrading elements of ECM and in the case of activated 
chondrocytes the profile of the released MMPs tend towards the more damaging 
side of the spectrum and contribute to the pathology.  




The overexpression of TNF-α, as already discussed, is a key target for 
therapeutic intervention by clinicians. It has long been established that there is 
an increase in production of TNF-α in the synovial lining of the joint, in the 
synovial fluid (Di Giovine, Nuki and Duff, 1988) and increased expression of TNF-
α receptors locally too (Sennikov et al., 2015). Another finding relating to this 
cytokine is that it appears to colocalise with areas of high bone erosion activity 
(Redlich et al., 2002).   
 
It is important to mention that this is not a one-sided process and that anti-
inflammatory cytokines are present in the synovium of RA patients. The TH2-
related cytokines IL-4 and IL-10 have been shown to attenuate the production of 
TH1-related cytokines like the aforementioned IL-1β, IL-6 and TNF-α which 
subsequently brings about a reduction in tissue damage (Sugiyama et al., 1995, 
van Roon et al., 1995). The quelling actions of these cytokines appear to be 
overwhelmed by their inflammatory counterparts. 
 
Bone cells are also implicated in the process here. The two main bone cells are 
osteoblasts and osteoclasts that synthesise and degrade bone tissue, 
respectively. Inflammatory cytokines like IL-1β, and TNF bring about 
hyperactivation in the degradative osteoclastic cells and this results in the 
release of more MMPs and the breakdown of bone tissue (Shingu et al., 1993). 
This bone erosion is a key pathological symptom of RA and one of the more 
debilitating features of the disease.  
 
Fibroblast-like synoviocytes (FLS) are key mesenchymal cells of synovial joints 
that synthesise, amongst other things, collagen which is required for optimal 
joint function (Dasuri et al., 2004). These cells differ from the canonical 
fibroblast cell-type in that they secrete lubricating factors into the joint which 
other fibroblastic cells are incapable of doing (Dasuri et al., 2004). One of the 
key examples of this is the protein lubricin which aids in joint movement (Al-
Sharif et al., 2015). During RA these cells lose their contact-inhibition (a 
proliferation regulatory mechanism) as well as adhesive properties both of which 
result in a marked increase in the number of these cells (Dasuri et al., 2004). On 
top of this it has been shown that FLS can secrete pro-inflammatory cytokines 
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like IL-6 and TNF which add to the pathological milieu of the joint by activating 
local cells (Smeets et al., 2003). They also secrete MMPs upon activation and so 
contribute to local tissue destruction (Sekine, Nanki and Yagita, 2014).  
 
5.1.7 Cells of the Innate Immune System 
Some of the main cellular drivers of local inflammation are those of the innate 
immune system. Cells of the innate immune system use pattern recognition 
receptors to sense potential problems such as infectious organisms, or damage, 
and during the inflammation in RA this is no different. This is discussed in more 
detail in the introduction to the thesis (section 1.1.1) but damage-associated 
molecular patterns (DAMPs) can activate leukocytes and many of them are 
expressed in the rheumatic joint (Foell, Wittkowski and Roth, 2007). Heat-shock 
proteins (HSP) are an example of this and they bind to receptors on leukocytes 
and cause activation (Tukaj et al., 2010). 
 
Although neutrophils appear not to be present within the synovial tissue they are 
the most abundant leukocyte in synovial fluid (Talbot et al., 2015). It has been 
shown in experimental models that blocking the infiltration of these cells 
contributes to a reduction in pathology (Eyles et al., 2008). These cells release 
potent immunomodulators that contribute to pathology such as prostaglandins 
and studies suggest that the cells may arrive, in this situation, under the 
guidance of CCR2 (Talbot et al., 2015). Of course, CXCL8 is the classic neutrophil 
chemoattractant in humans and this is still important in the recruitment of these 
cells during RA. One of the cell-types that is responsible for the secretion of 
CXCL8 are the FLS (Zhu et al., 2013). 
 
One of the main cell-types that contribute to inflammation in synovitis are 
macrophages (Cornish et al., 2009). The local milieu both attracts and activates 
these innate effector cells being high in cytokines such as macrophage colony 
stimulating factor (MCSF), granulocyte-macrophage colony stimulating factor 
(GMCSF) and granulocyte colony stimulating factor (GCSF) (Cornish et al., 2009). 
As macrophages are recruited into the hypoxic rheumatic joint they have to 
adapt to the low oxygen availability in order to survive (Strehl et al., 2014). One 
of the responses to hypoxia from these cells is to release pro-angiogenic factors 
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in order to improve the oxygen supply in the local area and lessen the metabolic 
pressure on nearby cells (Strehl et al., 2014).  
 
Mast cells become activated in the hypoxic joint and can release the potent 
mediators that are stored in the cytoplasmic granules of these cells (Suurmond 
et al., 2014). Among these are vasoactive amines which help promote the 
activation of local endothelial cells to further recruit inflammatory leukocytes, 
they also release potent cytokines into the local milieu (Lee et al., 2013). Mast 
cells secrete TNF, which has already been discussed in this introduction, but is a 
potent activator of inflammatory pathways (Gordon and Galli, 1990). Mast cells 
also release proteases which contribute to tissue breakdown in the joint (Di 
Girolamo et al., 2006). 
 
Although a non-cellular component of the immune system, platelets have also 
been shown to play a role in the inflammatory state of the RA-affected joint 
(Yeo et al., 2015). These anuclear fragments that come from cellular precursors, 
megakaryocytes, are highly active modulators of the immune system (Janeway, 
2001). One of the primary roles attributed to these fragments are to trigger and 
aid the clotting cascade but in RA they seem to have other roles in inflammation 
including the release of chemokines (Yeo et al., 2015). 
 
5.1.8 Cells of the Adaptive Immune System 
5.1.8.1 T cells 
Patients with RA have many T cells in their synovial tissue and these are thought 
to contribute to pathology largely through the release of pro-inflammatory 
cytokines (van Roon et al., 1995). Interestingly, when broad-spectrum T-cell 
depleting agents were trialled as potential therapeutics in RA, they were shown 
to be relatively ineffective (Panayi, 2006). 
 
CD4+ T cells arrive in abundance especially those of the TH1 and TH17 
background. During a normal acute immune response TH1 cells secrete pro-
inflammatory cytokines such as IL-1, IL-6 and TNF-α whilst TH17 cells secrete the 
potent cytokine IL-17 (Aggarwal et al., 2003). These cytokines activate cells such 
as monocytes/macrophages, neutrophils and FLS to produce a similar cytokine 
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signal which perpetuates the system (Aggarwal et al., 2003). Recriuted effector 
T cells arrive at the synovial tissue and require IL-15 as a growth factor but this 
cytokine has no relevance to effector function, purely survival (McInnes et al., 
1997).  
 
In RA there is not only an increase in activity of pro-inflammatory factors, but 
also a decrease in the anti-inflammatory processes that are in place to regulate 
inflammation (Choy and Panayi 2001). One of the best illustrations of this is the 
decreased activity of TREG cells in RA patients. The mechanisms of this 
defectiveness in these key cells are not fully understood but it has been 
proposed that the potent T cell modulating molecule CTLA-4 is defective on 
these cells due to over-expression of TNF (Flores-Borja et al., 2008). One of the 
classic effector cytokines of TH1 cells is interferon (IFN)-γ, during active RA these 
defective TREG cells cannot control the secretion of this inflammatory mediator 
(Ehrenstein et al., 2004). The paper by Muri et al. suggested that by treating the 
patient with anti-TNF molecules, Infliximab in this study, the effector functions 
of TREG cells is restored and may help reduce pathological markers (Ehrenstein et 
al., 2004). 
 
5.1.8.2 B Cells and Autoantibody Involvement 
B cells are responsible for producing antibodies and, as mentioned previously, 
autoantibodies can play a role in the pathology of RA. It has been shown that the 
presence of these autoantibodies can precede the onset of the arthritis by many 
years and the presence or absence of them has an effect on the resulting 
pathophysiology and disease course (Verheul et al., 2015).  
 
RF was first described around half of a century ago and, although its presence is 
not specific to RA patients, around 70% of RA patients express titres of this 
antibody at some level. The autoantibody exists mainly as an IgM molecule, 
although other isotypes can be present, and the titre tends to correlate with 
disease severity (Song and Kang, 2010). ACPA is another autoantibody implicated 
in RA pathogenesis and is a more recently discovered pathological player in 
comparison to RF. Like RF the titre of this autoantibody correlates with disease 
severity and with both RF and ACPA, the titres negatively correlate with disease 
remission rates (Gupta et al., 2015). It is important to mention that some RA 
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patients are seronegative and do not have the presence of detectable RA-
associated autoantibodies. 
 
It has now been shown that RF can have a synergistic affect on ACPA to further 
enhance pathogenesis. The study showed that patients who were positive for 
both RF and ACPA tended to have a higher DAS28 score when compared to single 
positive or double negative RA patients. They also suggested that the presence 
of both antibodies resulted in a higher peripheral inflammatory burden. They 
went on to suggest that this synergy brings about an increase in macrophage-
activating cytokines in patients (Sokolove et al., 2014).  
 
The involvement of B cells can be best observed with the efficacy of some of the 
drugs mentioned in the ‘Therapy’ section (5.1.4). RTX targets and depletes the 
system of all B cells, except plasma cells, and so ameliorates pathology by 
reducing the production of autoantibodies by these cells. The production of 
antibodies is one of the primary immunophysiological roles of B cells. They also 
secrete cytokines, such as IL-6 and IL-10, which can activate local cells and 
contribute to pathology. 
 
One of the pathological contributors to RA is the formation of ectopic germinal 
centres (GC) in the joints (Timmer et al., 2007). GC normally form in lymphoid 
tissues and serve to increase the efficiency of T cell-B cell interactions and 
activation. B cells mature and develop in GC and are important in the production 
of antibodies. The formation of ectopic GC in RA further promotes tissue damage 
and inflammation. RTX reduces the formation of these structures and this is one 
of the ways in which they contribute to aiding the reduction of pathology. 
 
5.1.9 Complement 
A contribution of the inflammatory milieu in the joint comes from activation of 
the complement system, there are strong correlations between complement 
activation and RA pathogenesis (Okroj et al., 2007). This is a key arm of the 
innate immune system that consists of a cascade of around 30 proteolytic 
proteins. There are three types of complement activation known as classical, 
alternative and lectin which involve sequential events which culminate in the 
lysis of target cells/organisms (Walport, 2001a, 2001b). It has been shown that 
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there is an increase in complement activation fragments in the peripheral blood 
of patients (Morgan, Daniels and Williams, 1988).  
 
5.1.10 Involvement of the Chemokine Network 
Chemokines play a fundamental role in the pathogenesis and maintenance of RA. 
The chemokine receptor expression of cells within the synovium and peripheral 
blood are altered in disease compared to healthy controls. There is a large body 
of evidence that suggests key roles for cytokines and chemokines in the 
pathology of RA (McInnes and Schett, 2007). It is worth noting that chemokine 
ligands and receptors have been the target of many clinical studies by the 
pharmaceutical industry and have achieved minimal efficacy in treatment. It is 
thought that this may be due to the proposed redundancy associated with the 
chemokine network (Zlotnik and Yoshie, 2000) although other theories exist. An 
intriguing, yet complicating, factor that has recently been described is the 
citrullination of chemokines in RA. Yoshida et al found that CCL2 and CXCL5 can 
become citrullinated and that his has an altering affect on their biological 
function (Yoshida et al., 2014). 
 
RA is a condition involving the influx of immune effector cells to joints along 
with marked angiogenesis. By definition the main role for chemokines in the 
body is to bring about the influx of leukocytes to sites of damage and they are 
also heavily implicated in angiogenesis. It is of no surprise then that chemokines 
play a substantial role in the orchestration and maintenance of the pathology. 
Given this it could also be suggested that chemokine and receptor interactions 
could play a vital role in the remission of the disease. Inflammatory chemokines, 
and their cognate receptors, are abundantly expressed in the rheumatoid joint.  
 
5.1.10.1 CC Chemokines 
Due to the inflammatory nature of RA it is unsurprising that inflammatory CC 
chemokines are implicated in the pathogenesis of the disease. CCL2, CCL3 and 
CCL5 have all been shown to induce the recruitment of cells such as T cells, 
monocytes and NK cells to the rheumatic joint (Koch et al., 1992, Villiger, 
Terkeltaub and Lotz, 1992, Volin et al., 1998).  As mentioned above CCL2 has 
been shown to be a target of citrullination during RA and this, in turn, affects its 
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biological function (Yoshida et al., 2014).  The CCL2/CCR2 axis is one of the 
main drivers of inflammatory monocyte recruitment to the joint (Smith et al., 
2008) but this modified ligand has been shown to be markedly less effective at 
this task (Yoshida et al., 2014). 
 
CCL20 is implicated in the pathology of RA due to its receptor CCR6 and its 
expression on TH17 cells. These potent producers of IL-17, hence their name, are 
highly pathological and are recruited to the joint via the CCL20/CCR6 axis 
(Hirota et al., 2007).  
 
It has also been shown more recently that the ligand-receptor pair of CCL28 and 
CCR10 have a role in angiogenesis in the joint (Chen et al., 2014). Another 
chemokine axis that has been implicated in the pathogenesis of RA is the CCR7-
CCL19/21. This axis is indispensible in the efficient transit of APCs to the 
draining lymph node and setting-up the adaptive immune response. In RA 
patients increased levels of CCL19 has been shown in synovial fluid and is 
secreted by fibroblasts and macrophages. CCL19 can induce the secretion of 
VEGF from fibroblasts (Pickens et al., 2011) and promote angiogenesis and the 
concentration of this in patient plasma is a predictor of a patient’s response to 
rituximab therapy (Sellam et al., 2013). 
 
5.1.10.2 CXC Chemokines 
Chemokines have been shown to aid the process of angiogenesis which helps 
perpetuate the rheumatoid pathology. The ELR motif that was mentioned earlier 
(section 1.2.2) is key to the angiogenicity of the CXC family of chemokines. ELR-
positive chemokines such as CXCL-1, 5, 7, and 8 promote the synthesis of new 
vessels in the joint. Like most biological processes there are negative regulators 
of angiogenesis in the joint. The ELR-negative chemokines are angiostatic (i.e. 
block angiogenesis) these include ligands such as CXCL4, 10, 12, and 13. The 
rheumatic joint has been shown to be an area of high angiogenic activity, in fact 
it has actually been compared to a neoplastic tumour. The ELR-positive CXC 
chemokines play an important role in driving the formation of new vessels which 
help perpetuate the pathology of the joint.  
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CXCL-8 acts on local vascular endothelial cells in a mitogenic manner and can 
induce chemotaxis of distal endothelial cells. This chemokine is produced by 
synovial macrophages (Koch et al., 1991). Another key role of CXCL8 is in the 
recruitment of neutrophils to sites of inflammation (Detmers et al., 1990). 
CXCL12 is expressed by synovial endothelial cells (Buckley, 2003) and is thought 
to contribute to lymphangiogenesis and T cell recruitment in RA (Bradfield et 
al., 2003). 
 
The formation of ectopic GC in RA increases the production of autoantibodies 
and, in turn, the formation of immune complexes. Chemokines have 
indispensible roles in lymphoid organisation. CCL21 and CXCL13 have been shown 
to drive the organisation of the T cell compartment and B cell follicles, 
respectively. This is no different in RA and these chemokines have been shown 
to function in this manner in the organisation of ectopic GC. It has been shown 
that serum levels of this key B cell-related chemokine CXCL13 is increased in 
patients of RA and that the levels of this chemokine correlate with the levels of 
RF (Jones et al., 2014).  
 
One of the earliest symptoms of RA is synovitis. A study by Scheel-Toeliner et al 
in 2015 set out to disseminate the differences between joint-recruited 
macrophages in very early RA versus resolving synovitis and long established 
disease. The finding of this work was that there was a significant increase in the 
synovial levels of CXCL4 and CXCL7 in the patients of very early RA. The 
expression of these chemokines reportedly colocalised with blood vessels, 
platelets and macrophages (Yeo et al., 2015). CXCL7 is produced by platelets 
and has been found in the sera and synovial tissue of RA patients (Castor et al., 
1992). This is an angiogenic chemokine that also induces proliferation of synovial 
fibroblasts and subsequent synovial fibrosis (Castor et al., 1992, 1993). In 
contrast CXCL4 is an ELR-negative, and hence, anti-angiogenic chemokine 
(Strieter et al., 1995). CXCL4 is produced by synovial macrophages and 
fibroblasts (Patel, Zachariah and Whichard, 2001) and recruits inflammatory 
leukocytes such as monocytes and neutrophils (Korniejewska et al., 2011). 
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5.1.10.3 C and CX3C Chemokines 
XCL1 has been shown to play an indirect role in the reduction in synthesis of 
MMP-2 which has a protective effect in RA. XCL1 also plays a role in facilitating 
the recruitment of CD4+ and CD8+ T cells in RA (Blaschke et al., 2003) which 
contribute to the reduction in MMP-2. CX3CL1, the only member of this family 
aids the recruitment of anti-inflammatory monocytes (Bazan et al., 1997). It also 
acts as a T cell adhesion molecule and may contribute to the cardiac 
comorbidities seen in RA patients (Volin et al., 2001, McDermott et al., 2003, 
Pingiotti et al., 2007). 
 
5.1.10.4 Chemokine Receptors 
It has been shown that expression of CCR2 on neutrophils plays an essential role 
in the tracking of these cells to the rheumatoid joint (Talbot et al., 2015).  CCL2 
is upregulated in the joints of RA patients and the same finding has also been 
shown in experimental models of arthritis. The CCR2/CCL2 axis is associated 
with inflammatory accumulation of leukocytes during normal immune responses. 
CCR5 is another key inflammatory chemokine receptor and is expressed by many 
cells recruited into the rheumatic synovium (Haas et al., 2005, Norii et al., 2006, 
Chou et al., 2010). Cells such as synovial macrophages and T cells both express 
CCR5 and single nucleotide polymorphisms (SNPs) in this gene have been shown 
to alter the severity in RA (Zapico et al., 2000, Pokorny et al., 2005). 
 
It has been shown that the TH17 cell-type has a key role in the pathogenesis of 
RA. The recruitment of TH17 is facilitated through interactions between CCL20 
and, its cognate receptor, CCR6. A polymorphism of CCR6, known as CCR6DNP, 
has been shown to increase the expression of CCR6 in humans and increase their 
susceptibility to a multitude of autoimmune diseases including RA. This 
polymorphism was also shown to be associated with an increase in serum IL-17 
levels, a key effector and inflammatory cytokine released by these cells (Kochi 
et al., 2010).  
 
FLS secrete increased levels of the CXC chemokine CXCL10 in experimental 
models of RA. The CXCR3 ligand has been shown to aid the infiltration of these 
cells to the joint which, in turn, increases the pathology thanks to the 
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inflammatory cytokines that FLS are known to secrete. In one study it was shown 
that in a rat model of RA, blocking CXCR3 reduced tissue damage and this was 
associated with a smaller number of these cells arriving to the joint. Animals 
that were given increased CXCL10 also showed increased infiltration of FLS and 
increased tissue damage (Laragione et al., 2011).  
 
Chemokine receptors are key targets for the pharmaceutical industry with 
regards to potential therapeutics in RA. It is mainly the inflammatory CC 
chemokine receptors that have been pursued as they are essential to the 
recruitment of inflammatory leukocytes that are so critical in driving the 
inflammatory state within the rheumatic joint. This, however, has been largely 
unsuccessful and in many ways illustrates the possible redundancy in the 
inflammatory chemokine response. One of the best examples of this is the CCR5 
antagonist Maraviroc, as discussed earlier. Unfortunately the clinical efficacy of 
this drug has been disappointing, providing little clinical efficacy and possibly 
worsening symptoms in some cases (Fleishaker et al., 2012).  
 
Interestingly, in vitro studies have shown that chemotaxis of human monocytes 
induced by human RA synovial fluid can be inhibited by neutralising antibodies to 
CCR1, CCR2 and CCR5 (Lebre et al., 2011). This is not recapitulated in vivo. The 
reasons for this remain a mystery but it would be reasonable to suggest that in 
the rheumatic joint there is just too great a proinflammatory signal that the 
neutralising antibodies are overwhelmed and unable to deliver any 
improvement. CCR1 neutralising antibodies have been shown to be efficacious in 
RA and at least two interventional molecules that target CCR1 are in clinical 
trials and showing promise (Tak et al., 2013, Santella et al., 2014).  
 
CCR1 ligands CCL15 and CCL23 are have been found in high concentrations in the 
synovial fluid of the RA joint (Berahovich et al., 2005, Chou et al., 2010). There 
is also a marked influx of CCR1 expressing leukocytes in the joint that are 
thought to play a key role in driving inflammation. Cells such as neutrophils, 
macrophages and osteoclasts all express high levels of CCR1 and, as mentioned 
in the previous paragraph, blocking this receptor seems to provide some promise 
in reducing inflammation. 
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5.1.10.5 Possible role for ACKR2 
More details on the structure, function, and normal expression of ACKR2 can be 
found in the introductory chapter to this thesis (section 1.4.4). However, from 
the studies mentioned above, it can be observed that many of the key 
chemokines involved in this pathology are the inflammatory CC chemokines. This 
would suggest that the atypical chemokine receptor, ACKR2, could have a role in 
the regulation of this condition. 
 
It has been observed that in the joint there is an up-regulation of ACKR2 at a 
transcriptional level (unpublished observations by Dr Helen Baldwin see appendix 
III). This data can be coupled with similar protein based data to intimate that 
ACKR2 is performing some function in this context. As described in the 
introduction to this thesis it has been shown that ACKR2 has a role in targeting 
and degrading the inflammatory CC chemokines. The theory then is that ACKR2 
is limiting the influx of cells to the joint by reducing the chemotactic signal that 
is causing the immigration of these cells. 
 
Previous work in our group has shown the presence of ACKR2 in the inflamed 
joint (McKimmie et al., 2008b). Immunostaining of human rheumatic samples 
have shown the presence of ACKR2. It has also been shown, in the same study, 
to be upregulated in the peripheral blood of patients. It was the purpose of the 
work presented in this chapter to attempt to elucidate possible causative factors 
for the upregulation in transcription of this gene.  
 
The hypothesis of the work done in this chapter was that the levels of 
transcription of the Ackr2 receptor could be used as a prognostic biomarker for 
patients with rheumatoid arthritis. 
 
5.2 Results 
5.2.1 Ackr2 in Peripheral Blood Cells of RA Patients 
This work was carried out with one of the aims of investigating if the 
transcription levels of Ackr2 in peripheral blood mononuclear cells (PBMCs) could 
be used as a biomarker for disease state and/or progression in RA patients. For 
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the work done in this study patients were split into three separate clinical 
groupings depending on the state of their condition. Patients were either: 
 
Clinic 1- Escalating RA: Patients whose current therapy regimen is no longer 
effective with disease diagnosed over 12 months before sample collection 
 
Clinic 2- Established RA: Well-managed disease diagnosed over 12 months before 
sample collection 
 
Clinic 3- Early RA: Diagnosed within 12 months of sample collection 
 
By splitting the patient samples into three distinct states of the disease this 
allowed us to look at Ackr2 transcription in these separate pathological contexts. 
We made this split depending on the clinic that the patient was attending at the 
time of the study. As patients go through their clinical pathway they change the 
clinics that they attend. It was using the clinics that enabled us to categorise the 
patients into these groupings defined above. 
 
Previous findings in our lab by Dr Helen Baldwin had suggested an increase in the 
levels of Ackr2 transcription in the peripheral blood of RA patients (see appendix 
III). As a result of this finding we decided to further investigate this. Samples of 
peripheral blood were taken from these patients and analysed for levels of Ackr2 
transcription in PBMCs. Below is a figure showing all of the samples from RA 
patients (samples from all groups pooled) and compared to healthy control blood 
samples in terms of Ackr2 transcription. 
 





It can be seen in figure 5.1A that there is no significant difference between the 
transcription levels of Ackr2 in the peripheral blood samples of RA patients when 
compared to that of healthy controls. Although there are two RA patients that 
have a higher level of Ackr2 transcription the means of both groups were almost 
identical at about 8 copies of Ackr2/105 copies of the reference gene TBP which 
is a low level of expression.  
 
In figure 5.1B it can be seen that patients in clinic 2 have a significantly higher 
level of ACKR2 transcription in peripheral blood compared to clinic 1 and clinic 3 
patients. Figure 5.1C shows the age spread of the patients involved in each of 
the clinics along with the healthy controls. 
 
When patient blood was taken the clinician would interview them, as per the 
normal clinical setting, and a disease activity score (DAS) would be taken. This 
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score was then correlated with the levels of Ackr2 transcription in the patients. 
To test correlation between Ackr2 transcription and disease severity, the data 
were split into the clinical groupings described at the top of this section. The 




The data above suggest that in the patients whose treatment regimen is working 
effectively that the level of Ackr2 transcription correlates positively with the 
DAS. The other two clinical groupings didn’t have the same significant 
correlation. Along with the DAS scores taken during the clinical meeting with the 
patient, a number of other pathological measurements were made. These 
included the erythrocyte sedimentation rate, the levels of C-reactive protein, 
rheumatoid factor levels, and age.  
 




C-reactive protein is known as an acute phase protein and is one of the key 
pathogenic markers in RA. Although trends may be visible in patients from clinic 
one and clinic two there is no significant correlation between the transcription 
of Ackr2 and CRP levels in patient peripheral blood samples. It may be of note 
that patients from clinic three show less of a pattern towards a correlation 
between CRP and Ackr2. These patients probably have the highest inflammatory 
burden and this may be contributing to this lack of a trend. 
 




Erythrocyte sedimentation rate is another clinical score that is used to make up 
the DAS28 score mentioned in section 5.1.3. In the graphs above it can be 
observed that in clinics 1 and 2 there is no correlation between ESR and Ackr2. 
Clinic 3 looks as though there is a trend although this is not significant, with a 
higher sample number this may reach significance. 
 
 





The above figures show all of the other clinical scores that were taken from 
patients as the blood was taken from them for this study. The data shows no 
other significant correlation of clinical scores and Ackr2 transcription in 
peripheral blood. One result that did stand out was that when patient samples 
are divided into their individual clinics the patients of clinic 2 have significantly 
higher levels of CCL2 than other groups. This is an interesting finding and is 
intriguing as clinic 2 patients also had significantly higher transcriptional activity 
of Ackr2 in their PBMCs. 
 
5.2.2 RA Luminex 
Having examined correlations between Ackr2 and clinical scores of RA patients, 
the next step was to investigate the blood plasma for protein levels of key 
cytokines, chemokines and growth factors that are involved in the pathogenesis 
of RA. This allowed us to see if there was any significant correlation between 
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the levels of Ackr2 transcription in peripheral blood mononuclear cells and the 
cytokine/chemokine profile in the plasma. 
 
 





Figure 5.6 represents the levels of each of the interleukins. In (A) the level of IL-
1 receptor antagonist (IL-1RA) is shown and it can be seen that between all 
clinical groups and the healthy control cohort there is no difference in the level 
of this analyte. (B) depicts the levels of the IL-2 receptor (IL-2R). This graph 
shows that in patients from clinic 3 there is a slight increase in the mean levels 
of IL-2R when compared to all other groups. This increase does not, however, 
reach statistical significance. (C) shows IL-6 levels. It can be seen that in all 
patient groups there is significantly higher levels of IL-6 when compared to the 
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healthy control samples. Patients from clinic 3 (newly diagnosed RA) have the 
most significantly raised IL-6 levels compared to healthy controls. The graph in 
part (D) of figure 5.6 shows the levels of IL-2 from the multiplex assay. All 
groups showed similar levels of this cytokine. In part (E) you can see the levels 
of the TH2 cytokine IL-10. Some of the patients from clinic 3 seem to have raised 
IL-10 when compared to the other groups but this does not reach statistical 
significance. Related cytokines IL-13 and IL-4 can be seen in (F) and (G), 
respectively. All groups have similar levels of these cytokines. In part (H) the 
levels of IL-5 can be seen and apart from minor individuals with markedly 
increased levels of IL-5 the general trend is that there is no difference between 
any of the groups here. For IL-12, depicted in part (I) there is no major 
difference between the mean levels of the cytokine across the groups. What may 
be worth noting is that the range of IL-12 levels in the patient groups are more 
varied than the control cohort of which all samples are around 200 pg/ml. Part 
(J) shows the levels of IL-17 which shows similar means of the expression of the 
cytokine in all groups except the samples from clinic 3. The increased mean in 
this population is due to a more varied range in cytokine a concentration with 
the other groups having a smaller spread in levels. This increase is not 
significant. (K) shows the concentrations of IL-15 in the samples. Samples from 
group 1 have significantly increased concentrations of this cytokine in their 
plasma than patients from all other groups. Samples from clinic 3 patients are 
slightly increased IL-15 concentrations too but this is not a significant increase. 
The concentrations of IL-1β are shown in figure 5.6 (L). Patients from group 1 
have quite varied levels of this inflammatory cytokine and an increased mean 
level of expression when compared to all of the other groups. This increase is 
not significant. Finally, part (M) of this figure shows the levels of IL-7. Apart 
from a single patient sample from clinic 3, the concentrations of this cytokine in 
the plasma seem to be at a very similar level across all samples. As well as some 
of the interleukins, this multiplex assay also had other inflammatory cytokines. 





Figure 5.7 depicts some key inflammatory cytokines involved in RA. (A) shows 
the levels of interferon (IFN)-α, a type I interferon. Clinic 1 patients have quite 
variable levels of IFN-α and the result of this is an increase in the mean 
concentration of this cytokine in the plasma of these patients. The other groups 
have similar levels and there is no significant difference between any of the 
groups. In figure 5.7 (B) the concentrations of IFN-γ are shown. All groups have 
very similar mean concentrations of this inflammatory cytokine. (C) depicts 
levels of TNF. The graph here shows an increase in the mean levels of TNF in the 
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patients of group 1 and 2 when compared to clinic 3 and healthy control 
samples. This is not a significant increase. In the penultimate graph of this figure 
(D) the concentrations of granulocyte-colony stimulating factor (G-CSF) are 
shown. The mean levels of all of the groups here are similar and there is no 
significant increase or decrease in G-CSF concentrations. Finally, (E) shows the 
concentrations of granulocyte-macrophage-colony stimulating factor (GM-CSF) 
and, mainly due to two patients who show anomalously high levels of the 




The growth factors present on the multiplex are shown in figure 5.8. (A) shows 
epidermal growth factor (EGF) concentrations and you can see that the levels of 
this in each of the groups are broadly similar. Basic fibroblast growth factor 
(FGFb) is shown in (B) and apart from one patient in each of the groups the 
concentration of this is expressed at a consistent level across all groups. 
Hepatocyte growth factor (HGF) is shown in (C). There are increased 
concentrations of HGF in all patient groups but this increase is slight and does 
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not reach statistical significance. In (D) the levels of vascular endothelial growth 
factor (VEGF) there is a very slight increase in clinic 1 patients when compared 
to healthy control samples. Clinics 2 and 3 have a higher level of VEGF again but 










The final grouping of analytes from the multiplex assay is the chemokine family. 
In (A) you can see the concentration of CXCL8, the key neutrophil 
chemoattractant, in the experimental samples. The levels of this chemokine do 
not differ significantly between the samples however, due to a large spread of 
concentrations in clinic 3, there is an increase in the mean level of CXCL8 in this 
group. CXCL9, the CXCR3 ligand, is shown in (B). Whilst the control group show 
little variation in the concentrations of CXCL9 the patients from clinic 3, and 
more so clinic 1, show highly variable concentrations of this chemokine. There is 
no significant change in the mean concentrations of this chemokine however. 
The patient samples show very little variation in the concentrations of CCL11 in 
part (C) however patient samples in all groups are highly variable. The mean 
concentration of CCL11 is raised in patient samples when compared to the 
healthy control samples, especially in clinic 2 patients however this is not a 
significant difference. The graph in part (D) shows the values for the 
concentration of CCL2 in the plasma of the cohort. The data in this graph 
suggests that patients from clinic 2 have significantly higher levels of CCL2 in 
their blood when compared to all other groups. The mean concentration of CCL2 
in clinic 1 and 3 patients are at a similar level and are both raised when 
compared to healthy controls although this is not significant. In (E) and (F) the 
plasma concentrations of CCL3 and CCL4 are shown, respectively. In these cases, 
which are similar, there is a slight increase in the level of these chemokines in 
clinic 1 patients but in general there is not much difference between groups. 
Figure 5.9 (G) shows the sample levels of CXCL10, all of the patient sample 
groups have a higher mean concentration of this chemokine when compared to 
healthy controls. The levels of this chemokine a markedly more variable amongst 
patient samples than control samples. Finally, (H) shows the levels of CCL5 and 
in this case the concentrations seem very high. In fact the healthy controls 
appear to have higher levels of CCL5 in their plasma than the patient samples 
which seems like there could have been an issue with this particular analyte as 
this seems highly counterintuitive.  
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From the data shown above there are very few significant correlations between 
the levels of Ackr2 transcription and the analytes in this plate. A couple of 
interesting results did appear after analysis however. Firstly, there is increased 
IL-6 in RA patients of every clinical grouping when compared to healthy control 
samples. Also, the levels of CCL2 in patients from clinic 2 (well controlled 
disease) is significantly up when compared to all other groups. This finding 
becomes even more interesting when compared with the graph of Ackr2 
transcription vs. clinical grouping. The same patient group have significantly 
more Ackr2 transcription and CCL2 is an ACKR2 ligand. 
 
5.2.3 Effects of Disease-Modifying Anti-Rheumatic Drugs 
(DMARDs) on ACKR2 Expression 
During the treatment of RA DMARDs are very widely used in an attempt to 
control the pathology of the disease. DMARDs are defined as a group of non-
related drugs that slow down the progression of RA. After finding that patients 
with well-controlled RA (clinic 2) had a significant correlation between Ackr2 
transcription and DAS score we wanted to look into this further. Patients in this 
group were all on a regimen of DMARDs so we wanted to see if any of the main 
drugs of this grouping had an effect on ACKR2 expression.  
 
To do this we harvested peripheral blood mononuclear cells (PBMCs) from a 
buffy coat and treated those cells with the most common DMARDs, namely 
methotrexate (MTX), dexamethasone (DXM) and acitretin (ACI). Cells were either 
incubated along side the drug for 6 or 24 hours before lysing the cells and 
analysing for transcriptional changes. The figure below shows the effect that 
each of these drugs had on the transcription of Ackr2. 
 





As can be observed in figure 5.10 every treatment condition of DMARDs caused a 
reduction in Ackr2 after 24 hours incubation when compared to a control 
sample. Interestingly, methotrexate, which is the most commonly prescribed 
DMARD, brought about an increase in the transcription of Ackr2 after a 
treatment time of 6 hours. 
 
5.2.4 The Effects of Hypoxia on Ackr2 Transcription 
It has been shown that one of the effects of cells being exposed to hypoxic 
conditions is that it can mimic inflammatory conditions. In the rheumatic joint 
there is a hypoxic environment as angiogenesis cannot keep up with the 
neoformation of the pannus (Strehl et al., 2014). It is suggested that this is a 
contributor to the generally inflammatory milieu in the rheumatic joint. Using 
the gene hypoxia inducible factor (HIF)-1α to confirm that a hypoxic state had 
been induced, we then investigated the transcription of ACKR2 within this 
environment. As mentioned in more details in the materials and methods section 
of this thesis, cells were incubated in normoxic conditions as a control or 
hypoxic conditions for 24 hours. After this the cells were lysed and analysed for 
ACKR2 transcription. The results from this assay are shown below. 
 





The results above suggest that in a hypoxic environment ACKR2 transcription is 
increased by around two-fold compared with those in a normoxic environment. 
These findings are in corroborate previous findings of our group in similar assays, 
but also seem to rule out a role for ACKR2 as a potential biomarker in differing 
stages of RA.  
 
5.3 Discussion of Chapter 5 
Taken together the findings from this work are inconclusive. The results 
presented above suggest that during well-controlled RA the levels of Ackr2 
transcription in the peripheral blood leukocytes of patients correlates with the 
DAS28 score. This finding does not seem to extend beyond this patient group 
however. Patients who have escalating RA or are newly diagnosed with the 
disease do not seem to display this. The reasons for this are many and further 
and more complex study would be require to tease out the details of this 
phenomenon. It has been previously shown that increased inflammation can 
result in increased expression of ACKR2.  
 
What is clear is that when simulating some of the conditions of the rheumatoid 
joint the level of Ackr2 transcription is increased. When cells were treated with 
a selection of the most common drugs that patients receive the transcription of 
the decoy receptor increased as it did in hypoxic conditions too. These findings 
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provide some basic evidence to suggest from this work that Ackr2 may have a 
role to play in the regulation of inflammation in RA. 
 
One of the main limiting factors of this study was the number of patient samples 
collected. Human samples are notoriously heterogeneous and so large sample 
sizes are required in order to create studies with the appropriate statistical 
power to draw the most appropriate conclusions. There was not enough time to 
collect enough patient samples from all three clinical groupings. The data 
presented shows a cohort of ten samples collected from each clinic along with 
ten healthy controls. Ideally we would have liked to increase the number of 
samples collected but time did not allow this. 
 
From the work done previously in our group by Dr Helen Baldwin, as mentioned, 
the levels of Ackr2 transcription in patients with RA was significantly increased 
when compared to patients with psoriatic arthritis, osteoarthritis and healthy 
controls. When all of the clinical samples were combined for this study we were 
unable to recapitulate this finding. The patients that were used for Dr Baldwin’s 
study would all have fallen into group two, as defined by this work, and so when 
we looked specifically at this group of patients we were able to see a similar 
finding.  
 
Another limiting factor to this work is the age of patient samples. Although the 
diagnosis of this condition usually happens around middle-age in patients, due to 
the chronic nature of the condition patient live for many years with this 
pathological burden (Innala et al., 2014). As a result of this, many of the 
samples collected during this study were of quite elderly patients. The average 
age of the total patient cohort was 56 whilst the average age of the control 
group was 37. Of course this could be an issue but since the control group were 
recruited in the lab this is the result. These controls would be more appropriate 
if they were more rigorously age matched.  
 
There are also other factors that could have been matched. Patients were not 
asked if they smoked or not and consideration was not taken on comorbidities 
patients presented with therefore there is no data on this. It has been noted 
that some diseases may have an effect on the progression of RA and taking into 
   
 
198 
account further conditions patients presented with may have added further 
validity to this study. 
 
The patients were grouped according to the clinic that they were attending. This 
was the best way in which to categorise the samples however with hindsight this 
could possibly have been improved. Obviously some patients would arrive at a 
given clinic and be told that they should change what clinic they attend upon 
the next visit. If this was due to an increased pathology and say a patient was 
recommended changing from clinic 2 to clinic 3 then this could skew the results. 
If this were to be done again it would be worth reviewing the patient’s 
pathological state after the interview with their clinician. This may lead to more 
exclusion but could bring about a more controlled patient cohort. This may have 
improved the study and possibly change the findings. Another condition that 
could have been better matched is gender. In appendix IV supplemental figure 5 
the gender of the patients recruited can be seen. It would possibly be worth 
recruiting a more evenly distributed gender cohort in the future. 
 
RA is a disease that can be affected by weather conditions (Cutolo et al., 2006). 
It is said that during cold and wet weather, which is not uncommon in Glasgow, 
patients tend to feel worse. This interesting occurrence means that it could have 
been useful to take notes on the conditions on given days when samples were 
taken to add more detail to the study. This statement is not a suggestion that 
the transcription of Ackr2 may be regulated by weather but it may have an 
effect on the DAS28 score. During the clinician’s interview of patients, just 
before the blood would be taken for this study, a DAS28 score for that patient is 
assessed. One of the factors that go into making up this score is to ask the 
patient how their condition has been over the previous 7 days. The point here is 
that if the week before the hospital visit and clinical interview had been 
inclement then the patient may feel worse than if it had been good. This would 
result in a patient having a higher DAS28, as mentioned, and may have played a 
role in altering the results presented here. To make this slightly easier, patients 
could have been ‘season-matched’ in order to investigate what, if any, effect 
this had on the results of the study. 
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Having investigated the effects of individual DMARDs on Ackr2 transcription in 
cell a line, it would be of great interest to look at this in RA patients. Patient’s 
notes could be investigated to see the current DMARD regimen that an individual 
was on and then by taking a blood sample and doing the QPCR assay used above 
this could be quantified. This would provide more physiologically relevant detail 
to the in vitro study described here. 
 
Of course, to truly assess any role for ACKR2 in RA the very best patients to 
study would be those that have had very little or no clinical intervention. This is, 
of course, extremely difficult and ultimately unfeasible. This study has shown 
again that the most common drug-type used in the treatment of RA can have a 
downstream effect on the transcription of the Ackr2 gene. It would be 
interesting to select patients on regimens of single DMARDs and investigate if 
this had any affect on Ackr2 activity. This could have been done for this work 
but, unfortunately, was overlooked during the design of the study.  
 
To re-assess the hypoxia study in more relevant physiological terms it would be 
worth carrying out another QPCR and looking at the transcription of the Hif-1α. 
This is a marker of hypoxia in cells and so could be correlated with the activity 
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Chapter 6 Discussion 
6.1 Introduction 
The atypical chemokine receptor ACKR2 has been shown to have key non-
redundant roles in mammalian biology (Graham and Locati, 2013). It has also 
been shown to be functionally distinct from classical chemokine receptors with 
the ability to scavenge inflammatory CC chemokines without desensitisation and 
efficiently limit their bioavailability (Blackburn et al., 2004, Weber et al., 2004) 
which, in turn, has been shown to limit inflammation in vivo (Jamieson et al., 
2005). As research has progressed into ACKR2 it has become apparent that it has 
roles beyond the limitation of inflammation including altering lymphatic vessel 
densities (Lee et al., 2014) and tumourigenesis (Nibbs et al., 2007). 
Studies have shown that this atypical chemokine receptor has key roles in 
multiple human pathologies related to this work. ACKR2 has been shown to alter 
the pathology shown in patients with the skin conditions psoriasis (Singh et al., 
2012) and scleroderma (Codullo et al., 2011) (a symptom of the disease systemic 
sclerosis), in allograft rejection in the eye (Hajrasouliha et al., 2013) and in 
rheumatoid arthritis (Dr Helen Baldwin, appendix III). It was therefore our goal 
to attempt to build on this body of evidence whilst investigating possible novel 
facets of ACKR2 function in the skin, the eye and in rheumatoid arthritis. 
6.2 General Overview 
The overall aim of this work was to investigate the role played by ACKR2 in 
tissue-specific inflammatory responses. It has been shown that ACKR2 plays a 
key role in controlling the resolution of inflammation in vivo (Jamieson et al., 
2005). Previous work on ACKR2 has illustrated the importance of this atypical 
chemokine receptor in the skin (Jamieson et al., 2005) (Singh et al., 2012) and in 
the rheumatoid joint (Dr Helen Baldwin, appendix III). This work set about to 
further our knowledge into the mechanisms of these findings as well as 
investigate the role of ACKR2 in inflammation of the eye. 
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The work presented here has compared the inflammatory response of ACKR2-null 
mice to that of wild-type mice in three anatomically and physiologically distinct 
tissues. The advantage of this is that we have been able to observe some 
parallels between the separate models and settings. This work has further 
demonstrated the key role that ACKR2 plays in the limitation of inflammation 
through its ability to scavenge inflammatory CC chemokines (Weber et al., 
2004). The results suggest that, not only is inflammation increased in the 
absence of ACKR2, but that the infiltrating cellular profile is also significantly 
altered. This alteration has down-stream effects on local cells. 
 
6.2.1 Overview of Chapter 3: The Role of ACKR2 in Cutaneous 
Inflammation 
6.2.1.1 ACKR2 in Wound Healing 
The work carried out here in two of the anatomical contexts, the skin and the 
eye, presented phenotypes that could be attributed to macrophages. In both the 
tissues mentioned there was an increase in collagen deposition during the 
resolution phases following inflammatory challenge.  
 
The main finding from the wound healing models carried out in chapter 3 was 
that mice lacking ACKR2 had less-well organised collagen fibres upon scar 
maturation compared to wild-type littermates. It was unclear if this phenotype 
was due to increased collagen synthesis or a failure to organise the fibres 
efficiently. Interestingly, when we removed macrophages from the mice before 
initiating, and during the development of the wounding model we found a 
complete reversal of the phenotype. It was also of note that removing these 
cells caused a temporal delay in wound closure in mice also lacking ACKR2. This 
allowed us to postulate that ACKR2 plays a fundamental role in regulating 
macrophage recruitment, a key cell in all stages of the wound healing process. 
During this work we also found a psoriasis-like inflammation at the injection site 
of ACKR2 null mice that was not present in wild type mice. 
 
In order to gain insight into possible mechanisms for this hyperfibrotic response, 
parallels may be drawn with the autoimmune condition systemic sclerosis (SSc). 
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One of the main symptoms of SSc is aberrant deposition of collagen which causes 
fibrosis. The ACKR2 ligands CCL2, CCL5 and CCL7 have all been implicated in the 
initiation and perpetuation of this overactivation of fibroblasts (Distler et al., 
2006, Yanaba et al., 2006). Work by Codullo et al. suggested that the 
transcription of Ackr2 in peripheral blood leukocytes is increased in leukocytes 
of patients with SSc (Codullo et al., 2011). The hypothesis from this work was 
that ACKR2 was aiding the regulation of the systemic levels of its ligands and in 
turn was protecting the patient (Codullo et al., 2011).  
 
It is reasonable to draw parallels from SSc to the pro-fibrotic responses seen in 
the inflamed skin and eyes of ACKR2-null mice. Firstly it would be interesting to 
see if the expression of the same ACKR2 ligands were increased in the plasma of 
the mice during these models in knockout mice. This would allow one to 
postulate that a similar mechanism may be responsible for this hypercollagenous 
response. The proposed model here would be that both systemic and local 
expression of ACKR2 alters the number of infiltrating cells which indirectly 
reduces the activation of collagen producing cells such as fibroblasts.  
 
To test this hypothesis a small molecule inhibitor of ACKR2 could be used to 
provide insights into this process. By carrying out a wounding model, for 
example, in a wild-type mouse one could control at what time-point after 
wounding to block the activity of ACKR2 and investigate the phenotypes brought 
about by intervention at set times. It would be of interest to take this further 
and investigate the effect of an absence of ACKR2 in other fibrosis contexts. A 
lung or liver fibrosis model, as examples, would allow us to determine whether 
this phenomenon was purely a skin-based function of ACKR2 or if it is more 
widespread. 
 
One of the key sites of expression of ACKR2 is on lymphatic endothelial cells 
(McKimmie et al., 2013). This expression has a key role in the efficiency of the 
immune response (Lee et al., 2011) but what is not clear is how much of a 
contribution this expression makes to the phenotypes found in this work. In 
order to address this it would be useful to repeat these models in chimeric mice. 
By taking wild-type mice and reconstituting them with ACKR2-null bone marrow 
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and vice versa it would allow us to determine the contributions of ACKR2 
expression on stromal tissue and leukocytes, respectively.  
 
6.2.1.2 ACKR2 in Other Models of Cutaneous Inflammation 
We also demonstrated a protective effect of ACKR2 in a mast cell degranulation 
model in mouse skin. Throughout this model, mice lacking the receptor had 
exaggerated inflammatory pathology when compared to wild-type mice in a 
process which in many ways mimics the cutaneous reaction to thermal damage. 
This was most obvious in the fact that ACKR2-null mice had significantly thicker 
skin than wild-type animals after the initiation of this inflammation. In the 
model of allergic contact dermatitis we saw very little difference between the 
responses of mice with and without ACKR2. 
 
The results shown in this section suggest a multi-faceted role for ACKR2 in 
cutaneous tissue. Not only have our results added to the body of evidence 
showing that the absence of ACKR2 results in a reduced capacity to resolve 
inflammation, but they have demonstrated a novel role for this molecule in the 
formation and maturation of collagen fibres in scar tissue. The proposed 
mechanism for this involves ACKR2 acting indirectly on collagen producing cells 
such as fibroblasts. The absence of ACKR2 would result in a higher local 
concentration of inflammatory chemokines. This would, in turn, bring about an 
increased influx of inflammatory cells such as macrophages. One of the key 
cytokines produced and released by alternatively activated macrophages is TGF-
β1 which has been shown to increase the levels of collagen synthesis by 
fibroblasts. In addition to this macrophages have a key role to play in the 
organisation of collagen fibres in the maturing scar. 
 
6.2.2 Overview of Chapter 4: The Role of ACKR2 in Ocular 
Inflammation 
In the second results chapter of this thesis we set about investigating the role 
that ACKR2 plays in the experimental autoimmune uveoretinitis model. 
This was done alongside Prof. John Forrester from the University of Aberdeen 
who has published on the subject of chemokines and chemokine receptors in 
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uveitis previously (Crane et al., 2001, 2006). The results gained from this series 
of experiments indicated that ACKR2 has a protective role in the model and that 
mice lacking the receptor have significantly increased pathology.  
 
Having shown this, we wanted to take a more translational approach and assess 
the likelihood of this finding being feasible in the human eye. To do this we 
investigated the human retinal pigmented epithelial cell line, ARPE-19 (Dunn et 
al., 1996), for expression of ACKR2. Our findings show that these cells express 
the ACKR2 and that it is functional. 
 
The results from in this chapter suggested that ACKR2 has a protective role to 
play in the prevention of pathological inflammation of the eye. They also suggest 
that this protection may be relevant to human tissue too. The next step in this 
study would be to gain human tissue and stain it for ACKR2 to see if the 
expression pattern of the atypical chemokine receptor is comparable between 
mouse and human tissue. The proposed mechanism here is that ACKR2 is 
reducing the local concentration of inflammatory chemokines resulting in a 
reduction of the numbers of recruited inflammatory cells which could go on to 
cause pathology in the local tissue. 
 
6.2.3 Overview of Chapter 5: The Role of ACKR2 in Rheumatoid 
Arthritis 
The study carried out in rheumatoid arthritis, the only work not carried-out on 
mice for this thesis, showed potential and added to work done previously in our 
lab (appendix III). The aim of this section was to assess the suitability of ACKR2 
as a biomarker of disease state and/or progression in patients with this 
inflammatory autoimmune disease. Although the results from this work 
suggested that ACKR2 was not appropriate for this task, they did add further 
validity to Dr Helen Baldwin’s previous finding that Ackr2 transcription is 
increased in peripheral blood leukocytes of patients with well-controlled 
disease. This did not seem to be the case for patients with newly diagnosed 
disease (diagnosis less than 12 months before participation in the study) or 
patients who were being screened for escalation of therapy. It would be of 
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interest to further investigate the well-controlled cohort of patients in an 
attempt to disseminate the possible mechanisms behind this. 
 
After investigating ACKR2 as a potential biomarker we looked into functional 
roles that the receptor may play in RA through in vitro studies. Again drawing on 
findings from previous studies carried out in our lab, we investigated the 
transcriptional response of Ackr2 when cells were exposed to hypoxic conditions 
and disease-modifying anti-rheumatic drugs (the most common therapeutic 
compounds used in clinics). 
 
The results from these experiments suggested that ACKR2 is not a particularly 
relevant biomarker for disease progression/state in rheumatoid arthritis. They 
did, however, show that in the environment of the rheumatic joints, cells may 
increase the levels of Ackr2 transcription. This may lead to greater control of 
the inflammatory state of the local cells. 
 
6.3 Additional Studies and Limitations 
A chimeric mouse study would give additional insights into the EAU model 
carried out in chapter 4.2.1 and the allergic contact dermatitis model presented 
in section 3.5.6. Both of these models have extensive involvement of the 
adaptive immune system and so the efficient transit of cells to the local draining 
lymph node is of great importance. Using this system one could observe the 
phenotypic individual contributions of ACKR2 expression on lymphatic 
endothelial cells and leukocytes more distinctly. Using this system would also 
provide insight into contributions made by tissue-resident cells that express the 
receptor, such as keratinocytes of the skin (Singh et al., 2012), in the limitation 
of inflammatory responses in specific tissues. 
 
Throughout the work done on murine models, one of the biggest limiting factors, 
as already mentioned in each chapter, was the lack of a reliable anti-ACKR2 
antibody for use on mouse tissue. Although we have developed a reliable 
monoclonal anti-ACKR2 antibody for human tissues in our lab, along with the 
availability of commercial equivalents, there is a distinct lack of antibodies that 
recognise the murine receptor. Having this would have allowed us to gain real 
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insight into both the temporal and spatial expression of ACKR2-expressing cells 
during the various models employed for this work. It would also have given a key 
insight into the kinetics of accumulation of inflammatory cells in the presence or 
absence of ACKR2. This would have given added detail to the results that we 
gained from carrying out experiments using ACKR2-null mice.  
 
Another great tool for investigating the mechanistic details of this work further 
would be an ACKR2-reporter mouse, although this is currently being made at the 
time of writing. Using this we could visualise, in real-time, where the ACKR2-
positive cells were being recruited and how they were interacting with other 
cells in the local area. Other advantages of this system over an antibody staining 
method include the ability to harvest these cells in order to thoroughly 
investigate their phenotype and an avoidance of antibody staining artefacts. The 
‘biological toolbox’ that has been available for this study has given great insight 
into the functions of ACKR2 but with some minor additions a great amount of 
added detail could be gained. 
 
6.4 Future Directions 
The results shown here have potential to provide the basis for the development 
of an ACKR2-based therapeutic intervention, certainly in inflammation of the 
skin and the eye. As explained in the introduction (section 1.4.4.2), the cell-
surface expression of ACKR2 under normal circumstances is very low (Blackburn 
et al., 2004). If a molecule could be developed to increase the levels of 
expression of this molecule on the cell surface, i.e. increase its bioavailability, 
and then this could potentially reduce inflammatory pathology further. This 
could also have a positive effect on scar formation after excisional wounding of 
the skin. 
In order to test if this would be beneficial to patients it would be useful to carry 
out ACKR2 overexpression studies. This could be achieved using one of two 
approaches. Firstly genomic engineering methods could be used or the other 
would be to use a viral vector to increase the levels of the receptor.  
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Having done this it would be of interest to carry out many of the studies 
presented in this thesis, as well as others, to investigate the resultant 
phenotypes. It would be intriguing to see if enhancing the expression of ACKR2 
would further reduce inflammatory pathology in these models and, perhaps, 
further reduce inflammatory damage in the eye or improve scar organisation in 
the skin. The work shown here suggests that a molecule that could increase 
ACKR2 expression could have wide-ranging positive effects for patients, certainly 
in inflammation of the skin and/or the eye. 
6.5 Conclusions 
The data reported in this study suggest that the absence of ACKR2 both increases 
inflammatory pathology in murine models of skin and eye inflammation and can 
alter the profile of the infiltrating cell population in these cases. The functional 
ablation of macrophages resulted in a phenotypic reversal in the pathology of 
the skin leading to the hypothesis that a lack of ACKR2 alters the macrophage 
response during inflammation. This finding is in keeping with our current 
knowledge on the mechanisms of ACKR2 function and helps build on this. We 
show, for the first time, that ACKR2 may have a role in the maturation of scars. 
Our findings further back-up and expand the repertoire of functions of ACKR2. 
These results demonstrate the importance of developing molecules that can 
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Chemokines are essential contributors to leukocyte accumulation at sites of 
inflammatory pathology.  Interfering with chemokine or chemokine receptor 
function therefore represents a plausible therapeutic option. However, our 
currently limited understanding of chemokine orchestration of inflammatory 
responses means that such therapies have not yet been fully developed. We have 
a particular interest in the family of atypical chemokine receptors which fine-
tune, or resolve, chemokine driven responses. In particular we are interested in 
ACKR2 which is a scavenging receptor for inflammatory CC-chemokines and 
which therefore helps to resolve in vivo inflammatory responses.   Here we show 
elevated expression of ACKR2 on peripheral blood cells as well as on leukocytes 
and stromal cells in synovial tissue. Expression on peripheral blood leukocytes 
correlates with, and can be regulated by circulating cytokines with particularly 
strong associations being seen with IL-6 and HGF. In addition, expression within 
the synovium is coincident with aggregates of lymphocytes, potentially atopic 
follicles, and sites of high inflammatory chemokine expression. Similarly 
increased levels of ACKR2 have been reported in psoriasis and systemic sclerosis. 




Introduction   
The in vivo migration of leukocytes is regulated by proteins belonging to 
the chemokine family[1]. This family is defined on the basis of the presence of a 
conserved cysteine motif in the mature protein sequence and is further divided 
into CC, CXC, XC and CX3C subfamilies according to the specific nature of the 
cysteine motif. Chemokines can be broadly classified as being either 
inflammatory or homeostatic depending on the contexts in which they 
function[2, 3]. Inflammatory chemokines are predominantly involved in 
recruiting inflammatory leukocytes to damaged or infected tissue sites, whereas 
homeostatic chemokines are involved in more precise tissue localisation of 
leukocytes. Chemokines interact with their target cells through receptors 
belonging to the seven transmembrane spanning family of G-protein coupled 
receptors[4]. There are 18 identified chemokine receptors and, again, these 
broadly distribute themselves into inflammatory and homeostatic subclasses. 
Given the essential roles played by chemokines and their receptors in regulating 
immune and inflammatory leukocyte migration, it is not surprising that they play 
essential roles in a broad range of autoimmune and inflammatory pathologies[5, 
6]. Disappointingly, despite two decades of study, there are currently no 
antagonists of chemokine receptor function licenced for use in inflammatory 
diseases. This represents a significant failing in the field and is likely to be 
related to our currently poorly-developed understanding of the full complexities 
of the chemokine orchestration of inflammatory responses[6]. 
In addition to the classical signalling chemokine receptors there exists a 
separate subclass of receptors characterised by an inability to mount typical 
signalling responses to chemokine binding[7]. These receptors also possess an 
altered DRYLAIV motif in the second intracellular loop and have been named 
'atypical chemokine receptors' on this basis. There are currently four members of 
the atypical chemokine receptor family[7-9]: ACKR1 (formerly known as DARC); 
ACKR2 (formerly known as D6 or ccbp2); ACKR3 (formerly known as RDC1 or 
CXCR7) and ACKR4 (formerly known as CCRL1 or CCXCKR). These molecules serve 
essential in vivo functions in fine-tuning, or resolving, chemokine-driven 
responses and represent important new contributors to the overall regulation of 
chemokine function.  
We have a particular interest in ACKR2 which is a highly promiscuous 
receptor for inflammatory CC-chemokines and which is expressed by lymphatic 
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endothelial cells, syncytiotrophoblasts and some subsets of leukocytes[10, 11]. 
Following ligand binding, ACKR2 internalises ligands and targets them for 
intracellular degradation[12, 13]. It is therefore a 'scavenging-receptor' for 
inflammatory CC-chemokines and its broad promiscuity ensures that it can 
scavenge essentially all CC-chemokines involved in inflammatory responses. 
Work from us, and others, has demonstrated a clear role for ACKR2 in the 
resolution of inflammatory responses at all tissue sites at which it is 
expressed[14-20]. In addition we recently demonstrated a role for ACKR2 in 
lymphatic vessel development[21]. We have also previously shown marked up-
regulation of ACKR2 expression in the epidermis and peripheral blood in 
psoriasis[22], and whole skin and peripheral blood in systemic sclerosis[23] 
suggesting an, as yet poorly defined, association with inflammatory disease. The 
purpose of the current study was to extend these analyses to incorporate 
inflammatory arthropathies, where ACKR2-binding inflammatory CC chemokines 
such as CCL1, 2, 3 and 5 play key roles in the propagation and maintenance of 





Materials and Methods  
Isolation of Peripheral Blood Mononuclear Cells (PBMC) and plasma 
Heparinised whole blood (10ml) was taken from healthy donors and 
inflammatory arthritis patients [(early rheumatoid (early RA), established 
rheumatoid arthritis (RA) and psoriatic arthritis (PsA)] with ethical permission 
from the West of Scotland Ethics Committee. Matched serum samples (10ml) 
were taken from each patient.  Heparinised blood was diluted 1:1 with wash 
buffer (PBS supplemented with 1% FCS and 2mM EDTA) and layered onto 
Histopaque (Sigma #1077-1) according to the manufacturer’s instructions. Blood 
was centrifuged at 400g for 30mins (with the brake removed) and the buffy layer 
was extracted. Cells were washed twice with wash buffer and counted using a 
haemocytometer. Cells were either re-suspended in RLT buffer (QIAgen #74004), 
containing β-mercaptoethanol, and stored at -80ºC for future RNA isolation or 
re-suspended at 1x106/ml in complete media (RPMI+10% FCS+2mM L-
Glutamine+Pencillin/Streptomycin) for future cell culture. Plasma samples were 
centrifuged at 8000 rpm for 10 minutes at 4ºC and serum was stored in 500µl 
aliquots at -80ºC for later analysis. 
 
Quantitative real time RT-PCR 
 PBMC samples stored in RLT buffer at -80⁰C were thawed at room 
temperature and RNA was extracted using the RNeasy micro kit (QIAgen #74004) 
according to the manufacturer’s instructions.  RNA concentrations and quality 
were measured using the Nanodrop-2000 (Thermo Scientific) and stored at -80⁰C 
for future cDNA synthesis.  RNA was thawed and was reverse-transcribed to cDNA 
(500ng) using Affinity Script (Stratagene #600559) according to the 
manufacturer’s instructions.  cDNA was stored at -20oC until used for 
quantitative real-time RT-PCR (qPCR) using methodology, and primers, as 
described previously[31-33]. Samples were run for 40 cycles on the 7900HT Fast 
Real-Time PCR System (ABI) and data were analysed using ABI Prism SDS 
software. The absolute number of ACKR2 copies was normalised to TATA-binding 
protein (TATA-BP) copy number.      
 
Quantification of cytokines and chemokines 
Plasma cytokines and chemokines were quantified using the human 
cytokine 30-plex luminex kit (Invitrogen #LHC6003).  The serum was analysed 
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undiluted.  The detection level of the luminex was 30pg/ml; all readings lower 
than this were designated non-detectable.  
 
Immunofluorescence staining of synovial tissue  
Paraffin-embedded RA synovial tissue was sliced into 5µm sections and 
mounted onto Superfrost slides (VWR #631-0108). Sections were rehydrated to 
water through xylene and successive concentrations of alcohol. Antigen was 
retrieved by boiling slides in 0.05M citrate buffer (pH6) for 8 min before slides 
were blocked for 30 mins at room temperature (RT) in 20% horse serum (Vector 
Labs #S-2000) and Avidin-D block (Vector Labs #SP-2001) diluted in Tris-Buffered 
Saline containing 0.01% Tween-20 (TBST). Slides were then incubated overnight 
at 4ºC with rabbit anti-human CCBP2 (ACKR2, 2.5µg/ml, Sigma #HPA013819) at 
4ºC in Dako REAL antibody diluent (Dako #S2022) supplemented with 2.5% horse 
serum/2.5% human serum (Sigma #H4522) and Biotin block (Vector Labs #SP-
2001). The following morning, slides were washed in TBST and incubated for a 
further 30 mins at RT with biotinylated horse anti-rabbit IgG (1/200, Vector Labs 
#BA-1100) in Dako REAL antibody diluent supplemented with 2.5% horse 
serum/2.5% human serum. Slides were washed in TBST and incubated with 
Fluorescein Avidin-D (1/500, Vector Labs #A2001) for 40 mins at RT.   
 Slides were then washed twice in TBST, and re-blocked with 20% horse 
serum (Vector Labs #S-2000) and Avidin-D block (Vector Labs #SP-2001) diluted 
in TBST for 30 mins at RT. Slides were washed and stained with antibodies 
against lineage markers overnight at 4⁰C in order to detect ACKR2+ macrophages: 
mouse IgG1 anti-human CD68 (clone PG-M1, 1µg/ml; Dako #M0876), mast cells: 
mouse IgG anti-human mast cell tryptase (clone AA1, 0.43µg/ml; Dako #M7052), 
CD3+ T cells:  mouse IgG1 anti-human CD3 (clone LN10, 1ug/ml, Vector labs #VP-
C429), CD20+ B cells: mouse IgG2a anti-human CD20cy (clone L26, Dako #M0755) 
or mouse IgG1 anti-human CCL3 (clone 93321, R&D Sytems #MAB270). The 
following day, sections were incubated with biotinylated horse anti-mouse IgG 
H+L (Vector Labs #BA-2000) and subsequently stained with Avidin-D Texas Red 
(Vector Labs #A2006) for 40min. Slides were washed, mounted using Vectashield 
mounting medium with DAPI (Vector Labs #H1200) and analyzed on an 
epifluorescent imaging microscope (Carl Zeiss). Images were captured using 




Immunofluorescence staining of cell cytospins 
PBMC were isolated as described above and re-suspended in PBS 
containing 2mM EDTA at 0.5x106/ml. Cells (0.1x106) were spun onto superfrost 
slides (VWR) at 800 rpm for 3 mins using a Shadon Cytospin Centrifuge (Thermo 
Scientific), fixed in 100% methanol for 10mins at RT and left to air dry. Slides 
were then blocked with 20% horse serum (Vector Labs #S-2000) diluted in TBST, 
before being stained overnight at 4⁰C with rabbit anti-human CCBP2 (ACKR2, 
2.5µg/ml, Sigma #HPA013819), mouse IgG1 anti-human CD3 (Dako) and mouse 
IgG2a anti-human CD20 (Dako). Antibodies were diluted in TBST supplemented 
with 2.5% horse serum (Vector Labs #S-2000) and 2.5% human serum (Sigma 
#H4522). The following day, slides were washed and incubated with goat anti-
rabbit FITC (1/300, #4030-02), goat anti-mouse IgG1 Cy5 (1/300 #1070-15), and 
goat anti-mouse IgG2a TRITC (1/300, #1080-03, all from Southern Biotech) in 
TBST containing 2.5% horse serum/2.5% human serum for 30 mins at RT. Slides 
were washed, mounted using Vectashield mounting medium with DAPI (Vector 
Labs #H1200) and analyzed on an epifluorescent imaging microscope (Carl Zeiss). 
Images were captured using Axiovision software Rel 4.8.2.  
 
Stimulation of PBMC to detect ACKR2 expression 
PBMC were cultured at 1x106/ml in 6-well plates in complete media 
(RPMI+10% FCS+ 2mM L-Glutamine + Penicillin/Streptomycin) at 37⁰C for 6, 24 or 
48 hours with combinations of cytokines, or chemokines, all from Peprotech at 




For all statistical tests, non-parametric data were analysed using the 
Mann Whitney U test and parametric data using an unpaired t-test. To detect 
significant correlation between variables, Spearman’s correlation-coefficient 
was used, where r=1 denotes a perfect positive correlation and r=-1 a perfect 






Patient Cohort  
A summary of the patient details is shown in Supplementary Table 1.  
Patients classified as early RA (early inflammatory disease) were defined as 
having a disease course of less than 1 year and had been taking disease 
modifying anti-rheumatic drugs (DMARDs) for less than 6 months. All patients 
with RA and PsA had been treated with DMARDs for the majority of the duration 
of their disease (over 1 year).  There were no significant differences in ESR or 
CRP between the patient groups (Supplementary Figures 1A and 1B).  
 
ACKR2 expression is elevated in PBMC from inflammatory arthritis patients 
To determine the expression levels of ACKR2 in PBMC from established 
psoriatic arthritis (PsA), rheumatoid arthritis (RA) or early rheumatoid arthritis 
(Early RA) in comparison with healthy controls we used qPCR as previously 
described. As shown in Figures 1A and B all three patient populations displayed 
significantly elevated PBMC ACKR2 expression relative to healthy controls. 
Specifically we found ACKR2 expression to be increased by a median of 
approximately 2-fold in established PsA (p=0.005), 5-fold in established RA 
(P=0.004) and 9-fold in early RA (p=0.0002). There was also a significant 
difference in ACKR2 expression between PsA and early RA patients (p=0.04).  
Some patients displayed extremely elevated levels of ACKR2 expression and, 
overall, there was an almost '5 Log' spread in ACKR2 levels when data from 
healthy controls, and all three arthropathy groups, were pooled (Figure 1C).  
To attempt to identify the peripheral blood leukocyte subpopulations 
responsible for the elevated ACKR2 expression we performed immunostaining of 
PBMC cytospins from RA patients (Figure 1D). Quantitation of the numbers of 
ACKR2-positive cells per field of view revealed a highly significant increase in 
the % ACKR2+ve cells in RA patients compared to healthy controls (Figure 1E). 
Co-staining for ACKR2 and CD14, CD3 or CD20 indicated that ACKR2 expression 
was detectable in peripheral blood monocytes, T cells and B cells (Figure 1F). 
Thus elevated PBMC ACKR2 expression is seen on a variety of leukocyte 
subtypes in a range of inflammatory arthropathies. 
 




Whilst there were significant differences between the ages of the healthy 
controls and the patient groups, and also between patient groups 
(Supplementary Figure 1C), there was no correlation between age and ACKR2 
expression in PBMC (Supplementary Figure 2A). This suggests that age was not a 
contributing factor to the data obtained. We next tested for correlations 
between ACKR2 expression and markers of disease severity (ESR and CRP). This 
analysis showed no significant correlation between ACKR2 and ESR or CRP 
(Supplementary Figures 2B and 2C). Thus PBMC ACKR2 expression levels do not 
correlate with age or disease severity in arthropathies.   
 
ACKR2 expression correlates with peripheral blood cytokine and chemokine 
levels. 
To attempt to define possible regulators of ACKR2 expression on PBMCs, 
we measured levels of a broad range of circulating cytokines and chemokines 
using Luminex and tested for correlations with PBMC ACKR2 expression levels. As 
shown in Figure 2, when data from all patient and control groups were 
combined, statistically significant correlations with ACKR2 expression levels 
were seen for IL-6, IL-1β, IL-2, TNF, IL-7, IL-15, IL5 and HGF. Each correlation 
detected was positive in the sense that increased cytokine levels correlated with 
increased ACKR2 levels. By far the most persuasive correlations were with IL-6 
and HGF concentrations. In addition, for chemokines, there was a positive 
correlation between CCL2 levels and ACKR2 expression (Figure 3A) and whilst no 
overall correlation was detected with CCL3 (Figure 3B), patients expressing 
ACKR2 levels above the median of the whole population display significantly 
higher CCL3 levels than those below the median (Figure 3C). Interestingly, when 
broken down to disease subtypes, the strongest correlation between IL-6 levels 
and ACKR2 expression was seen for Early RA and between IL-1 and IL-2 and 
ACKR2 for PsA 
Thus ACKR2 expression on PBMCs correlates positively with circulating 
levels of select cytokines and chemokines.  
 
Combinations of cytokines and chemokines can up-regulate ACKR2 expression on 
PBMCs 
To determine whether the correlating cytokines described above were 
functionally involved in regulating ACKR2 expression we took PBMC from healthy 
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individuals, with low levels of ACKR2, and tested the ability of cytokines to 
increase expression levels. By far the strongest overall correlation between 
circulating cytokine levels and PBMC ACKR2 levels were seen for IL-6 and HGF. 
As shown in Figure 4A, IL-6 was unable to modulate ACKR2 expression levels on 
PBMC. In a similar manner HGF was also unable to modulate expression levels 
(data not shown). Thus these cytokines are unable to independently induce 
ACKR2 expression over a 48 hour time frame. Next, to test combinatorial 
cytokine regulation of ACKR2 expression, we combined the cytokines that 
correlated with ACKR2 to produce a ‘cytomix’ containing IL-6, IL-1β, IL-2, TNF-α, 
IL-7, IL-15, IL-5 and HGF. In addition we generated a ‘chemomix’ containing the 
chemokines CCL2 and CCL3. Healthy PBMC were stimulated in-vitro with these 
agents following which we detected a significant and sustained increase in 
ACKR2 expression after stimulation with the cytomix but no increase in 
expression after stimulation with the chemomix (Figures 4B and C). Thus PBMC 
expression of ACKR2 correlates with select circulating cytokines and mixtures of 
these cytokines are capable of increasing ACKR2 expression suggesting a 
functional association in peripheral blood. 
 
Expression of ACKR2 within Rheumatoid Arthritis Synovium 
Next we used immunohistochemistry to examine expression of ACKR2 in 
RA synovium. Initial staining (Figure 5A) revealed ACKR2 positive signals 
associated with cells at the tissue/synovial fluid interface as well as on 
numerous cells internal to the synovial tissue structure. Co-staining for CD45 and 
ACKR2 (Figure 5B) demonstrated that the receptor is expressed by numerous 
leukocytes but also by stromal cells throughout the tissue. Interestingly, 
ACKR2+ve leukocytes were generally not randomly distributed within the tissue 
and were present predominantly within leukocyte aggregates. Notably, co-
staining for ACKR2 and one of its ligands, CCL3, indicates that there is significant 
overlap in their expression patterns and that ACKR2 is therefore expressed at 
appropriate tissue positions for effective intra-synovial chemokine scavenging 
(Figure 5C). We have previously reported expression of ACKR2 by T cells, B cells, 
monocytic cells and mast cells[31]. In agreement with this, co-staining for 
markers specific to these leukocyte populations demonstrated ACKR2 expression 
on these cellular populations (Figure 6A-D). Particularly strong co-staining was 
seen with aggregates of T and B cells (Figure 6E) suggestive of ACKR2 expression 
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within ectopic follicles. Thus ACKR2 is expressed on both leukocyte, and non-





 ACKR2 is an important regulator of inflammation and we have previously 
reported marked up-regulation of expression in skin, and peripheral blood 
leukocytes, in psoriasis and systemic sclerosis[23]. The purpose of the present 
study was to extend these observations and to examine expression of ACKR2 in 
arthropathies. Here we present data demonstrating up-regulation of ACKR2 in 
PsA, RA and early RA. We conclude, on this basis, that elevated peripheral blood 
ACKR2 expression is a consistent feature of inflammatory pathologies. We 
further demonstrate an association between select circulating cytokines and 
ACKR2 expression and show that mixtures of these cytokines are capable of 
increasing ACKR2 expression levels on healthy PBMC. The strongest association 
between circulating cytokines and ACKR2 expression was seen for IL-6 and HGF 
although neither cytokine alone was capable of inducing ACKR2 expression. 
Interestingly, whilst a similar association with HGF was seen in psoriatic 
patients, these patients displayed no association between IL-6 and ACKR2 (data 
not shown). This contrasts with the ACKR2-inducing effects of IL-6 seen on 
lymphatic endothelial cells[32]. Together our observations suggest alternative 
molecular drivers for enhanced ACKR2 expression in different inflammatory 
pathologies and cell types. Surprisingly in the arthropathy groups studied (as 
well as in psoriatic patients) there is no apparent correlation between peripheral 
blood ACKR2 expression and disease severity. As circulating inflammatory CC-
chemokines will predominantly have derived from the original inflamed site, one 
intriguing possibility is that ACKR2 limits the activity of circulating chemokines 
and therefore potentially ameliorates the development of chemokine associated 
comorbidities (e.g. atherosclerosis) in patients. This possibility, however, 
remains to be tested. 
 In addition we demonstrate expression of ACKR2 on both leukocytes, and 
resident stromal populations, in patient synovial biopsies. The demonstration of 
expression on stromal cells, especially those at the synovium/synovial fluid 
interface, extends observations made in psoriatic skin which demonstrated 
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inducible expression on keratinocytes[22]. We hypothesise that stromal cell 
expression serves to reduce inflammatory chemokine bio-availability, or to limit 
its domain of influence, and this is supported by the coincident expression of 
ACKR2 and CCL3 in synovial tissues. Strikingly, many of the leukocytes that are 
positive for ACKR2 expression are B and T cells present in large leukocyte 
aggregates within the synovial tissues. We propose that these correspond to 
ectopic follicles although the roles for ACKR2 within these structures is not 
immediately apparent. It may be that ACKR2 is important to ensure the relative 
absence of inflammatory leukocytes within these ectopic lymphoid follicles[34, 
35]. 
In summary, therefore, we provide evidence demonstrating up-regulation 
of ACKR2 in peripheral blood cells and in cells within the synovium. This, 
coupled with previous observations from psoriasis, and systemic sclerosis, 
patients suggests that elevated ACKR2 levels are a consistent feature of human 
inflammatory pathologies. Further work is required to determine the functional 
implications of elevated expression in these pathological contexts.  
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Figure Legends  
Figure 1. ACKR2 expression is elevated in PBMCs from inflammatory 
arthropathy patients.   
A) ACKR2 expression was measured by qPCR in PBMC from PsA, RA and Early RA 
patients using absolute quantification and normalised to TATA-BP expression 
levels. 
B) Fold change in expression was calculated by dividing the ACKR2 
expression/1X106 TATA-BP by the median ACKR2 expression/1x106 TATA-BP of 
healthy controls.  
C) A graph of compiled data showing the overall spread of ACKR2 expression 
across healthy controls and the three patient groups. 
D) Cytospins of PBMC from healthy controls and RA patients were stained with 
rabbit anti-human ACKR2 (2.5 µg/ml) which was detected using biotinylated 
horse anti rabbit IgG/Streptavidin FITC. 
E) The numbers of ACKR2+ cells per view were counted over ten fields of view 
and the mean ACKR2 expression is shown from 7 healthy donors and 10 RA 
donors. 
F) Co-staining for ACKR2 (green), and CD14, CD3 or CD20 (each in red) on 
cytospins of PBMC from RA patients. The overlay is shown in the 3rd panel of the 
images. Slides were mounted with DAPI and expression was measured using a 
Zeiss epifluorescent microscope (Axiovision rel 4.8.2).   
 
Figure 2.  Correlation of ACKR2 expression in PBMC with plasma cytokines.  
Peripheral blood mononuclear cells (PBMC) and paired serum samples were 
taken from healthy controls, psoriatic arthritis patients (PsA), rheumatoid 
arthritis patients (RA) or early rheumatoid arthritis patients (early RA). ACKR2 
expression was measured using qPCR with absolute quantification and 
normalised to 106 copies of TATA binding protein (TATA-BP). Plasma was 
analysed by 30-plex luminex analysis. ACKR2 expression is shown against 
significantly correlating cytokines: IL-6, IL-1β, IL-2, TNF-α, IL-7, IL-15, IL5 and 
HGF. Correlation analysis was performed using Spearman’s Correlation 
Coefficient. 
 
Figure 3.  Correlation of ACKR2 expression in PBMC with ACKR2-binding 
chemokines. Peripheral blood mononuclear cells (PBMC) and paired plasma 
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samples were taken from healthy controls, psoriatic arthritis patients (PsA), 
rheumatoid arthritis patients (RA) or early rheumatoid arthritis patients (early 
RA). ACKR2 expression was measured using qPCR with absolute quantification 
and normalised to 106 copies of TATA binding protein (TATA-BP). Plasma was 
analysed by 30-plex luminex analysis. ACKR2 expression is shown correlated with 
against CCL2 (A) and CCL3 (B). CCL3 levels between ACKR2-high and ACKR2-low 
patients (C). Correlation analysis was performed using Spearman’s Correlation 
Coefficient. 
 
Figure 4.  Regulation of ACKR2 expression by cytokines and chemokines.   
A) Healthy PBMCs were treated with PBS or with IL-6 in the presence, or 
absence, of soluble IL-6 receptor for 6, 24 and 48 hours. RNA was isolated and 
ACKR2 expression assessed using qPCR. Data at each time point are expressed 
relative to ACKR2 expression in fresh untreated PBMCs. 
B) Cytokines correlating with ACKR2 expression were pooled into a ‘cytomix’ 
containing IL-6, IL-1β, IL-2, TNF-α, IL-7, IL-15 and IL-5 and HGF (all at 100ng/ml) 
and the mix used to stimulate PBMCs for 6, 24 and 48 hours. Expression of ACKR2 
was measured and expressed as described above. 
C) A ‘chemomix’ containing CCL2 and CCL3 (both at 10µg/ml) was similarly used 
to stimulate PBMC, and ACKR2 expression measured and expressed as described 
above. 
 
Figure 5. ACKR2 is expressed within the rheumatoid arthritis synovium in 
leukocytes and stromal cells.   
A) Paraffin embedded rheumatoid arthritis synovial tissue sections (5µm) were 
stained for ACKR2 using rabbit anti-human ACKR2 (2.5 µg/ml) and expression was 
visualised using DAB.  Slides were counterstained with haematoxylin, visualised 
under a Zeiss light microscope and analysed using Axiovision Rel 4.8.2 software.  
B) Co-staining for ACKR2 (green) and CD45 (red) and showing the overlay of the 2 
stains (yellow) on paraffin-embedded synovial tissue sections. Slides were 
counterstained with DAPI (blue) to reveal nuclei. Images were taken using a 
Zeiss epifluorescent microscope and Axiovision Rel 4.8.2 software.  
C) Paraffin embedded rheumatoid arthritis synovial tissue sections were stained 
for ACKR2 (green) and CCL3 (red). The third image shows the overlay of the two 
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colours. Slides were counterstained with DAPI and visualised on a Zeiss 
epifluorescent microscope with AxioVision rel 4.8.2 software.   
 
Figure 6.  ACKR2 is expressed within rheumatoid arthritis synovium on 
defined leukocyte subpopulations.   
Paraffin embedded rheumatoid arthritis synovial tissue sections (5 µm) were 
stained for ACKR2 (green) together with CD3 (A), CD20 (B), CD68(C), or MCT (D) 
to identify leukocytes within the synovium expressing ACKR2. Yellow represents 
the overlay of the 2 colours and indicates co-incident expression. Slides were 
counterstained with DAPI and visualised on a Zeiss epifluorescent microscope 
with AxioVision rel 4.8.2 software. Percentages of ACKR2+ Lineage+ cells were 
quantified over 10 fields of view and the results are shown in (E).  
 
Supplementary Figure 1.  ESR, CRP and age of the individuals used in this 
study. 
Patients were recruited from Stobhill hospital and the Victoria Infirmary, 
Glasgow.  ESR (A), CRP (B) and age (C) were plotted for each patient group.   
 
Supplementary Figure 2.  Correlation between ACKR2 expression in PBMC and 
age, ESR and CRP.   
Peripheral blood mononuclear cells (PBMC) were taken from healthy controls, 
psoriatic arthritis patients (PsA), rheumatoid arthritis patients (RA) or early 
rheumatoid arthritis patients (early RA). ACKR2 expression was measured using 
qPCR with absolute quantification and normalised to 106 copies of TATA binding 
protein (TATA-BP).  ACKR2 expression is shown against age (A), ESR (B) and CRP 
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Age (mean±SD) 44.4 ± 5.9 48.9±10.6 60.8±10.5 57.7±10.1
Sex (F:M) 7:4 17:2 10:5 14:1
Disease duration
(years±SD)






N/A 6/8/1/3/1 7/5/0/2/1 0/12/0/3/0
ESR N/A 19.1±16.1 25.5±51.4 19.2±12.8
CRP N/A 16.6±18.2 26.5±28.8 7±9.1
RhF +/-/unknown N/A 1/17/1 9/6 4/9/2
ACPA+/-/unknown N/A 0/18/1 4/11 2/11/2
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